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Gene expression requires balance between synthesis and decay of mRNAs. Aberrant 
expression of genes results in disease. PUF proteins are a family of eukaryotic RNA binding 
regulators characterized by a conserved RNA binding domain that binds 8-12 nucleotide 
sequence elements, called PREs, in target mRNAs. PUFs are thought to regulate processes 
including cell proliferation and memory formation. In model organisms, PUFs block translation 
and enhance deadenylation and mRNA decay. Humans have two PUFs: PUM1 and PUM2. 
Despite a substantial foundation of knowledge about PUFs in model organisms, the RNA targets 
of PUMs and mechanisms by which they repress remain unclear. I will present evidence herein 
that PUM1 and PUM2 are regulators in human cells. PUM1 and PUM2, which exhibit identical 
RNA binding specificities, employ a conserved mechanism of repression via direct recruitment 
of the CCR4-NOT deadenylase complex, causing translational inhibition and accelerated mRNA 
decay. PUMs also repress a non-adenylated mRNA; therefore, PUMs utilize a second, 
deadenylation-independent repression mechanism. RNAs regulated upon PUM knockdown in 
human cells were identified in this study and compared with RNAs in the genome that contain at 
least one PRE and previously classified, bound PUM mRNA targets to yield a dataset of 487 
direct PUM targets. Direct PUM target mRNAs encode proteins involved in cancers, signaling, 
development, and neurological functions. This study demonstrates direct, potent PUM repression 
in human cells, illuminates mechanisms by which they enact repression, and identifies 487 direct 
RNA targets of PUM regulation; together revealing PUM regulated pathways in human cell 
networks. 
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  Introduction 
 
Expression of genetic information encoded by eukaryotic genes involves numerous 
tightly controlled and coordinated processes. The central dogma asserts that DNA is transcribed 
to RNA, which is translated to protein (1). Among those steps exist intricate and dynamic 
regulatory networks that serve to ensure timely and proper gene expression. Each gene must be 
turned on or off at precisely the right time, at the right place, and in the right quantity; gene 
expression depends on the particular tissue, cell type, developmental stage, and biological 
response to a particular environmental stimulus. Aberrant gene expression results in disease.  
DNA is transcribed to RNA by transcription. To produce a mature protein encoding 
messenger RNA, the RNA must be co-transcriptionally processed and exported from the nucleus 
to the cytoplasm. Throughout these processes, the mRNA is packaged with protein factors, 
together called messenger ribonucleoprotein particles (mRNPs), which ultimately must help the 
mRNA escape destruction by nuclear exoribonucleases and export the molecule to the cytoplasm 
(2). There, complexes of RNA binding factors, decay machinery, and the translational apparatus 
work to ultimately regulate gene expression; either by controlling translation or by interfering 
with mRNA stability and promoting its decay. Destructive enzymes and protein complexes seek 
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to destroy all but correct messenger RNAs and thus function as key quality control regulators in 
gene expression (3). Each of these steps in gene expression is subjected to a host of regulatory 
activities: transcriptional regulators positively and negatively affect synthesis of mRNA, 
regulators control splicing and alternative cleavage and polyadenylation to generate different 
forms of each gene (4, 5). Furthermore, mRNA localization, stability, and translation efficiency 
are subjected to stringent regulatory controls (6, 7). The work presented in this dissertation 
highlights the nexus of regulatory activity between expression of an mRNA transcript and its 
translation to protein using the PUF family of proteins as a model for regulation.   
Messenger RNA processing and 3’ end formation 
 Transcription of protein coding genes and many noncoding genes begins when RNA 
Polymerase II binds the promoter of the gene, together with many general transcription factors, 
to form a preinitiation complex (8). The DNA double helix is melted in an ATP dependent 
manner, and the template strand moves down into the base of the active site cleft of the 
polymerase (8). The polymerase adds several complementary ribonucleotides, pauses briefly, 
and then elongation of the transcript begins, during which sequential addition of nucleotides is 
processive, reaching rates of 1-4 kb/minute (9). During the early phase of transcription 
elongation; specifically within the first 40 nucleotides, a modified 7-methylguanosine cap is 
added to its 5’ end (10, 11). During the elongation phase, introns are removed by splicing and, 
with the exception of histone mRNAs, mRNAs are subjected to cleavage and addition of a 3’ 
poly (Adenosine) tail (10). Key structural elements including the 5’ cap and poly (A) tail, as well 
as mechanisms of 3’ end formation will be discussed subsequently. 
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The 5’ 7-methylguanosine cap  
 The 7-methylguanosine cap is added to the 5’ end and serves several purposes: it 
promotes splicing, mRNA export, and translation (12-17). Addition of the cap was confirmed by 
radioactive labeling experiments in both mouse myeloma and human HeLa cells (18, 19). In 
translation systems and wheat germ extracts, the presence of the 5’ cap allows translation of 
mRNA to protein to proceed, whereas little or no translation is observed in its absence (17). The 
5’ cap plays a protective role by shielding the body of the mRNA from cellular 5’exonucleolytic 
degradation (20). In addition, the cap promotes translation (21) Poly (A) binding protein (PABP) 
is bound to the poly (A) tail at the 3’ end, and interacts with cap-bound eIF4G to circularize the 
mRNA: it is thought that translation is facilitated by formation of this closed loop structure (22).  
The poly (Adenosine) tail  
 Termination of transcription of Pol II transcripts, cleavage, and polyadenylation are 
intimately linked. The processing machinery in mammals that carries out mRNA 3’ end 
formation is complex, consisting of upwards of 80 different proteins (23-25). The length of the 
poly (A) tail varies widely among organisms. For example, in yeast the tail is approximately 80 
adenosines, whereas in mammals the poly (A) tail is between 200 -250 adenosines in length (26).  
The poly (A) tail serves many functions: it protects the 3’ end of the mRNA from 
degradation and promotes translation of the coding region by binding to regulatory factors. The 
poly (A) tail is formed by cleavage and polyadenylation, often co-transcriptionally. Within the 
mRNA, a number of sequence elements direct this process: the poly (A) signal is located 
approximately 20 nucleotides upstream from the poly (A) site, where the poly (A) tail is added, 
and a downstream U/GU rich element further direct the process (5, 27, 28). Upstream and 
downstream auxiliary sites affect cleavage and polyadenylation as well. While a canonical 
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AAUAAA poly (A) signal is often found in mRNAs, several noncanonical alternative poly (A) 
signals have been identified and are thought to make up ~ 14% of poly (A) signals in humans 
and mice (5). The strength of the poly (A) site affects the efficiency of transcriptional 
termination: weakened poly (A) sites in human β-globin and α-globin genes reduce termination 
frequency and efficiency (29-31).  
Canonical cleavage and polyadenylation occurs at the end of the elongation phase of 
transcription when cleavage and polyadenylation specificity factor (CPSF) interacts with the 
carboxyl terminal domain (CTD) of RNA Pol II: it recognizes the poly (A) signal, AAUAAA or 
another non-canonical signal, and then at the downstream GU-rich processing signal the protein 
CStF (cleavage stimulatory factor) binds and recruits CPSF, by which Pol II is released, and the 
transcript is cleaved and polyadenylated (9). After co-transcriptional cleavage and 
polyadenylation, the newly generated RNA fragment has an unprotected 5’ end and is left 
vulnerable to exoribonucleolytic degradation by XRN2 (9). 
In addition to cleavage and polyadenylation, mRNAs are alternatively polyadenylated to 
generate different 3’ untranslated regions (5). More than half of mRNAs are alternatively 
processed: this depends on cell type, disease state, and cell cycle and differentiation (32, 33). 
Alteration of the mRNA 3’ end has a number of implications for localization, stability, function, 
and regulation of the mRNA (5, 32, 34). For example, mRNAs are alternatively polyadenylated 
after upstream poly (A) signals to generate shortened 3’UTRs upon activation of primary T 
lymphocytes in mice (32). Further, alternatively polyadenylated, shortened 3’UTRs correlate 
with cell proliferation (32). Thus, changing the 3’ UTR of an mRNA results in significant 
changes to its expression and regulation by RNA binding proteins, its translation, as well as its 
response to environmental changes.   
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 Poly (A) binding proteins in mammals bind and coat the poly (A) tail and play roles in 
translation and mRNA stability. Nuclear PABPs exist in mammals, and function to stimulate 
polyadenylation of the mature mRNA transcript (35, 36). Poly (A) tails in the cytoplasm are 
coated with multiple poly (A) binding proteins (PABP), which bind specifically to poly (A) 
through four RNA recognition motifs (RRMs) in their N terminal regions (35). Mammals have 5 
canonical cytoplasmic PABPs, though the most widely studied PABP in mammals is PABC1, 
which is the major form of the protein (36). PABC1 has several functions: the 70 kDa protein 
coats the tail and interacts with the cap-binding complex, bringing the mRNA into a closed loop 
structure, thereby stimulating translation (35). PABC1 is ejected from the poly (A) tail as the tail 
is shortened by deadenylases, but may also play roles in recruitment of decay factors (37).   
Translation and mRNA decay are interconnected processes  
Mature mRNA encodes protein; however, less than half of its sequence contains the open 
reading frame (ORF) and the remainder consists of regulatory sequences (38). The ORF is 
flanked on either side by 5’ and 3’ untranslated regions: sequence that is not translated to protein, 
but instead specifies regulatory instructions for the gene product. Many sequence elements 
located in the body of the mRNA interact with RNA binding proteins and complexes to 
positively or negatively affect translation and stability of the mRNA. Examples of specific 
regulatory activities conferred by cis regulatory sequences and trans acting factors will be 
discussed in later sections. 
 After co-transcriptional processing and 3’ end formation, the mature mRNA is exported 
from the nucleus to the cytoplasm in a process that is ATP-dependent (39, 40). There in the 
cytoplasm, the mRNA can engage with the translational apparatus or decay machinery. Upon 
export, poly (A) binding protein (PABP), which binds with high affinity to short poly (A) 
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stretches, binds and coats the poly (A) tail (41). Together, the 5’ cap and poly (A) tail protect and 
ensure the stability of the messenger RNA and synergize to promote translation of the mRNA 
(42, 43).  
 Translation and decay are opposed in function; therefore, each process is tuned to 
promote proper spatial and temporal control of mRNA degradation and protein synthesis. 
Initiation of translation is rate limiting and occurs when the 40S – mRNP complex and 60S 
ribosomal subunits join in a highly ordered fashion. The nascent protein is then produced while 
the mRNA is held in a circularized conformation, joined together by cap bound initiation factors 
and poly (A)-bound PABP. In this conformation, the mRNA can load multiple ribosomes, to 
form polysomes, along its coding region and be translated efficiently many times: it is estimated 
that translation rates reach 750-1300 proteins per mRNA per hour (44). Disruption of the closed 
loop structure and dissociation of translation factors is thought to make the mRNA accessible to 
decay factor binding, which allows degradation to proceed rapidly. Thus, translation and decay 
are intricately linked processes and work in opposition to control gene expression; these 
processes and their interrelationship will be described in the ensuing sections.  
Regulation of translation initiation 
Translation begins with initiation, a process that is rate limiting and extensively 
regulated. The mRNA is activated when an mRNP complex consisting of mRNA bound to 
eIF4A, eIF4B, eIF4E, and eIF4G and PABP. eIF4E binds directly to the 5’ cap and PABP coats 
the poly (A) tail (45). During initiation, a ternary complex consisting of eIF2 and the initiator 
methionine tRNA forms (45). Initiation factors eIF1, eIF1A, eIF3, and eIF5 aid to recruit the 
ternary complex to the 40S ribosomal subunit to form the preinitiation complex (PIC) (45). The 
activated mRNP is recruited to the preinitiation complex, at which point the PIC binds the 5’ end 
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of the mRNA and begins to scan along the molecule to find the first methionine codon, called the 
start codon (AUG) (46-48). The sequences flanking the AUG start codon are crucial for 
enhancing translation of mRNAs; called the Kozak sequence, the consensus motif 
(GCC)GCC(A/G)CCATGG promotes efficient translation (46, 49).  
Once the start codon is recognized, eIF1 can be released and GTP on eIF2 is hydrolyzed 
to GDP, a process that stops scanning until the 60S subunit joins. At this point, eIF2-GDP and 
eIF5 are released so that eIF5B can aid in joining the 60S subunit to the 40S subunit bound to the 
mRNP and remaining initiation factors (45). Once the two subunits have united, another 
molecule of GTP is hydrolyzed and initiation factors are released, allowing translation of the 
open reading frame to protein (45).  
mRNAs are subjected to a very broad range of translation efficiencies (44). Initiation 
factor activity is often regulated by phosphorylation. For example, phosphorylation of eIF-2α 
inhibits translation, by blocking its recycling by the eIF2B, a GDP/GTP exchange factor (50).  
Conversely, phosphorylation of eIF-4E appears to enhance its cap-binding activity and thereby 
increases translation (50). The cap promotes translation by binding eIF4E, which recruits eIF4A 
and eIF4G to form the eIF4F complex to ultimately recruit the 43S pre-initiation complex and 
form the 48S initiation complex (21, 22).  In addition to regulation of components of the 
translational machinery, elements in the mRNA affect translational efficiency as well. Secondary 
structure in the 5’ UTR inhibits translation efficiency (51). RBPs can bind elements in the 3’ 
UTR to regulate translation, either by activation or repression (52-54). One of our goals in this 
work and beyond is to determine if and how human PUF proteins, PUM1 and PUM2, affect 
translation.  
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mRNA deadenylation and decay 
One consequence of gene expression is that mRNA will be degraded: its destruction is 
necessary to turn off genes. Transcription rates and mRNA decay work in opposition to dictate 
steady state levels of mRNAs. mRNA levels and half lives vary over several orders of 
magnitude, and range from minutes to many hours (44). In mammals, the median half life is 7-10 
hours, and ranges from <1 hour to several hundred hours, though these values depend largely on 
cell type and environmental conditions (44, 55-57). mRNAs encoding structural or housekeeping 
genes such as GAPDH, for example, have very long half-lives; conversely, mRNAs encoding 
signaling genes have very short half-lives, making them available only briefly for translation. A 
genome-wide study predicted rates of synthesis of proteins and mRNAs: certain groups of genes, 
arranged by function, evolved characteristic half lives (44). For example, genes with unstable 
mRNAs and proteins are involved in strictly timed and regulated processes such as mitosis and 
regulation of transcription; whereas stable mRNAs and their stable protein transcripts are 
involved in housekeeping processes such as metabolism and translation (44). All this is to say 
that mRNA decay must be carefully controlled such that expression of the appropriate amounts 
of proteins are properly timed and spatially controlled: without high levels of regulation, aberrant 
gene expression will occur and disease will likely follow. A range of regulatory mechanisms is 
therefore necessary to control mRNA abundance and degradation. 
Deadenylation initiates mRNA decay  
Deadenylation, or 3’ exonucleolytic digestion and removal of the poly (A) tail, is often 
the rate limiting step of mRNA decay (41, 58, 59). Shortening of the poly (A) tail acts as a 
dimmer switch: longer tails promote translation and shortened tails act as a signal to RNA decay 
factors that will go on to degrade the mRNA (Fig. 1.1). Pathways by which mRNAs are further 
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degraded occur by either decapping and 5’ degradation or 3’ degradation (Fig. 1.1). Over the 
lifetime of specific mRNAs, the poly (A) tail may change in length depending on the phase of 
the cell cycle or environmental conditions: for example, during oocyte development (41, 60).  
There is diversity among deadenylase enzymes in eukaryotes. All known deadenylases 
belong to one of two superfamilies; EEP (exo-nuclease-endonuclease-phosphatase) or DEDD 
type deadenylases, named for their active site residues (41). DEDD type deadenylases employ 
catalytic aspartate and glutamate residues dispersed between three Mg2+-coordinating 
exonuclease motifs and include POP2 orthologs, PAN2, and PARN families (41, 61). EEP type 
enzymes are also Mg2+- dependent and include CCR4 orthologs: these enzymes contain 
conserved catalytic aspartate and histidine residues in their putative active sites (41, 62).  
Multiple deadenylases can work together to degrade poly (A) tail: CCR4 and POP2 
deadenylases work together as a heterodimer, yet they can also work sequentially as in the case 
of PAN2 and the CCR4-POP2 heterodimer. In mammals, the enzyme PAN2 in complex with 
PAN3 first shortens the poly (A) tail to approximately 110 nucleotides (63). In yeast, this 
complex regulates shortening of the poly (A) tail in the nucleus, whereas CCR4 is the 
predominant deadenylase in the cytoplasm (41, 64). After initial shortening of the poly (A) tail in 
mammals, degradation of mRNA occurs by decapping and 5’ decay or by further deadenylation 
and decay from the 3’ end (Fig. 1.1). The remainder of the poly (A) tail is removed by CCR4 and 
POP2 deadenylase enzymes (63). Ccr4p and Pop2p are required for cytoplasmic deadenylation 
in yeast; if Ccr4p is overexpressed in a Δpop2 strain, defects in deadenylation are rescued 
suggesting that Ccr4p is the major deadenylase (65, 66). After deadenylation by the CCR4-NOT 
complex, the remaining mRNA body can be degraded by the exosome in the 3’-5’ direction (3, 
67, 68). 
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CCR4 and POP2 are components of the CCR4-NOT deadenylase complex, which exists 
in several forms in mammals depending on its subunit composition (69, 70). This heterogeneous 
complex is formed by core non-catalytic components, including CNOT1, CNOT2, CNOT3, 
CNOT9, CNOT10 (71). CNOT4, which in yeast is called Not4, is not stably associated with core 
components of the complex as it is in yeast (71, 72). The CCR4-NOT complex also contains two 
catalytic subunits, orthologs of CCR4 and POP2. Mammals have two active CCR4 orthologs, 
CNOT6 and CNOT6L, as well as two POP2 orthologs, CNOT7 and CNOT8 (71, 73-77). These 
orthologs can form heterodimers, contributing to variation within CCR4-NOT complexes. 
Therefore, heterodimerization of CCR4 and POP2 orthologs results in the formation at least 4 
different multisubunit CCR4-NOT complexes in mammals.  
Decapping factors cause removal of the 5’ cap and potentiate rapid mRNA decay 
Decapping normally occurs after shortening of the poly (A) tail, at which point the 5’ cap 
will be removed by decapping enzymes and the remainder of the mRNA will be degraded by 
XRN1, which is the major cytoplasmic exoribonuclease (Fig. 1.1) 
(78-80). The 5’ cap structure is typically removed by a heterodimer of DCP1 and DCP2 
in yeast, whereas in humans the decapping complex consists of DCP1 and DCP2 linked via 
HEDLS protein (3). In mammals, upwards of seven different decapping enzymes have been 
identified including DCP2 and NUDT16, as well as several other NUDT family members (81). 
Decapping in yeast requires removal of the cap-bound eIF4E (82). Several factors enhance 
decapping and promote 5’-3’ mRNA decay by the exosome, including the LSM1-7-Pat1 
complex, which helps to coordinate decapping after deadenylation by binding the short poly (A) 
tail of deadenylated mRNA (80, 83).  
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Interplay between translation and mRNA decay 
 During translation, the mRNA is held in a closed loop by interactions with RBPs at the 5’ 
and 3’ ends (43, 84). Displacement of initiation factors and RBPs linking the 3’ or 5’ ends must 
occur before decay factors gain access to the mRNA. Ccr4p deadenylase activity is inhibited by 
excess Pab1p, which coats the tail to promote translation(66). Shortening of the poly (A) tail, a 
process which ejects PABP and causes the disruption of the closed loop structure, initiates the 
decay process and thereby inhibits translation, as poly (A) binds initiation factors to enhance 
translation (58, 78, 85-88).  
Furthermore, blocking translation elongation in yeast with cycloheximide stabilizes the 
MFA2 mRNA, suggesting that modulating translation has a direct or indirect effect on decay 
(15). In yeast, bound eIF4E blocks decapping activity in yeast by interfering with Dcp1 binding 
to the cap; once eIF4E dissociates, the decapping complex is free to bind and initiate the process 
of mRNA decay (82). Mutations that inactivate translation initiation factors result in an increased 
rate of mRNA decay, which illustrates that regulatory proteins affecting one process directly can 
have secondary effects on other steps (89). I will discuss examples of such interplay throughout 
this work. PUF proteins enhance deadenylation, which can disrupt translation and cause mRNA 
decay. Alternatively, PUFs may block translation directly: as a consequence, decay is enhanced. 
Identifying direct interactions between PUFs and deadenylases is therefore crucial for 
discrimination between these models. 
3’ UTR cis elements and trans-acting factors confer post-transcriptional regulation 
 It is likely that hundreds of RNA binding proteins exert combinatorial control of gene 
expression (90-93). At the foundation of these processes lie direct interactions between mRNA 
and RNA binding factors, including proteins and other RNAs. Sequences embedded within the 
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mRNA transcript direct a cadre of regulatory complexes to positively or negatively affect its 
translation and decay. RNA binding factors act in trans to recognize these elements to activate or 
repress gene expression. Many of these RNA binding factors and their target sequences have yet 
to be characterized, though one thing is known: RNA binding factors are responsible for 
immense post-transcriptional regulation and precision and loss of their ability to control gene 
expression can cause catastrophic problems in biological processes (94).  
Mutations and changes in expression of RBPs results in a number of diseases: for 
example, increased expression of the RBP eIF4E is found in transformed cancer cells (94). 
Additionally, defects in microRNA function or expression is associated with many cancers (95, 
96). Aberrant changes in mRNA sequences can have drastic physiological consequences. For 
example, repeats of 70-120 CGG triplets in the 5’UTR of the FMR1 gene results in increased 
FMR1 mRNA levels and are associated with the Fragile-X Tremor Ataxia Syndrome (FXTAS), 
which causes late onset disruption of neurological function (97). Similarly, CAG expansions 
result in Huntington’s disease and spinocerebellar ataxia (SCA) and CUG repeat expansions 
resulting in a gain-of-function mutant mRNA are associated with myotonic dystrophy (97). With 
the discovery of hundreds of new RNA binding proteins, it is clear that a great deal of 
information remains to be discovered regarding interactions between mRNA sequences and 
RNA binding factors, and how they affect normal physiology and disease. 
Posttranscriptional control of gene expression depends on cis elements and trans acting 
factors 
Cis elements are sequences found in the body of the mRNA, most frequently in the 
untranslated regions. Broadly, they provide a roadmap for regulation of the gene in which they 
reside: that is, they direct regulatory complexes to the body of the mRNA so as to control its 
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expression in different ways. Cis elements direct localization of the mRNA in the cell, activate or 
repress protein expression, and stabilize or destabilize the mRNA (60, 98-100). They integrate 
cellular signals and act as tunable regulators to adjust levels of protein expression and to control 
mRNA stability and decay. These sequences recruit trans acting factors, which include 
translational machinery and decay factors. Several well-characterized examples of cis elements 
and associated trans-acting RNA binding factors including miRNA response elements, AU rich 
elements (AREs), and Pumilio response elements (PREs) will be discussed in subsequent 
sections, which will focus on highlighting known mechanisms and trends in their regulatory 
activities.  
miRNAs are trans-acting factors that inhibit mRNA translation and promote decay 
 In the early 1990s, the Ambros and Ruvkun labs made striking discoveries related to a 
gene, lin-4, that appeared to be involved in timing cell division between the first and second 
larval stages in C. elegans. The small lin-4 RNA, only 22 nucleotides in length, had antisense 
complementarity to a region in the 3’ UTR of the lin-14 mRNA, and somehow directed 
translational repression of its protein product, LIN-14 (101, 102). Over the ensuing years, many 
hundreds of small RNAs, called microRNAs (miRNAs), were discovered to bind to sites in the 
3’ UTR of as many mRNAs to down-regulate their expression (103).  
 MicroRNAs are encoded in the genome as long transcripts called primary miRNAs (104). 
These transcripts are processed twice: first, the pri-miRNA is cleaved by the RNase III 
endonuclease Drosha, which is specific for dsRNA, to a smaller 60-70 nucleotide stem loop 
structure called a precursor miRNA, or pre-miRNA (105). The shortened pre-miRNA is 
transported from the nucleus to the cytoplasm, where it subjected to final processing steps. 
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Transport of the pre-miRNA requires the karyopherin family member Exportin-5, a nucleo-
cytoplasmic nuclear export factor that uses the GTPase Ran-GTP (106, 107).  
 Once localized to the cytoplasm, the pre-miRNA is cleaved by another RNase III 
endonuclease, Dicer, to its final 22 nucleotide structure (108-110). The final dsRNA miRNA 
product is then deployed to bind and repress its targets along with a mRNP complex called 
miRISC consisting of a conserved Argonaute (AGO) proteins and GW182 (in humans, its 
orthologs are TNRCA1, 2, and 3) (111). MiRNAs basepair with perfect or imperfect 
complementarity to miRNA response elements in the 3’UTR of target mRNAs, which indicates 
that a single miRNA can bind and regulate a number of different mRNAs (103, 111-114).   
 MicroRNAs in complex with the miRISC machinery bind a target sequence in an mRNA 
sequence and recruit regulatory factors to it to inhibit its expression. miRNAs alter gene 
expression of over half of mammalian genes in a number of ways: they cause mRNA decay by 
recruitment of deadenylases, and inhibit translation before and after initiation (112). miRNAs 
inhibit cap-dependent translation at the initiation step (115-119). Another proposed mechanism 
of miRNA mediated translation inhibition involves blocking translation at steps beyond initiation 
(120-123). A host of studies implicate miRISC in enhancing mRNA decay by interacting with 
decapping factors and deadenylation enzymes (124-126). GW182-mediated repression by 
miRISC correlates with its ability to bind PABP, CCR4-NOT deadenylase complex member 
NOT1, and the deadenylase PAN2 (127, 128). Intriguingly, a new study showed that the 
miRNA-associated scaffold protein GW182 can also reduce association of PABP and eIF4E with 
the poly (A) tail and 5’ cap in order to block translation independently of deadenylation in 
Drosophila (129). In humans, GW182 has three paralogs, TNRC6A, B, and C (129). Many of 
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the protein corepressors that bind miRISC are recruited by other cis elements, which will be 
described in subsequent sections. 
AU-rich elements positively and negatively affect mRNA translation and stability 
 One of the first examples of a cis element responsible for conferring gene regulation is 
the AU rich element (ARE) (130). AREs are found in the 3’ UTRs of many genes including 
chemokines, cytokines, and proinflammatory enzymes (131). Early experiments suggested that 
the sequence AUUUA in the 3’UTR of mRNAs triggers the rapid and selective degradation of 
the transcript(130). Typically this ARE is embedded within a U-rich setting (131). However, 
over the years it was discovered that there are at least three classes of AREs within 3’UTRs: 
class I contains several copies of the AUUUA sequence within a U-rich environment, class II 
contains two overlapping UUAUUUA(U/A)(U/A) nonomers, and class II contains regions rich 
in Us but do not contain the canonical AUUUA sequence (132). Multiple ARE binding proteins 
(ARE-BPs) have been identified and are able to bind to many mRNAs, often with no preference 
for a particular class of ARE (132). ARE-BPs recruit deadenylase and decapping factors, as well 
as the exosome to repress ARE mRNAs (133-135).  
 AREs function as bifunctional switches: they direct activation or repression of a specific 
mRNA by recruiting different RNA binding proteins. An early example of regulation of an ARE 
mRNA by an ARE-BP was demonstrated using a β-globin reporter. A highly conserved AT-rich 
sequence found in the 3’ UTR of the gene coding for lymphokine granulocyte-monocyte colony 
stimulating factor (GM-CSF) was inserted into the 3’UTR of rabbit β-globin gene and caused 
significant reduction of globin transcripts and decreased mRNA stability (130). Deletion of an 
AU rich element from the c-fos mRNA results in stabilization of the gene and slowing of 
deadenylation (85). 
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 Tristetraprolin (TTP) is a negative regulator that binds class II AREs elements through its 
tandem zinc finger domain and promotes decay of the mRNA target (132, 136). TTP functions in 
physiological processes as a tumor suppressor as well as in inflammatory processes (136). The 
ARE-BP TTP binds with very high affinity to the ARE containing IL-2 mRNA: in TTP knockout 
mice, IL-2 protein is overproduced and its mRNA is stabilized (137). It was later demonstrated 
that TTP associates with decapping enzymes and CNOT1, a subunit of the CCR4-NOT 
deadenylase complex to repress its targets (135, 136). By recruiting deadenylases and mRNA 
decay factors, TTP acts as a potent repressor of target mRNA expression.  
 As discussed previously, AREs are bifunctional: the ARE-BP HuR, a member of the 
RRM superfamily, is a stabilizer of bound ARE mRNAs. One example of HuR stabilization is 
the regulation of the VEGF mRNA. Under hypoxic conditions, the vascular endothelial growth 
factor (VEGF) mRNA undergoes significant stabilization and, under these conditions, mediates 
angiogenesis, which has important implications in cancer and heart disease (138). HuR stabilizes 
of the VEGF mRNA by binding to its ARE under hypoxic conditions (138). There are many 
potential targets of HuR activity, which were identified using PAR-CLIP (photoactivatable-
ribonucleoside-enhanced crosslinking and immunoprecipitation). (139, 140). PAR-CLIP is a 
technique during which photoreactive ribonucleoside analogs are incorporated into RNA 
transcripts in live cells (141). Labeled transcripts are then crosslinked to bound proteins (RBPs), 
and immunoprecipitated from lysates (141). RNAs bound to immunoprecipitated proteins are 
isolated and converted to a cDNA library, which can be sequenced by high throughput 
techniques (141). The mechanism(s) by which HuR stabilizes ARE mRNAs is (are) not fully 
understood, though recent transcriptome-wide studies suggest that HuR is involved in pre-
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mRNA processing and mature mRNA stability (139, 140). Alternatively, HuR may work by 
displacing repressors by competitively binding to the ARE.  
PUF response elements recruit PUF proteins to cause mRNA decay  
The PUF response element (PRE) is a cis element that directs regulation of mRNAs by 
binding to PUF proteins and enhancing mRNA decay. PUF proteins, named for the founding 
family members Pumilio in Drosophila melanogaster and FBF in C. elegans, are conserved 
eukaryotic RNA binding proteins characterized by a homologous RNA binding domain (RBD) 
(142-146). A PRE is an 8-12 nucleotide consensus sequence, typically in the 3’UTR of target 
mRNAs. PUFs regulate genes underlying many important biological processes in model 
organisms, including stem cell proliferation, development, and neuronal function (143, 145-163). 
The proposed ancestral function of PUFs is that they support germline stem cell 
maintenance, though they are involved in many processes (151, 164). For example, during 
Drosophila development, maternal hunchback (hb) mRNA is repressed at the posterior of the 
developing embryo by Pumilio (PUM) and Nanos (NOS). Here, the Pumilio RNA binding 
domain binds to the PRE in the 3’ UTR of hb originally called the Nanos Response Element 
(NRE) with low nanomolar affinity (142-144, 165).   
 While PUFs in model organisms repress target mRNAs, the mechanisms by which they 
do so in humans remain unclear. PUFs in model organisms are thought to employ a number of 
distinct mechanisms to repress translation of specific mRNAs: they recruit deadenylation and 
decay machinery to destabilize the mRNA, and they directly inhibit translation (145, 160, 166-
174).  
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PUF proteins repress messenger RNAs 
There exist many potential targets of PUF regulation, and PUFs form complexes with 
many different regulatory proteins to carry out repression. PUFs have no known catalytic activity 
themselves, and thus are thought to serve as a scaffold that binds the mRNA PRE and regulatory 
complexes, to then direct regulatory complexes to the mRNA to carry out repression by 
interfering with translation and promoting mRNA decay. For example, yeast PUFs bring the 
Ccr4p-Pop2p deadenylase complex in proximity to the poly (A) tail of the mRNA, such that the 
Ccr4p deadenylase subunit may shorten the tail, signaling to decay complexes that the RNA is to 
be degraded.  
In addition to causing repression of mRNAs, there is some evidence that suggests a role 
for PUFs in mRNA localization (175, 176). Yeast Puf3p was reported to localize to the 
mitochondria, where it localizes mRNAs and is thought to play a role in mitochondrial 
biogenesis (176, 177). Yeast Puf6p represses translation of the ASH1 mRNA in the bud tip 
before the mRNA is localized to the bud cortex during late anaphase (178). Limited evidence 
also suggests a role for PUFs in activation of RNAs (179). It is unclear whether PUF activation is 
widespread, and this intriguing role of PUFs should be extensively tested. 
PUFs bind RNA via a conserved binding domain 
PUFs bind RNA nucleotides via a conserved modular RNA binding domain, consisting 
of 8 imperfect alpha-helical repeats of 36 amino acids each (142, 145, 146, 180-182). Each RNA 
base makes contacts with an individual repeat, with binding conferred by hydrogen bonding, van 
der Waals contacts, and base stacking interactions with exposed RNA recognition amino acid 
side chains along the inner, concave surface of the RBD (Fig. 1.2) (181). The outer surface of the 
crescent may contact co-repressors. Despite similarities in their modular structure, PUF RNA 
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binding domains vary among species in terms of their specificity of nucleotide binding. They 
bind 8-12 nucleotide RNA sequences, which differ with the exception of the first three 
ribonucleotides, UGU, which are required for binding (142). Such modularity welcomes efforts 
to alter binding specificity of PUFs, which has tremendous implications for research and clinical 
applications: for example, PUFs have been re-engineered to bind different PRE sequences such 
that in the future, it is feasible that they could be used to bind new RNA targets selectively (183-
186). 
PUF regulatory mechanisms in mammals have yet to be determined. Mammals have two 
PUF proteins, PUM1 and PUM2, which are orthologous to canonical PUF family members in 
other organisms. Human PUM1 and PUM2, which are the focus of this study, share 83% 
similarity and 75% identity, respectively (187). Their 361 amino acid long PUM RNA binding 
domains, or RBDs, share 91% identity and 97% similarity, and they differ in sequence primarily 
in their amino termini (187). PUM1 and PUM2 bind the consensus sequence UGUANAUA 
where N is any nucleotide (188, 189). Outside the conserved RNA binding domain, the amino 
and carboxyl terminal extensions of PUFs across species are divergent outside of their highly 
conserved RNA binding domains. 
Global analyses of PUF gene regulation 
Efforts to characterize the breadth of PUF regulation in model organisms have been made 
in recent years. RIP-Chip, RNA immunoprecipitation and microarray, is a method often used to 
identify bound RNA targets of proteins (190). Targets of all five yeast PUFs were identified by 
RIP-Chip assays in 2004 and thus provided new testing ground for understanding mechanisms of 
PUF regulation (191). Global analysis of Drosophila PUM has also been performed (191, 192). 
Together, studies in model organisms illustrate that PUFs bind hundreds of potential target 
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RNAs. Mammalian PUM1 and PUM2 bind and potentially repress hundreds of genes between 
them, as indicated by RIP-Chip (161, 163, 188, 189, 193, 194). In 2008, RIP-Chip studies 
indicated that purified PUM1 and PUM2 RNP complexes from human HeLa cells bound to 1424 
and 751 RNA transcripts, respectively (188). Perhaps most striking was the finding that a high 
percentage, 88%, of PUM2 targets overlapped with those of PUM1 (188). Another RIP-Chip 
study performed in HeLa cells looked at bound targets of PUM1 and reported that 726 genes 
were bound to PUM1 (189). The authors used qRT-PCR to assess stabilization of a handful of 
target mRNAs upon PUM1 knockdown. Targets that were modestly stabilized upon PUM 
depletion include PCNA, Cks2, Cyclin B1, Cyclin E2, SLBP, and PUM2. RIP-Chip analysis in 
mice to identified 1527 putative PUM1 target genes (161).  
 Deletion of PUM1 in mice caused no apparent defects in lifespan, though they are 
smaller than wildtype mice and males exhibit testicular hypoplasia (161). This study was 
intriguing, in that it identified repression of many upstream targets of the p53 tumor suppressor 
gene by PUM1 in its analysis, shedding light on a potential regulatory role of PUMs in cell 
proliferation and disease (161). PAR-CLIP was used to identify targets of PUM2 upon 
overexpression in HEK293 cells and obtained ~3000 genes associated with PUM2 (141).  
It is important to note that limited functional validation was performed in the above 
referenced studies. Less than half of the RIP-Chip and PAR-CLIP targets had identifiable PREs. 
Thus, it is likely that many targets identified were indirectly associated with PUMs. Bound 
RNAs were identified, though only in a few cases was mRNA stability of PUM targets assessed. 
Furthermore, an important consideration of these studies is that, in the majority of cases, mRNAs 
bound to only one PUM protein were identified. In addition to the observations described above 
that PUM1 and PUM2 targets significantly overlap, omitting one or the other from global target 
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analysis will inevitably weaken and cloud interpretation of the data (188). While RIP- ChIP and 
PAR-CLIP experiments provide valuable insight, functional analysis of regulation by PUMs is 
necessary to fully define their target mRNAs.  
PUFs enhance deadenylation and mRNA decay 
 PUF regulation in model organisms correlates with mRNA decay. In yeast, PUFs 
enhance deadenylation of target mRNAs through a direct interaction with the CCR4-POP2 
deadenylase complex (173, 195). This direct interaction between PUF and POP2 is conserved in 
yeast, C. elegans, and D. melanogaster. (160, 166, 167, 196, 197).  
Yeast PUFs promote the decay of target mRNAs by recruitment of deadenylases and 
decapping factors (173, 174, 195, 198, 199). In yeast, PUFs bind directly to the Pop2p 
deadenylase subunit and thereby bring the remainder of the CCR4-POP2 deadenylase complex in 
proximity to the target, allowing Ccr4p to carry out deadenylation of the mRNA (173, 195, 199). 
Based on the high degree of conservation among RBDs and interaction with deadenylases, it 
begs the question: do human PUMs regulate mRNA via deadenylation? That question will be 
explored in Chapter 3 of this thesis, within the broader context of investigating specific 
mechanisms of human PUM repression. 
Evidence from yeast also indicates that PUFs can enhance decapping of target mRNAs. 
An intriguing new mechanism of yeast Puf5p regulation involves the eIF4E binding protein 
Eap1p and its association with decapping factors to cause repression. Eap1p is required for Puf5p 
repression and is proposed to associate with Puf5p and Dhh1p to accelerate decapping of the HO 
mRNA (174). Conceptually, it is then feasible that human PUMs could affect mRNA decapping 
or other decay steps including exonucleolytic degradation following deadenylation and 
decapping.   
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One of the founder PUF family members, Drosophila Pumilio, represses translation of 
the hunchback mRNA to control anterior-posterior formation in the developing embryo. The 
development of Drosophila abdominal segments involves localization of two factors, bicoid 
mRNA at the anterior and nanos mRNA at the pole plasm: translation of each gives rise to 
gradients originating at each pole of the embryo (144). Maternally deposited Pumilio and Nanos 
repress hunchback (hb) mRNA in the developing embryo before the zygotic genome is expressed 
after the maternal to zygotic transition (143, 144). 
 Pumilio is maternally deposited and ubiquitously expressed throughout the embryo. Early 
genetic experiments found that cold sensitive Drosophila pum mutant embryos have defects in 
abdominal segmentation: only two of eight segments were formed and later experiments showed 
that Pumilio is essential for formation of abdominal segments (150, 153). Mutations in pum and 
nos cause defects in embryos due to absence of hb repression (153, 200). It was later shown that 
Pumilio could recognize and bind the NRE (144). It was originally surmised that Pumilio 
represses hb by activation of deadenylation, based on the correlation between repression and 
poly (A) tail shortening, which was thought to cause later translational inhibition(160). Years 
later, the Lehmann laboratory injected synthetic mRNAs lacking poly (A) tails or non-adenylated 
histone stem loop RNAs which remain unadenylated into Drosophila embryos and demonstrated 
that a poly (A) tail is unnecessary for Pumilio repression (167). However, the efficiency of 
repression of the non-adenylated reporter was reduced, which argues that the tail plays a role in 
PUM repression (167). Together these data support a deadenylation dependent mechanism of 
PUM regulation in Drosophila. 
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PUFs repress translation  
 Repression of RNAs by PUF proteins is correlated with reduced translation; this 
mechanism could be a direct repression of translation or could occur via secondary effects of 
mRNA deadenylation and decay. Limited data is available that demonstrates a direct effect of 
PUFs on translation. In vitro cell-free translation assays were used to measure direct effects of 
PUFs on translation: the authors found that recombinant yeast and C. elegans PUFs repressed 
reporter mRNAs that contain 3’ UTR sequences of four known mRNA targets (169). While it is 
known that yeast Puf5p interacts with the CCR4-POP2 deadenylation complex to repress the HO 
mRNA, the Wickens lab sought to characterize translational repression of new RNA targets 
using in vitro biochemical assays (169). Yeast Puf5p was added to in vitro translation extracts 
along with reporter RNA containing the 3’UTRs of target genes; then, using this assay, the 
authors demonstrated translational repression of HO, CIN8, DHH1, and RAX2 reporter RNAs 
(169). Another study implicates PUM2 from Xenopus in translational control by directly 
interfering with 5’ cap recognition, thereby blocking initiation complex assembly on the cap 
(171). 
In a recent study, in vitro experiments demonstrated that a complex consisting of human 
PUM2, Ago, and eIF1A formed to block translation elongation independently of miRNA 
association (170). The authors report that PUM2 binds Ago and eEF1A, which is a GTPase 
required for elongation: this complex is purported to inhibit GTPase activity and block 
translation.    
PUMs in physiological processes 
Evidence in the literature suggests that mammalian PUMs are involved in many 
biological processes, including stem cells, cell proliferation, spermatogenesis, and neural 
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function (141, 159, 161, 163, 188, 189, 193, 194, 201). We know that they bind many hundreds 
of targets from RIP-Chip and PAR-CLIP studies, but very little evidence ties human PUM 
binding and regulation to physiological function (141, 161, 188, 189). At the time we began this 
work, human PUM regulatory activity was relatively unstudied in functional assays: by 
association with their relationship to yeast PUFs, mammalian PUMs were believed to be 
repressors but rigorous examination of direct PUM1 and PUM2 repression was absent from the 
literature. In Chapter 3, I will discuss our finding that human PUM1 and PUM2 are potent 
repressors on their own and each can compensate for loss of its paralog. Many studies have been 
done to attempt to clarify the roles of human PUM1 and PUM2 in distinct biological phenomena 
and have provided insight into their functions in mammals. A great deal of information 
pertaining to localization and expression of PUM1 and PUM2 is available in the literature and 
will be discussed in this section. Furthermore, recent literature that proposes putative 
mechanisms of PUM repression in humans will be discussed through examples of mammalian 
systems that study the physiological functions and demonstrated targets and binding partners of 
human PUM proteins, thereby illustrating and highlighting their significance and the need for 
further experimental inquiry. 
Mammalian PUMs function in the germline 
 PUM1 and PUM2 are expressed among most tissue types, arguably with some 
enrichment in the brain and heart (159, 187). Mouse PUM1 and PUM2 are expressed in fetal and 
adult hematopoietic stem cells and in mature blood cells (202). It has also been shown that 
human PUM2 is expressed in embryonic stem cells and germ cells, which contributes to the 
argument that the PUF proteins’ primordial function lies in maintaining the germline (203). 
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PUFs in model organisms have long been known to be involved in germline stem cell 
maintenance (147-149, 151, 204, 205). FBF in C. elegans promotes commitment to the mitotic 
cell cycle by repressing the gld-1 mRNA, which promotes meiosis, thereby controlling 
proliferation of germline stem cells (151). Furthermore, C. elegans FBF represses the fem-3 
mRNA, ultimately regulating the sperm-oocyte differentiation switch (166).  
A gene trap approach was used to inactivate mouse PUM2 by introducing insertional 
mutations to produce a non-functional protein (162). This resulted in reduced testes size, but did 
not indicate that PUM2 is essential for reproduction or viability: the authors thusly speculated 
that PUM2 is required for normal testicular development (162). In a similar vein, 
coimmunoprecipitation experiments showed that the proteins DAZ, which is required for 
spermatogenesis in males, and DAZL are expressed in germ cells bind to human PUM2 (203, 
206, 207). Furthermore, the protein BOL, which in fly is required for progression through 
meiosis in males, forms a complex with PUM2 (208). Such complexes appear to be RNA 
dependent, indicating that the proteins co-occupy the same RNAs (208). More evidence that 
PUM1 plays a role in spermatogenesis was presented recently in a study in which PUM1 null 
males showed a reduction in sperm count and fertility and regulate components in the p53 
pathway (161).  
Together, these studies highlight the likelihood that PUMs play a role in the germline, but 
functional evidence and studies inclusive of regulation by both PUM proteins are needed. 
Overlapping function of PUM1 and PUM2 may complicate the interpretation of these 
experiments: knockout of both proteins is required to fully assess their functions in mammals. In 
Chapters 3 and 4, I present data showing that both PUM1 and PUM2 are repressors that bind the 
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same sequence, further strengthening the argument that both PUMs must be considered in future 
experimental inquiries.  
PUMs are involved in the nervous system   
 The central nervous system (CNS) is composed of intricate networks of different cell 
types transmitting information to one another in a complex and well-organized manner via 
synapses. Specialized cells in the brain receive and respond to signals from the environment and 
from within the body. Healthy cognitive function is dependent on highly regulated signaling 
between cell types to form dynamic networks of information transfer.  
Given the complexity and dynamic nature of neural signaling, it becomes quite clear that 
strictly timed production of genes and their regulated decay is essential for healthy brain and 
CNS function. RNA binding factors play key roles in regulation of genes expressed in the 
nervous system. Thusly, a large number of neurological diseases are caused by defects in RBP 
function, mRNA expression, and translation. For example, Fragile X syndrome is caused by a 
loss of function of FMR1, a gene encoding the RBP FMRP: this mutation is a CGG tri-
nucleotide repeat expansion and can be repeated more than 200 times in the promoter region of 
the gene (209, 210). Reduction of FMRP in the brain results in a number of neurobiological 
changes that are thought to be due to changes in synaptic plasticity and structure, including 
defects in learning and memory, autism-like symptoms, and hyperactivity (209). This is not a 
unique case, as many RBPs function in the nervous system to control mRNA localization and 
translation in synaptic function (211). The PUF family of proteins has been implicated in 
neurological function.  
A large body of work implicates Drosophila Pumilio in neural function, observations that 
laid the foundation for examining mammalian PUMs in the nervous system. A number of 
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Drosophila protein mutants including Pumilio that disrupt long term memory but have normal 
short term memory were identified in a genetic screen and DNA microarray analysis (152). In 
vivo experiments indicate that Pum mutants cause neuronal excitability by way of negative 
regulation of para, which encodes a voltage gated Na+ channel and conversely, that para 
overexpression results in loss of function of Pum which can be rescued with a full length Pumilio 
transgene (154). Genetic experiments in female flies indicate that Pum partially rescues the 
sterility and other defects in neuronal function caused by a mutation in the bem gene (158). In 
Drosophila 3rd instar larvae, Pum affects the neuromuscular junction by binding the eIF4E 3’ 
UTR to reduce its accumulation. Further, Pum localizes to the postsynaptic side of the synapse 
and in loss of function mutants, synaptic boutons are larger and fewer in number: together this 
data implicates Pum in pre- and post-synaptic function (155).   
 Mammalian PUM2 functions in the nervous system (159, 201). Fluorescence microscopy 
identified that PUM2 is found as part of mRNP complexes in rat hippocampal neurons and, 
under conditions of stress by arsenic treatment, localizes to dendritic stress granules (159). In 
later studies in rats, it was shown that loss of PUM2 in developing neurons affects dendritic 
outgrowth, arborization, and synaptic function (201).  In the same study eIF4E mRNA was 
identified by immunoprecipitation with PUM2 and their interaction confirmed by gel gift assays 
(201). Further, eIF4E protein levels were increased by PUM2 knockdown, which provides some 
evidence that eIF4E is repressed by PUM2 (201).  
 PUM2 deficient mice exhibit abnormal behavior, increased locomotor activity, decreased 
body weight, low seizure thresholds, and significant changes to neuronal ion channel expression; 
all of which provide substantial evidence for a role for PUM2 in the nervous system (212). More 
recent work found that PUM2 is localized to the mouse neuromuscular junction and that PUM2 
28  
knockdown by shRNA transfection led to upregulation of the neurotransmitter 
acetylcholinesterase (AChE) (213). Recent studies show that PUM2 binds the voltage gated Na+ 
channel transcript (NaV1.6) to regulate Na+ ion channels in neurons: loss of PUM2 results in 
increased current across Na channels and increased numbers of action potentials (214).  
One intriguing example of PUM function in the nervous system is a recent study looking 
at traumatic brain injury in mice. Upon brain injury, astrocytes (a type of glial cell) undergo a 
process called reactive astrogliosis, which is thought to occur in response to increased Ca2+ 
levels and has both positive and negative affects on surrounding injured tissues. During this 
process, N-cadherin, which, owing to its 3’UTR PRE, the authors speculate is normally 
translationally repressed by PUM2, is upregulated in response to high Ca2+ and downregulated 
PUM2 expression (215).  They demonstrate PUM regulation of N-cadherin using a reporter 
system, and depletion of the PUM2 RBD abrogates regulation of N-cadherin in their study (215). 
The importance of PUM regulation in the nervous system is evident and future work should 
focus on providing functional evidence of individual PUM repression of specific targets in 
neurons.  
PUMs, miRNAs, and cell proliferation 
Recent work suggests that PUMs interact functionally with the miRNA regulatory 
pathway (163, 170, 188, 194). p27 downregulation is required for entry into the cell cycle from 
quiescent cells and the authors suggest that a structural change in the p27 mRNA induced by 
PUM1 binding, which renders miR221/222 sites accessible for binding and repression, was 
responsible for miRNA mediated repression (163). Their data does point to a role for human 
PUM1 in cell proliferation, which is consistent with PUM function in other studies and PUF 
function in model organisms (161, 194). In the same vein, the E2F3 oncogene, which is typically 
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overexpressed in cancers, is reported to be a target of concerted repressive action between miR-
503 and human PUMs in bladder cells (194). Thus, in bladder carcinomas in which PUMs and 
miRNAs are downregulated, repression of E2F3 is significantly reduced and the protein is 
upregulated. The authors postulate a similar mechanisms used by PUMs to open up secondary 
structure to render the miRNA site accessible by miR-503 and vulnerable to miRNA-mediated 
repression. Given the sheer number of miRNA sites already identified in mRNAs, PUMs and 
miRNAs likely share many targets. PUFs and miRNAs share corepressors: both recruit members 
of the CCR4-NOT deadenylase complex to enhance deadenylation and subsequent decay of 
mRNA targets. Thus, miRNA and PUM pathways in humans may cooperate to confer regulation 
of mRNA targets.  
Discovery of the mechanism of repression by PUMs is essential to understand their 
biological functions 
 The work outlined in this dissertation examines the mechanisms by which human PUMs 
repress their target RNAs. Little is known about which human biological processes are regulated 
by PUMs, and even less is known about how they go about doing so. In this dissertation, I 
completed work with the ultimate goal of understanding the RNA targets and mechanisms of 
human PUM repression.   
I will describe tools to address mechanistic questions related to PUM repression in 
Chapter 2. In Chapter 3, I will demonstrate use of the tools developed in the previous chapter to 
address the hypothesis that PUMs are repressors and to study mechanisms of human PUM 
repression. Specifically, I will show that PUM1 and PUM2 repress a luciferase reporter 
containing 3 PREs in its 3’ UTR. In Chapter 4, I will discuss the identification of high 
confidence targets of human PUMs using a deep sequencing technique, RNA-Seq, and will 
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compare the results from that study with those already published. It is my hope that the results of 
this study illuminate the biological significance of PUM regulation, and provide insights into 
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Figure 1.1 PUMs bind single stranded RNA via their RNA binding domains.  
A cartoon depiction of a human PUM RNA binding domain interacting with its consensus 8 nucleotide binding 
sequence, termed the PUM response element. Stick diagrams of human PUM1 and PUM2 are depicted below, 
























Figure 1.2 PUMs bind single stranded RNA via their RNA binding domains.  
A cartoon depiction of a human PUM RNA binding domain interacting with its consensus 8 nucleotide binding 
sequence, termed the PUM response element. Stick diagrams of human PUM1 and PUM2 are depicted below, 


















Overall: 75% IdenƟcal PUF repeats: 91% IdenƟcal
Adapted from Wang et al., 2002, Cell, Vol. 110, Galgano et al., 2008, PLoS ONE, Vol. 3
Figure 1.2 PUM response element
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Abstract 
Post-transcriptional regulatory mechanisms are pervasive in the control of gene 
expression. Regulatory sequences within transcripts can control RNA processing, localization, 
translation efficiency, and stability of the RNA. Regulation is mediated by a diverse set of RNA 
binding regulators, including proteins and RNAs, which interact with specific mRNA sequences 
that are often found in untranslated regions. The potential for vast post-transcriptional control 
exists: mammalian mRNAs contain extensive untranslated regions and their genomes encode 
many hundreds of RNA binding proteins and non-coding RNAs. Facile quantitative methods are 
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necessary to study the activities and mechanisms of regulatory sequences and the RNA binding 
factors that recognize them. Here we discuss the design and implementation of luciferase-based 
reporter assays to measure the effect of regulatory RNA sequences on protein and RNA expres- 
sion. Protocols are described for transfection of the reporter into cells, measurement of protein 
expression levels with luciferase activity assays, RNA purification, and measurement of mRNA 
levels by reverse transcription and quantitative polymerase chain reaction. For each assay, 
troubleshooting of common problems and critical controls are discussed. We present our 
optimized techniques and data from studies that measure specific and direct repression (i.e. 
negative regulation) of mRNAs by members of the PUF family of RNA binding proteins in 
cultured human cells. 
Introduction 
 Gene expression - the complex process of decoding genetic information from DNA to 
RNA to protein – is controlled by numerous regulatory factors at multiple steps.  Messenger 
RNA (mRNA) is synthesized in the nucleus where, before its export to the cytoplasm, introns are 
spliced out and 5’ and 3’ ends are capped and polyadenylated, respectively (1).  Once in the 
cytoplasm, mRNA is translated, localized, stored, or degraded (1, 2).  These cytoplasmic 
processes can be regulated by sequences often found in untranslated regions (UTRs) within the 
mRNA.  Regulatory sequences control translation efficiency, RNA stability, and in some cases 
act as zip codes that direct the mRNA to specific intracellular locations: in many instances, trans-
acting factors recognize these regulatory sequences to control the message (2, 3).  Regulation can 
be positive or negative.  Hundreds of potential regulatory proteins and small RNAs are encoded 
within mammalian genomes; therefore, there is enormous potential for RNA-mediated regulation 
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of gene expression.  Quantitative methods that can measure and dissect post-transcriptional 
regulatory mechanisms are necessary. 
 Regulation of natural mRNAs can be detected using techniques such as Northern blotting 
or reverse transcription coupled with quantitative polymerase chain reaction (RT-qPCR).  To 
detect post-transcriptional regulation of protein expression, Western blotting can be performed 
with a specific antibody, but is often limited in detection range and sensitivity.  On a global 
scale, changes in RNA levels can be analyzed using microarrays or high-throughput RNA 
sequencing approaches.  Likewise, global changes in protein synthesis can be assessed, for 
instance by labeling with amino acids containing stable isotopes coupled with relative 
quantitation by mass spectrometry.  Yet these approaches are technically demanding and require 
sophisticated instrumentation.  While these approaches are valuable, outside of a genetically 
tractable model system, dissection of the regulatory sequences in natural mRNAs can be difficult 
if not impractical. 
 Reporter genes have proven valuable to isolate regulatory elements and dissect their 
impact on expression of the reporter mRNA and protein.  Reporters provide a quantitative 
readout at both the RNA and protein levels.  Insertion of a regulatory sequence into the context 
of a reporter gene provides a powerful test for its activity.  Expression can then be monitored at 
both the RNA and protein level to detect the elements effect on translation and mRNA stability.  
Reporter protein assays offer broad dynamic range of detection with increased sensitivity relative 
to other protein detection assays such as Western blotting.  In this context, the regulatory 
sequence can be dissected, manipulated and mutated.  In this manner, the minimal regulatory 
element can be delineated and mutations that alter its function can be identified.  The regulatory 
impact of specific trans-acting factors can be investigated by depleting the factor using RNA 
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interference or by over-expressing a wild type or dominant negative form of the factor and then 
measuring its impact on reporter mRNA and protein expression.  Once established, the reporter 
gene assay can also provide a powerful tool for screens designed to identify trans-acting 
regulators, responses to stimuli, and to identify molecules that can alter the regulatory response. 
 Here we describe a luciferase reporter gene-based approach to study mRNA regulation.  
This chapter is designed especially to assist researchers new to investigating post-transcriptional 
regulation, but the information will likely prove useful to experienced scientists.  First, the 
regulatory sequence of interest is engineered into the appropriate location of the reporter gene.  
While our focus is on regulatory sequences located in the 3’UTR, the approaches are adaptable 
to analysis of 5’UTR elements.  The reporter gene is introduced into a model cell line by 
transfection.  To measure protein expression, luciferase activity assays are performed; the 
amount of light produced is directly proportional to the amount of protein expressed.  To 
measure effects on mRNA expression, the luciferase mRNA levels are measured by RT-qPCR. 
 We demonstrate the utility of this approach in the study of RNA regulation by PUF 
proteins.  PUF proteins are RNA binding proteins that recognize specific regulatory sequences 
typically found in the 3’ UTR of certain mRNAs (3).  In model organisms, they are known to 
repress protein expression; however, the activities of human PUF proteins, PUM1 and PUM2, 
were not known (3).  PUM1 and PUM2 bind to the same RNA sequence, termed the Pum 
Response Element (PRE) (4-7).  To study their function, we introduced PREs into the 3’UTR of 
a Renilla luciferase reporter gene.  We found that both PUMs repress reporter protein expression, 
measured by luciferase enzyme activity assays.  Negative regulation by the PUMs correlates with 
a reduction in reporter mRNA level, as measured by RT-qPCR and Northern blotting (8, 9).  
Importantly, mutations in the PRE that inactivate PUM1 and PUM2 binding completely alleviate 
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regulation of the reporter (8, 9).  This powerful system provides a means of interrogating the 
mechanism of repression, and allowed us to discover the role of specific RNA degrading 
enzymes (8, 9).  A similar approach can be taken to study other RNA regulatory sequences 
and/or trans-acting factors including activators or repressors.   
Description of methods 
Overview 
Here we outline the steps needed to optimize the reporter-based model for studying RNA 
regulatory sequences including design of the reporter construct, transfection optimization, and 
measurement of reporter protein and RNA levels (Fig. 2.1).  We discuss critical controls, data 
analysis, and keys to success.  We provide protocols and examples resulting from our studies of 
mRNA regulation by PUF proteins (8, 9). 
Reporter construct design 
When designing reporter gene constructs, there are several key considerations: reporter of 
choice, promoter, 3’ UTR, and transfection strategy.  Numerous reporter genes are available, the 
most popular of which are luciferases (e.g. derived from firefly and Renilla) and fluorescent 
proteins (e.g. green fluorescent protein, GFP).  Luciferase assays are sensitive and have a broad 
dynamic range, and different luciferases with unique substrates are available to permit 
multiplexing.  For example, in our research on PUF protein mediated mRNA regulation, we used 
a dual luciferase reporter approach: Renilla luciferase serves to monitor regulation and firefly 
luciferase serves as an internal control (Fig. 2.2).  Luciferases are amenable to multi-well plate 
analysis and they report on relative differences between populations of cells.  Fluorescent 
proteins are commonly analyzed on a per cell basis by high content screening or flow cytometry 
and reported as the percentage of cells expressing the reporter.  Reporters that have been 
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optimized for expression in mammalian cells and engineered to minimize cryptic regulatory 
sequences are ideal to maximize expression changes specific to the test sequence of interest  (10, 
11).  When choosing the reporter and its corresponding plasmid expression vector, it is important 
to ensure they do not already contain the regulatory sequence. 
An important consideration is the promoter driving reporter expression.  The chosen 
promoter should be active in the chosen cell type.  The promoter strength can have an impact on 
the ability to detect regulation; if expression is too strong, the regulatory mechanism can be 
overwhelmed.  If the promoter is too weak, the signal to noise ratio would be too low.  Ideally, 
the promoter should be minimal in size to avoid introducing unnecessary variables that might 
confound analysis. 
The reporter construct should contain a well-defined transcription unit, including a 
defined transcription start site, 5’ UTR and 3’UTR.  Some reporter genes also contain an 
efficiently spliced intron, which may be beneficial for optimal expression.  For analysis of 
3’UTR mediated regulation, a minimal 3’ UTR with a strong, well-defined 
cleavage/polyadenylation site is important.  Ideally the 3’ UTR should contain one or more 
unique restriction sites into which the test regulatory sequence can be cloned.  Mammalian 
cleavage/polyadenylation signals can be somewhat degenerate; therefore, the SV40 signal is a 
good choice for efficient production of a well-defined 3’ end. 
To create a regulated reporter gene, the regulatory sequence of interest must be cloned 
into the proper context, such as the 3’UTR.  As a critical control, create an unregulated reporter.  
To do so, the regulatory sequence should be mutated to inactivate its activity.  If inactivating 
mutations are not yet known, the original reporter gene lacking a regulatory sequence is an 
appropriate control.  The inserted regulatory sequence may be a minimal binding site for a 
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sequence specific regulatory protein (e.g. the Pum Response Element) or larger RNA sequence 
(e.g. a full length 3’UTR).  A shorter sequence is less likely to contain multiple regulatory 
elements that affect expression.  Be aware that full length 3’ UTRs may contain alternative 
cleavage/polyadenylation signals that have the potential to cause heterogeneous processing of the 
reporter’s 3’ end. 
Specific features will also be required depending on the transfection strategy used.  
Include a selectable marker if you plan to create stable cell lines.  Constructs for transient 
transfections may include a second reporter that serves as an internal transfection control.  
Alternatively, a second plasmid can be co-transfected as the control.  Lentiviral regulatory 
elements and strategy may be necessary to overcome difficulties associated with transfecting 
primary cells.   
Transfections 
Lipid-based transfection reagents that offer high efficiency with minimal impact on cell 
health are ideal for introducing reporter plasmids into the majority of cell lines.  Cell type-
specific protocols are available either from the transfection reagent manufacturer or in the 
scientific literature.  For best results, optimal transfection conditions should be determined 
empirically (12).  The transfection reagent will dictate the optimization variables.  Important 
variables include the lipid to DNA ratio, mass of DNA, and the exposure time. 
During the optimization phase of establishing transfection conditions, a single reporter 
can be used, such as the unregulated reporter.  This removes any experimental treatment 
variables and focuses on achieving the best transfection conditions possible.  Monitor both 
reporter expression and viability to find the optimal balance of high reporter expression with 
minimal toxicity from the procedure.  For cell types that are sensitive to the transfection and 
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exhibit reduced cell health, incorporate a medium change after transfection using medium pre-
equilibrated under optimal CO2 and temperature conditions.  Also, give consideration to the 
plasmid purification method used.  Traditional purification chemistries can co-purify endotoxin 
(lipopolysaccharide from E.  coli outer membrane) with the plasmid DNA that can cause toxicity 
or other inadvertent effects on cell biology.  Choose a purification chemistry designed to give 
transfection-quality DNA with minimal endotoxin.  Replicate transfections should always be 
performed to assess variability in the transfection technique.  Highly variable transfections will 
negatively impact your ability to measure regulation.  To assess and normalize sample to sample 
variation in transfection efficiency, it is advisable co-transfect an internal control.  In the dual 
luciferase strategy, a plasmid expressing firefly luciferase is co-transfected with the Renilla 
luciferase reporter gene plasmid, and firefly luciferase activity is used to normalize the resulting 
data (see below).   
Critical controls should be included in all transfection experiments.  Untransfected and/or 
mock transfected cells are essential to measure background signal in the luciferase activity 
assays (and later, RNA assays).  An unregulated reporter such as the reporter plasmid lacking 
regulatory sequences or containing mutated inactive regulatory sequences is crucial for 
discerning effects of a regulatory sequence of interest. 
Cell culture considerations 
There are several points to consider for optimizing performance; most are cell type-
specific.  The number of cells plated per well will depend on the plate format used, the cell line’s 
optimal growth density (e.g. whether they thrive with contact or respond to contact inhibition), 
the growth rate, and intended length of the assay.  The latter two points should be considered 
together, as the goal is to prevent overgrowth and exhaustion of the medium throughout the 
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duration of the assay.  These effects will negatively impact cell health and thus the reliability of 
reporter assays. 
Both the passage number and the confluence of the cells prior to transfections can affect 
the reproducibility of cell based assays.  Cells generally take several passages after thawing to 
exhibit regular healthy growth patterns.  Using them too soon will make them more likely to 
experience toxicity during the transfection.  Later passage cells are susceptible to genetic 
changes that could alter the biological response of interest.  Be cautious until you have 
determined the reliable passage number range in which the cells’ responses are stable.  The 
confluence prior to plating for transfection can also affect overall reproducibly: allowing cells to 
overgrow just prior to transfection can drive them into a senescent state, making them less 
amenable to transfection and exogenous gene expression.  Monitor confluence closely and 
passage at a consistent density for optimal results. 
The conditions during the plating process are another important consideration for optimal 
results.  For adherent cells, it is important to allow a recovery period after trypsinization during 
which surface proteins recuperate and cells adhere to culture plates.  For 96 well plate formats, 
the outer perimeter wells should be filled with medium, but no cells, to avoid causing detrimental 
edge effects.  Edge effects are caused by evaporation from wells in the outer edges of the plate 
and may produce artifacts.  The choice of plate should be considered carefully: luminescent cell-
based assays should employ white tissue culture treated plates to maximize reflection and signal 
intensity.  This is in contrast to fluorescent assays, which are typically performed in black plates 
to minimize background signal.  Another key consideration is that signal bleed through between 
wells may be problematic if there is a wide range of signal intensity generated within a single 
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plate, thus, it is important to note that plates vary widely and that some may perform better than 
others. 
Balance of multiple plasmids 
It is often desirable and advisable to incorporate multiple plasmids into the transfection.  
When doing so, it is important to maintain the optimal transfection conditions.  From there, it is 
simply a matter of adjusting the ratio of the reporter plasmids to find the best balance for your 
assay.   
The most common reason to transfect multiple plasmids is to include an internal control 
to normalize for variation in transfection efficiency of the experimental reporter.  The internal 
control should be constitutively expressed and, ideally, of the same vector backbone as the 
experimental reporter (for example, see Figure 2.2).  Include the internal control as a minimal 
fraction of the total DNA transfected that still gives significant signal above background.  To 
determine this, compare the signal from untransfected or mock transfected cells to that of cells 
transfected with increasing ratios of control to experimental plasmid.  The signal from individual 
reporter plasmids and the internal control should be at least 3 standard deviations above the 
background signal.  Typical mass ratios of experimental to internal control plasmid are in the 
range of 2:1 and 20:1. 
An effector plasmid may be included to express a putative regulator, such as a trans-
acting RNA binding protein.  Effector plasmids are typically the highest proportion in the total 
transfected plasmid pool.  Luciferase-encoding plasmids optimized for bright, efficient 
expression, can be included at relatively low amounts while still maintaining high signals above 
background, making them ideal for multi-plasmid transfections.  Determine the minimum 
amount of reporter plasmid that produces significant signal above background.  If studying a 
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repressor, it is important to leave enough range above background to accurately detect decreases 
in reporter regulation.  The remainder of the plasmid pool may then be used to titrate in the 
effector plasmid.  The total amount of plasmid DNA must be balanced to maintain the optimal 
mass of transfected DNA.  When necessary, use an empty plasmid vector to balance the total 
mass.  Ideally the empty vector is identical to the effector plasmid except that it lacks a protein 
coding region.  In any experiment testing the impact of an effector plasmid, always include the 
following critical control: co-transfect the plasmid lacking the effector protein coding region.  
Alternatively, co-transfect a mutated inactive form of the effector; however, be aware that over-
expressed mutant proteins may potentially have a dominant negative effect. 
Protocol: Transfection of exogenous luciferase reporters 
Here we describe transfection conditions in 96 well format for subsequent analysis of 
luciferase protein expression.  The protocol is based on our work analyzing PUF mediated 
mRNA regulation by human PUM1 and PUM2 in human HEK293 cells (8).  Transfections for 
RNA analysis can be performed as described below, but should be scaled up to yield sufficient 
amount of RNA.  For instance, a 6 well dish format will produce 10-20 µg of cytoplasmic RNA.   
1. Select mammalian reporter vector.  We chose psiCHECK™-1 (Promega) which contains key 
features shown in Figure 2.2, including a constitutive SV40 promoter, the coding sequence 
for Renilla luciferase, a minimal 3’UTR with unique restriction sites, and an efficient 
cleavage/polyadenylation signal.  To measure regulation by human PUFs, PUM1 and PUM2, 
3 copies of the Pumilio Regulatory Element (PRE) were inserted into the 3’ UTR of to 
produce psiCHECK-1 3xPRE (Fig.  2.2).  As unregulated reporters, we use psiCHECK-1 No 
PRE, which lacks a PRE element, or psiCHECK-1 3xPREmt, which containing 3 mutant 
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PREs.  As an internal control, we used the plasmid pGL4.13 (Promega) that encodes firefly 
luciferase with expression driven by the SV40 promoter (Fig.  2.2).  To express effector 
proteins, we use the mammalian pFN21A vector (Promega) as it contains a strong CMV 
promoter to drive effector protein expression as a protein fusion to Halotag, which can be 
specifically detected by fluorescent labeling. 
2. Purify plasmids using the PureYield™ Plasmid Midiprep System (Promega) or similar 
chemistry yielding transfection-quality plasmid DNA. 
3. Measure the concentration and purity of the DNA using a spectrophotometer. 
4. Culture HEK293 cells at 37°C under 5% CO2 in DMEM and 10% FBS.  Passage at 70-90% 
confluence.  Use cells between 5-40 passages. 
5. For reporter protein assays, plate cells in sterile, tissue culture-treated, white walled 96 well 
plates at 2 x 104 cells per 100µl per well.  Allow the cells to recover overnight. 
6. Transfect cells with FuGENE® HD (Promega) following the manufacturer’s protocol.  Use a 
3:1 ratio of FuGENE HD:DNA.  Allow DNA to complex with FuGENE HD for at least 10 
but not more than 15 minutes at room temperature.  Add a total mass of 100ng DNA per well 
of 96 well plate.  Here are two examples of multiple reporter transfections: 
a. For dual reporter transfections without effector, transfect 75ng psiCHECK-1 reporter 
with 25ng pGL4.13 internal control per well.   
b. For dual reporter transfections with effector, transfect 10ng psiCHECK-1 reporter 
with 5ng pGL4.13 and a total of 85ng pFN21A-based effector expression plasmid per 
well.  To titrate in the effector, divide the 85ng mass of pFN21A between effector-
containing pFN21A (0-85ng) and pFN21A control (85-0ng, proportionately).  In this 
case, we used pFN21A empty vector as the negative control. 
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7. Return cells to incubator for 48 hours. 
Reporter protein analysis 
Reporter protein assay 
Luciferase activity assays are a convenient, rapid way to measure luciferase reporter 
protein expression.  Light production, catalyzed by luciferase enzyme activity, is measured using 
a luminometer.  Depending on the reaction chemistry, luciferase activity can be measured in a 
reaction with brief, high light output, known as flash format, or in a format that produces 
stabilized light output but reduced brightness.  Use of flash reagents requires use of substrate 
injectors built into the detection instrument for immediate readings; while use of a stabilized 
light output is more amenable to multiwell plates.  Assays can be performed by adding substrate 
to cell lysates or directly to cells in culture (i.e.  homogeneous assays).  The latter option reduces 
manipulation and hands-on time and is highly recommended for 96 well analyses.  We use a dual 
luciferase assay format in which both Renilla reporter and firefly internal control can be 
sequentially measured in the same sample.  Ensure all reagents and plates have been pre-
equilibrated to room temperature before performing the assay.   
The optimal time after transfection necessary to detect reporter activity is another 
important consideration.  For early optimization experiments, defaulting to a convenient time 
~24 hours after transfection is often sufficient.  However, regulatory sequences will influence the 
peak expression time frame.  Before experimental conditions are finalized, analyze replicate 
transfections at a range of time points to determine the time that gives the best measure of the 
experimental effect.  Typically an optimal time is 18-48 hours after transfection.  Avoid 
prolonged incubations in which cells might become overgrown, deplete their medium, and die. 
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Reporter assay data analysis 
Analysis of reporter activity data is a multistep process and, if done diligently, will allow 
monitoring of experimental design and execution quality.  This gives the means to quickly 
identify and troubleshoot issues that can arise.  There are 3 phases to analyzing the data: 
1. Evaluate raw data (luciferase data are expressed as Relative Light Units, RLU):   
a. Calculate the mean background.  Background refers to the luciferase signal from 
untransfected or mock transfected cells.  In dual reporter experiments, you will have a 
mean background for firefly and Renilla luciferases.   
b. Subtract the mean background from the corresponding RLU values from each 
transfected sample. 
Background subtracted RLUfirefly = RLUfirefly – mean Backgroundfirefly 
Background subtracted RLURenilla = RLURenilla – mean BackgroundRenilla 
c. Calculate the mean signal from replicates of background subtracted firefly and 
Renilla data and assess variability (Fig.  2.3A and 2.3B) 
High variability between samples can indicate inconsistency in plating and/or 
transfections.  When possible, use master mixes of common components.  Strive for accuracy 
and precision in pipetting technique by using calibrated multichannel pipettes, changing tips 
between replicate pipetting, and ensuring even cell suspension during plating. 
The internal control should remain relatively consistent across all transfected samples and 
be at least 3 standard deviations above background.  The test reporter may fluctuate depending 
on the effect of the experimental variable.  Variable internal control data may indicate variations 
in transfection efficiency.  Normalization of your reporter to the internal control in the next stage 
of data analysis will allow you to correct for this variation (13).  In some instances an effector 
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may alter internal control expression.  A strategy to compensate for this is to use the same vector 
backbone for both the reporter and internal control, varying only the reporter and the test 
regulatory sequences (13).  In this way, the internal control will normalize the effects that are 
independent of the test regulatory sequences.   
2. Normalize reporter data by calculating the Relative Response Ratio (RRR): 
a. For each sample, divide the reporter luciferase value by the corresponding internal 
control luciferase value to yield a Relative Response Ratio (13).  Use background 
subtracted RLU for this calculation.  The luciferases used for the reporter versus the 
internal control will depend on your experimental design. 
RRRregulated = RLUregulated reporter / RLUinternal control 
RRRunregulated = RLUunregulated reporter / RLUinternal control 
b. Calculate the mean of all replicate RRR and assess variability (Fig.  2.3C). 
 
3. Calculate change for all samples to determine the effect of the regulatory sequence on protein 
levels 
a. % repression = [1 – (RRRregulated / mean RRRunregulated )] x 100 ,  
or for activators, calculate fold change = (RRRregulated / mean RRRunregulated ) 
b. Determine the mean of the replicates and assess variability (Fig.  2.3D). 
Protocol:  Reporter activity analysis using dual reporter assay  
The following protocol is based on our work analyzing PUF mediated mRNA regulation 
by human PUM1 and PUM2 in human cells and is a continuation of the protocol outlined above 
(8).   
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1. Forty-eight hours after transfection, measure luciferase activity with the Dual-Glo® 
Luciferase Assay System (Promega) using a GloMax®-Multi+ plate-reading luminometer 
(Promega) according to the manufacturer’s instructions. 
2. Analyze the data: 
a. Average the firefly and Renilla RLUs from the mock transfected wells.  This is 
background. 
b. Subtract the average background from the corresponding luciferase RLUs in each 
individual well. 
c. Calculate the mean Renilla RLU and standard error of the mean (SEM) for each 
background-subtracted sample set.  Do the same for the firefly luciferase RLU values.   
d. Normalize data by calculating the Relative Response Ratio (RRR).  Using the 
background-subtracted values for each sample well, divide the experimental reporter 
value (Renilla) by the corresponding internal control value (firefly activity from 
pGL4.13).  Calculate the mean RRR and Standard Error of the Mean (SEM) for each 
sample set and graph the resulting data.  As an example, Figure 2.4 shows RRR 
values from three reporters that we used to measure PUM Response Element 
mediated repression of Renilla luciferase expression in HEK293 cells.  Reporters, 
described in Figure 2.2, include the unregulated psiCHECK-1 No PRE reporter and 
the regulated reporter, psiCHECK-1 3xPRE, which is bound and repressed by 
endogenous PUF proteins, PUM1 and PUM2.  The unregulated reporter psiCHECK-1 
3xPREmt, wherein the PRE was mutated to prevent PUF binding was also tested 
(Fig.  2.4).  In this example, the presence of wild type PREs cause a substantial 
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reduction in the RRR values, relative to the unregulated No PRE reporter (Fig.  2.4).  
Mutation of the PREs alleviated the repressive effect (Fig.  2.4). 
e. To determine the impact of an effector protein on the regulation, RRR values can be 
calculated for psiCHECK-1 No PRE, psiCHECK-1 3xPRE, and psiCHECK-1 
3xPREmt reporters at each mass of transfected effector plasmid (Fig.  2.4, effector 
plasmid amounts of 0, 20, 50, or 85ng).  Recall that the total mass of transfected DNA 
in each sample is held constant by balancing with expression vector lacking the 
effector protein coding sequence.   
f. Calculate the percent repression caused by the regulatory element.  For PUF mediated 
repression via the 3xPRE (8, 9), the equation % repression = [1 – (RRRpsiCHECK-1 3xPRE 
/mean RRRpsiCHECK-1 no PRE)] x 100 was used.  RRRpsiCHECK-1 3xPRE are from the 
samples transfected with psiCHECK-1 3xPRE and pGL4.13.  Mean RRRpsiCHECK-1 no 
PRE is from the samples transfected with psiCHECK-1 No PRE and pGL4.13.  The 
resulting percent repression data are shown in Figure 2.4. 
g. To ascertain the change in PRE mediated repression caused by the effector, percent 
repression values are determined for psiCHECK-1 3xPRE relative to unregulated 
psiCHECK-1 No PRE and compared to the values from samples transfected with 
empty effector plasmid (Fig.  2.4, effector = 0 ng).  In the example shown in Figure 
2.4, the effector was a dominant negative form of the deadenylase enzyme CNOT8, 
which specifically reduced percent repression of the 3xPRE reporter in dose 
dependent manner (8, 9) 
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Reporter RNA analysis 
RNA purification 
 Mammalian RNA should be purified quickly after harvesting cells in an RNase free 
environment, using RNase free reagents and equipment.  Aerosol barrier tips should be used for 
all pipetting steps.  A number of resources are available for more information on the maintenance 
of RNase free conditions (14, 15).  Multiple methods are available for purifying RNA.  Most 
techniques yield sufficiently high quality RNA for this application, but some purification 
systems offer advantages through streamlined methods that minimize potential error, save time, 
and allow batch processing.  Regardless of the purification protocol used, it is always best to 
purify RNA from fresh cells.  Trizol extraction uses phenol and guanidinium isothiocyanate to 
isolate RNA and is an inexpensive means of RNA purification.  Kits for RNA purification are 
readily available from a variety of manufacturers and use column purification to isolate RNA.  
Keep in mind that the binding capacity of columns in each kit varies.  Column purification kits 
and automated nucleic acid purification systems are fast and reliable, and will aid in processing 
multiple samples in a short period of time to consistently yield high quality RNA.  Our 
laboratory uses a modification of the automated Maxwell® 16 LEV simplyRNA purification 
system (Promega), which allows us to purify high quality RNA samples in about an hour.   
 For RNA extractions, scale up transfections to larger well dishes depending on the RNA 
yield desired.  Although RNA can be extracted from the same 96 well format used above, higher 
yields are typically needed for RNA analysis, especially during optimization.  Scale up by 
adjusting all components of the transfection proportionately to the differences in well surface 
area.    
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 Contaminating plasmid DNA present in RNA preparations is often the main culprit 
contributing to high background signal in qPCR assays.  A number of methods can be used to 
reduce such background in RNA measurements.  DNA can be reduced by isolating the 
cytoplasmic pool of RNA.  This involves mild detergent-based cell lysis and removal of nuclei 
by centrifugation prior to extracting the RNA.  As this is not sufficient to remove all plasmid 
DNA, additional DNase treatment is necessary (discussed in next section). 
 Once an RNA sample has been obtained, perform quality control measurements to assess 
its purity and integrity before proceeding with analysis of gene expression.  The UV absorbance 
of RNA should be measured to determine concentration and purity.  A 260nm/280nm ratio of 
1.8-2.2 indicates sufficient purity.  Next, to check integrity of the RNA, perform formaldehyde 
denaturing agarose gel electrophoresis on 0.5-1 µg of RNA (14).  The 18S and 28S ribosomal 
bands on the gel should be clear and crisp, not smeared, and the 28S band should be roughly 
twice the intensity of the 18S.  Alternatively, a Bioanalyzer (Agilent) can be used to assess RNA 
integrity. 
Removal of contaminating DNA using DNase enzyme  
 Plasmid DNA contamination in RNA samples can mask changes in gene expression 
detected by qPCR; therefore, it is crucial to treat RNA samples extensively with RNase-free 
DNase enzyme.  Standard DNase treatments included during some purification protocols can be 
effective at minimizing genomic DNA; however, plasmid DNA may persist after purification.  
Therefore, an additional extensive DNase treatment after RNA purification should be included.  
Importantly, divalent metal ions necessary for DNase activity pose a hazard to the integrity of the 
RNA samples:  heating in the presence of these divalent metals hydrolyzes RNA.  Therefore, do 
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not heat inactivate DNase.  Instead, precipitate the RNA with ethanol and resuspend in a solution 
of EDTA and EGTA chelators to protect the RNA during subsequent heating steps. 
Reverse transcription and quantitative PCR analysis of reporter gene expression 
 Reverse transcription is performed to create complementary DNA from the RNA.  
Reverse transcriptases require magnesium.  Depending on the volume of RNA used in the RT 
reaction it may be necessary to adjust the magnesium concentration to offset the presence of 
chelators.  Reverse transcriptases also require a primer to initiate transcription.  This primer can 
be gene specific for detection of a single RNA, oligo-dT for detection of poly-adenylated 
mRNAs, or random hexamers for detection of all RNAs.  All steps are performed using RNase 
free aerosol barrier pipette tips.   
 Once cDNA has been prepared, sequences are detected using gene-specific primers in 
quantitative PCR.  Several qPCR chemistry choices exist based on the use of probes, fluorescent 
primers or DNA binding dyes (16-19).  Variability in qPCR measurements can be assessed by 
performing replicates including technical and biological replicates.  To minimize variability, use 
master mixes and calibrated multichannel pipettes when possible.  Also, always use low 
retention aerosol barrier pipette tips. 
Critical controls must be performed to interpret the data with confidence.  First, a control 
PCR is performed in the absence of nucleic acid.  This “no template control (NTC)” measures 
environmental contamination.  Another critical control is performed in the absence of reverse 
transcriptase but in the presence of RNA template.  qPCR is then performed on these “no RT 
control” samples to assess the presence of contaminating DNA in the RNA preparation or 
identify nonspecific products generated by the qPCR primers.   
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Quantitative PCR primer design considerations 
  There are many resources widely available to aid in the design and optimization of qPCR 
assays  (16, 18-20).  We suggest consulting the technical manual of the qPCR kit you plan to use 
for specific optimization parameters.  The design of efficient and specific qPCR primer sets is 
crucial for detecting changes in gene expression.  There are a number of helpful resources and 
software programs available to assist in primer design such as Primer 3 and Lasergene 
(DNASTAR) (20).  The primary goal of qPCR primer design is to create primers that amplify a 
specific small target, generally between 75 and 250 nucleotides in length.  In general, primers 
should be 17-25 nucleotides in length and contain between 50 to 60 percent GC content.  Primer 
3’ ends should not be complementary to avoid hairpin or dimer formation.  We typically aim to 
create primers with melting temperatures near 60°C.  Commercial primer sets are also available 
but may require optimization.  Perform a BLAST search using the primer sequences against the 
relevant genome database (NCBI) and the reporter plasmid sequences to confirm specificity of 
the primers for target sequences.  New primer sets should be validated by confirming that they 
amplify the expected PCR product, as determined by DNA agarose gel electrophoresis.  For each 
new primer set, qPCR conditions are optimized for primer concentration and annealing 
temperature.  A standard curve is used to evaluate amplification efficiency (19, 20).  Use 
conditions under which the primers are most efficient (between 90 and 110%) for subsequent 
qPCR reactions.  Multiple replicates should be performed to assess experimental variability. 
qPCR data analysis 
Reporters and internal control mRNAs can be measured in separate qPCR reactions.  
Alternatively, both can be measured simultaneously in the same sample using a multiplexed 
qPCR assay.  Multiplexed qPCR relies on measurement of fluorescence from primers containing 
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different fluorophores.  For either format, qPCR raw data are expressed as cycle threshold (Ct) 
values.  For each sample, the Ct value of the reporter is normalized to the Ct value of the internal 
control, thereby normalizing for variation in transfection efficiency.  To do so, calculate the ΔCts 
as follows (14-16, 18-20): 
ΔCtregulated = Ctregulated reporter – Ct internal control 
ΔCtunregulated = Ctunregulated reporter – Ct internal control 
To assess the standard error, calculate both the regulated and the unregulated results relative to 
the mean value of the unregulated ΔCt.  Use the comparative ΔΔCt method to calculate ΔΔCt for 
each sample (16-20): 
ΔΔCtregulated = ΔCtregulated – mean ΔCtunregulated 
ΔΔCtunregulated = ΔCtunregulated – mean ΔCtunregulated 
 
Finally, for all samples calculate the relative change to determine the effect of the regulatory 
sequence on mRNA levels: 
 Percent repression = 100*[1 - 2-ΔΔCt], or for activation,  
 calculate fold change = 2-ΔΔCt 
Determine the mean repression or change for each sample and assess variability.  See Figure 2.5 
for an example of these calculations. 
Protocols 
Purification of human cytoplasmic RNA from HEK293 cells 
1. Harvest cells 48 hours after transfection: aspirate growth medium, rinse cells once with 
sterile, room temperature 1X PBS, transfer plate to ice and add 175 µl/well ice cold 
cytoplasmic RNA lysis buffer (50 mM Tris-HCl, pH 8.0, 140 mM NaCl, 1.5 mM Mg MgCl2, 
69  
0.5% Nonidet P-40 and 1000 units/ml RNasin® Ribonuclease Inhibitor (Promega) added 
immediately prior to use).  Scrape cells with a cell scraper and transfer lysates to pre-chilled 
1.5 mL microfuge tubes on ice. 
2. Incubate lysates on ice for 10 minutes then centrifuge lysates at 300 x g for 5 minutes at 4°C.   
3. Carefully transfer supernatant to fresh pre-chilled 1.5 mL microfuge tube and keep on ice.   
4. Prepare Maxwell® 16 LEV simplyRNA Blood cartridges according to manufacturer 
instructions. 
5. Add 200 µL ice cold simplyRNA Homogenization Solution (with 1-thioglycerol added) to 
lysates and transfer tubes to room temperature.  Mix completely by vortexing. 
6.  Add 200 µL simplyRNA Lysis Buffer to lysates.  Mix well by pipetting.   
7. Transfer lysates to well #1 of Maxwell® 16 LEV simplyRNA cartridge, transfer cartridge 
rack to Maxwell® 16 instrument, and run the Maxwell simplyRNA Blood purification 
program.   
8. Measure RNA concentration and purity by UV absorbance.  Analyze 0.5-1 µg RNA by 
denaturing agarose gel electrophoresis. 
DNase treatment of cytoplasmic RNA samples with DNase  
1. Dilute 10 µg RNA to a final volume of 38 µL with nuclease-free water.   
2. Add 5 µL 10X Turbo™ DNase (Life Technologies) reaction buffer to the RNA sample. 
3. Add 2 µL RNasin® Ribonuclease Inhibitor.   
4. Add 5 µL Turbo™ DNase (2 units/µL).  We suggest using 1 unit per µg of RNA, which is in 
excess of the manufacturer instructions but worked well for minimizing plasmid DNA 
background in qPCR.   
5. Mix well by pipetting and incubate at 37°C for 3 hours.   
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At the end of the incubation, DO NOT heat inactivate the DNase enzyme as this can 
cause divalent metal-mediated RNA hydrolysis.  Proceed directly with ethanol 
precipitation. 
Ethanol precipitation of RNA 
1. Add 10% v/v 3M sodium acetate pH 5.2 to DNase reaction.   
2. Add 2.5X reaction volume of 100% ethanol and mix well.  Glycogen may be added as a 
carrier for small amounts of RNA. 
3. Precipitate RNA at -80°C or on dry ice for at least 1 hour.   
4. Centrifuge samples at 14,000 x g in a 4°C microfuge for 30 minutes. 
5. Carefully aspirate the supernatant without disrupting the RNA pellet.   
6. Add 900 µL 70% ethanol to each RNA sample and vortex well for 30 seconds.   
7. Centrifuge samples at 14,000 x g in a room temperature microfuge for 15 minutes.   
8. Aspirate supernatant without disrupting pellet.   
9. Briefly spin samples to collect remaining ethanol. 
10. Use a P-10 pipette tip to wick away residual ethanol by capillary action. 
11. Uncap samples and let sit for 5 minutes on the bench to allow remaining ethanol to evaporate.  
Do not dry more than 5 minutes, as it will become very difficult to resuspend the RNA pellet.   
12. Resuspend pellet in 10 µL sterile 10 mM EDTA, 10 mM EGTA.  Vortex and incubate briefly 
at 37°C to dissolve the pellet. 
13. Assess RNA concentration by UV absorbance using a spectrophotometer, blanking the 
instrument with the resuspension solution. 
14. When optimizing RNA purification protocols, we recommend visualizing the RNA samples 
using denaturing gel electrophoresis after DNase treatment and ethanol precipitation. 
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Reverse transcription   
1. Dilute 1 µg RNA to 250 ng/µL in water.   Assuming the initial stock of RNA is ~1µg/µl, the 
final concentration of EDTA and EGTA in RT reactions will be 0.5 mM each which is 
sufficiently low to not interfere with the GoScript™ Reverse Transcriptase (Promega) 
reaction.   
2. Add 4 µL RNA to 1 µL random hexamers (500 ng/µL).  Include a no RT control reaction for 
each sample.   
3. Incubate at 65°C for 5 minutes.  Transfer to ice for 5 minutes.  Centrifuge briefly to collect 
any evaporated liquid in the lids of tubes. 
4. Prepare reverse transcription master mixes and proceed with the reverse transcription 
reaction according to the manufacturer instructions.  Use 3 mM MgCl2 and 20 units RNasin 
per final 20 µl total reaction.   
5. Proceed immediately to qPCR or store cDNA at -20°C until ready to use. 
Multiplexed quantitative PCR detection of luciferase cDNAs  
1. Using the Plexor® qPCR System (Promega), have the following primers synthesized 
(Biosearch Technologies) and prepare 2.5 µM dilutions of each primer set in Plexor® qPCR 
System MOPS/EDTA Buffer.   
-­‐ firefly forward:  5’-dGATCCTCAACGTGCAAAAGAAGC- 3’ 
-­‐ firefly reverse:  5’-d FAM-isoC-TCACGAAGGTGTACATGCTTTGG-3’ 
-­‐ Renilla forward: 5’-d CAL Fluor Orange 560-isoC-CGCAACTACAACGCCTACCTTC-
3’ 
-­‐ Renilla reverse:  5’-dCCCTCGACAATAGCGTTGGAAAA-3’ 
2. Thaw all Plexor® reagents on ice.   
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3. Prepare qPCR master mix as indicated below, scaling up for the number of samples plus an 
additional 10%.   
Component 
Volume (µL) per 
amplification 
2X Plexor Master Mix 25 
Renilla primer mix (2.5 µM ea) 1 
firefly primer mix (2.5 µM ea) 1 
Water 18 
Total volume 45 
 
4. Pipet 5 µL reverse transcription reaction per well of a 96 well qPCR plate.  We typically 
perform duplicate qPCR reactions on each cDNA sample to monitor technical variability.  
Include corresponding no RT and no template controls.   
5. Add 45 µL PCR master mix to each well and pipet to mix. 
6. Seal the plate thoroughly using adhesive qPCR film and centrifuge briefly to collect liquid to 
the bottom of the wells. 
7. Amplify using the following thermal cycling conditions.  We used the CFX96™ Real-Time 
PCR Detection System (Bio-Rad):   
a. 95°C 2 minutes 
b. 95°C 5 seconds 
c. 60°C for 35 seconds 
d. Repeat steps b-c 40 times 
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e. Perform thermal melting curve 
8. Upon completion of the program, export the qPCR data from the CFX Manager Software and 
import it into the Plexor® Analysis Software (Promega).   
9. Analyze the data (As an example, see Figure 2.5): 
a. For each regulated reporter sample, calculate ΔCtpsiCHECK-1 3xPRE = CtpsiCHECK-1 3xPRE  – 
CtpGL4.13 
b. For each unregulated reporter sample, calculate ΔCtpsiCHECK-1 No PRE = Ct psiCHECK-1 No 
PRE – CtpGL4.13 
c. Then calculate the mean ΔCtpsiCHECK-1 No PRE 
d. Next, for each regulated reporter sample, calculate ΔΔCtpsiCHECK-1 3xPRE = ΔCtpsiCHECK-
1 3xPRE – mean ΔCtpsiCHECK-1 No PRE 
e. For each unregulated reporter sample, calculate ΔΔCtpsiCHECK-1 No PRE = ΔCtpsiCHECK-1 
No PRE – mean ΔCtpsiCHECK-1 No PRE 
f. Finally, for each regulated reporter sample, calculate  
Percent RepressionpsiCHECK-1 3xPRE = 100*[1 – 2^-ΔΔCtpsiCHECK-1 3xPRE]  
g. For each unregulated reporter sample, calculate  
Percent repressionpsiCHECK-1 No PRE = 100*[1 – 2^-ΔΔCtpsiCheck-1 No PRE] 
h. Calculate mean % repression and assess variability for all replicate samples.  The data 
shown in Figure 2.5 demonstrate that the presence of the PREs caused a 78% 
decrease in the amount of reporter mRNA from psiCHECK-1 3xPRE, measured 
relative to the unregulated psiCHECK-1 No PRE reporter.  This result is consistent 
with the role of PUF proteins in binding to PRE containing mRNAs and promoting 




 The methods described here may be adapted to study different aspects of post-
transcriptional mRNA regulation including:  mRNA processing, mRNA degradation including 
deadenylation, decapping, decay by exo- and endo-nucleases, and translational control.  These 
approaches are widely applicable to study of trans-acting RNA binding proteins and small 
regulatory RNAs, such as microRNAs and short interfering RNAs.  Once an assay is established 
that specifically measures regulation, rapid progress can be made through structure/function and 
mutational analysis of the regulator sequences and effectors.  Furthermore, RNA interference 
mediated depletion, genetics, and/or cotransfection of regulators can be used to interrogate the 
factors and pathways involved in the mechanism of regulation.  Reporter genes offer versatility 
in testing experimental parameters using quantitative assays, but it is always essential to validate 
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Figure 2.2 Schematic of regulated and unregulated reporter constructs used in cell based luciferase assays.   
These specific reporters were created using the psiCHECK-1 plasmid (Promega).  Reporter transcription is mediated by 
the SV40 promoter, derived from Simian Virus 40.  An efficiently spliced intron is present in the 5’UTR to promote 
expression.  The reporter encodes the Renilla luciferase open reading frame (ORF).  The 3’UTR of psiCHECK-1 No 
PRE contains a multi-cloning site (MCS) with 6 unique restriction sites into which regulator elements can be inserted. 
Three copies of the Pumilio Response Element (PRE) or mutated PRE (mt) were inserted into the reporter 3’UTR.  


















































Figure 2.3 Example of dual luciferase assay data output.  
A.  Mean Renilla luminescence, measured as Relative Light Units (RLU) of regulated and unregulated reporters.  B.  
Mean firefly luminescence from internal control that was co-transfected with either the regulated and unregulated Renilla 
luciferase reporters.  C.  Relative response ratio (RRR), or Renilla RLU/firefly RLU of both unregulated and regulated 
reporters.  D.  Percent repression of the regulated reporter relative to the unregulated reporter.  These data are derived 
from our analysis of repression mediated by Pum Response Elements (PREs) in human cells.  Regulated reporter 
psiCHECK-1 3xPRE encodes Renilla luciferase and contains three PREs whereas unregulated reporter psiCHECK-1 
3xPREmt contains mutant PREs.  The pGL4.13 plasmid, encoding firefly luciferase, served as the internal control.  The 












































































































































































Figure 2.4 Example of overexpression of an effector protein and its effect on relative response ratios of regulated and 
unregulated reporters.  
The amount of transfected effector plasmid per well of a 96 well plate is shown at the bottom.  Effector protein mass was 
balanced using an identical plasmid that lacked the effector coding region.  In this example, the effector protein was a 
mutant form of CNOT8, which acts in a dominant negative manner to block mRNA degradation and repression of the 
regulated reporter, psiCHECK-1 containing three PRE elements (psiCHECK-1 3xPRE), but not the unregulated reporters 
that lack a PRE (psiCHECK-1 No PRE) or contain mutant PREs (psiCHECK-1 3xPREmt).  The percent repression in 
each condition is indicated at the bottom of the figure.  In this experiment, percent repression for each test condition was 
calculated relative to the unregulated reporter, psiCHECK-1 No PRE.  The data demonstrate that the effector inhibits 






































Figure 2.5 Example of calculations of percent repression of reporter mRNA levels from data obtained using reverse 
transcription and multiplexed, quantitative PCR.  
Renilla luciferase mRNA levels were measured in three samples expressing the regulated psiCHECK-1 3xPRE or the 
unregulated psiCHECK-1 No PRE reporters. In each sample, firefly luciferase mRNA levels from internal control 
pGL4.13 were also measured.  Cycle threshold values (Ct) for each sample are reported.  Calculations were then made as 
described in sections 2.5.5 and 2.5.6.5.  Percent repression of psiCHECK-1 3xPRE mRNA level was then determined 






Regulated Reporter: psiCHECK-1 3xPRE
Unregulated Reporter: psiCHECK-1 No PRE
Sample 1    24.1                            24.1              0         -0.1         2.33  0.20                79                            1.0
Sample 2    24.3                            24.1              -0.2          2.13  0.23









Sample 1    26.5   24.4         -2.1      -2.3          0.23   0.85               0.0                17
Sample 2    26.5   24.4         -2.1           0.23             0.85






















CHAPTER 3  
 
Human Pumilio proteins recruit multiple deadenylases to efficiently repress 
messenger RNAs 
 
This article was originally published in the Journal of Biological Chemistry. Van Etten, J., 
Schagat, T.L., Hrit, J., Weidmann, C.A., Brumbaugh, J., Coon, J., and Goldstrohm, A. Human 
Pumilio proteins recruit multiple deadenylases to efficiently repress messenger RNAs. Journal of 
Biological Chemistry. 2012, Vol 287: 36370-36383. © the American Society for Biochemistry 
and Molecular Biology. Van Etten wrote the manuscript and carried out experiments in figures 
3.1F, 3.1G, 3.3, 3.4A, 3.5, 3.6B-D, and 3.7. Schagat carried out experiments in figures 3.1A, C, 
D, and 3.E, 3.2, and prepared samples for mass spectrometry. Hrit carried out experiments in 
figures 3.1B, 3.4B-D. Weidmann carried out the control in figure 3.6A. Brumbaugh and Coon 
carried out mass spectrometry analysis.  
 
Summary 
PUF proteins are a conserved family of eukaryotic RNA binding proteins that regulate 
specific mRNAs: they control many processes including stem cell proliferation, fertility and 
memory formation. PUFs repress protein expression from their target mRNAs but the 
mechanism by which they do so remains unclear, especially for humans. Humans possess two 
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PUF proteins, PUM1 and PUM2, which exhibit similar RNA binding specificities. Here we 
report new insights into their regulatory activities and mechanisms of action. We developed 
functional assays to measure sequence specific repression by PUM1 and PUM2. Both robustly 
inhibit translation and promote mRNA degradation. Purified PUM complexes were found to 
contain subunits of the CCR4-NOT (CNOT) complex, which contains multiple enzymes that 
catalyze mRNA deadenylation. PUMs interact with the CNOT deadenylase subunits in vitro and 
in vivo. We used three approaches to determine the importance of deadenylases for PUM 
repression: First, dominant negative mutants of CNOT7 and CNOT8 reduced PUM repression. 
Second, RNA interference depletion of the deadenylases alleviated PUM repression. Third, the 
poly(A) tail was necessary for maximal PUM repression. These findings demonstrate a 
conserved mechanism of PUF mediated repression via direct recruitment of the CCR4-POP2-
NOT deadenylase leading to translational inhibition and mRNA degradation. A second, 
deadenylation independent mechanism was revealed by the finding that PUMs repress an mRNA 
that lacks a poly(A) tail. Thus, human PUMs are repressors capable of deadenylation-dependent 




Introduction   
 Messenger RNAs (mRNAs) are subject to extensive regulation throughout their lifespan 
(1). Synthesis and processing events of precursor mRNAs in the nucleus are regulated to yield 
mature mRNAs. Once exported to the cytoplasm, translation and stability of mRNAs are 
controlled to ensure that the appropriate amount of encoded protein is produced at the proper 
time and cellular location. The discovery of factors and mechanisms responsible for gene 
regulation is crucial to deepening our understanding of how misregulation contributes to disease.   
 PUF (Pumilio and Fem-3 binding factor) proteins are trans-acting factors that regulate 
mRNAs by binding specific sequences in 3’ untranslated regions (3’UTR)(2). Members of the 
PUF family share a conserved RNA binding domain composed of eight alpha helical repeats (3-
8). These PUF repeats adopt a crescent shape, whose concave side binds to specific single-
stranded RNA sequences. Each PUF repeat recognizes a single ribonucleotide base, mediated by 
three RNA recognition amino acids, and these contacts dictate the RNA binding specificity of 
each individual PUF protein (7).  
 Humans and other vertebrates possess two canonical PUF proteins, PUM1 and PUM2, 
collectively referred to as PUMs (9). PUMs share significant sequence similarity: amino acids 
outside of their RNA binding domains (RBD) share 75% identity whereas those within are 91% 
identical (9,10). Both PUM1 and PUM2 bind with high affinity to the consensus sequence 
UGUANAUA, hereon referred to as a PUM response element, PRE (7,11-13). PUMs are widely 
expressed in tissues and cell types (9,14). Given their similar RNA binding specificities and 
broad expression, it is possible that PUMs compete for many of the same mRNAs, supported by 
identification of mRNAs that associate with PUMs (13). 
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Genetics in model organisms demonstrated that PUFs control embryonic development, 
fertility, stem cell proliferation, and neurological functions, including the formation of memories 
(4,5,15-29). In mice, PUFs are involved in fertility through control of spermatogenesis (30,31). 
In cell culture, human PUMs were reported to affect cell proliferation (32). Insight into the 
functions of human PUMs emerged from identification of mRNAs that co-immunopurified with 
each PUM (13,33). Hundreds of mRNAs were enriched in the PUM1 and PUM2 
immunoprecipitates, suggesting an extensive regulatory network. The list of putative target 
mRNAs included genes involved in gene expression, signal transduction, cell cycle and 
proliferation, among others (13,33). Importantly, regulation of these mRNAs remains to be 
demonstrated.  
In model organisms, PUFs generally act as repressors, though in several instances they 
affect mRNA localization and perhaps activation of mRNAs (2,34-37). In Drosophila and C. 
elegans, PUF repression correlates with shortening of the poly(A) tail (i.e. deadenylation) 
(29,38-41). In yeast, PUFs repress by promoting degradation of target mRNAs, specifically 
deadenylation and decapping (42-46). Yeast PUFs bind to the Pop2 deadenylase subunit to 
enhance removal of the poly(A) tail, catalyzed by the Ccr4 deadenylase (43-45). The 
consequences of deadenylation are known to include translational down-regulation and initiation 
of mRNA degradation (47). In other cases, PUFs have been reported to directly inhibit 
translation, with several potential mechanisms having been proposed (5,48-51). 
The mechanism(s) of mRNA regulation by human PUMs remains to be elucidated and a 
complete understanding of PUM repression will facilitate identification of biologically relevant 
target mRNAs. A repressive role for human PUMs is supported by several observations: Over-
expression of PUM2 reduces expression of reporter genes (52) and over-expression of PUM 
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together with a putative partners NANOS3 was reported to inhibit E2F3 expression (53). 
Another study reported that reduction of PUM1 by RNA interference stabilized several mRNAs 
(33). PUMs were reported to repress the mRNA encoding CDKN1B tumor suppressor (32) and, 
unique to this mRNA, PUM1 was postulated to license microRNA mediated repression by 
disrupting basepairing between specific PUM and  microRNA binding sites (32). 
The role of deadenylases in yeast PUF repression suggested that human deadenylases 
might serve as PUM co-repressors. Humans possess multiple orthologs of the Pop2 and Ccr4 
deadenylase enzymes (47). The human CNOT7 and CNOT8 proteins are related to yeast Pop2 
while human CNOT6 and CNOT6L are orthologous to yeast Ccr4 (47,54-56). All four proteins 
have been reported to possess deadenylase activity (47,57-59). Like their yeast counterparts, 
CNOT7 and 8 form heterodimers with either CNOT6 or 6L, and these pairs assemble with 
human orthologs of the yeast Not proteins to form large multisubunit complexes referred to as 
Ccr4-Not (CNOT) complexes (60-62). 
In this report, we explore the activities of human PUM1 and PUM2. We show that both 
PUMs are potent repressors that inhibit protein expression and reduce mRNA levels. We then 
investigate the mechanism of repression and show that purified PUM complexes contain CNOT 
deadenylases. Two deadenylase subunits interact directly with the PUMs. In vivo, we find that 
deadenylases are important PUM co-repressors and the poly(A) tail is necessary for efficient 
repression. We also present evidence for a poly(A) independent mechanism of PUM repression. 
This research reveals two modes of PUM repression and thereby enhances our understanding of 




Plasmids. Renilla luciferase reporters (RnLUC) are based on psiCheck1 (Promega) with either 
three wild-type PRE or mutant PRE elements inserted into the Xho1 and Not1 sites in the 
3’UTR. The PRE sequence is as follows, with the PRE underlined: 5’-
TTGTTGTCGAAAATTGTACATAAGCCAA and the PREmt sequence is: 5’- 
TTGTTGTCGAAAATACAACATAAGCCAA. The altered specificity reporter, RnLUC 3xPRE 
UGG, was constructed with the following sequence: 5’-
TTGTTGTCGAAAATTGGACATAAGCCAA. RnLUC HSL was created by replacing the 
cleavage/polyadenylation site from the psiCheck1 3’ UTR with a histone stem loop (HSL) 
sequence from the human H1F3 gene. Two or four PRE sequences were inserted upstream of the 
HSL to create RnLUC 2xPRE HSL and RnLUC 4xPRE HSL. The Firefly luciferase (FfLUC) 
plasmid pGL4.13 (Promega) was used as a control.  
To express proteins as Halotag fusions in human cells, CNOT6, CNOT6L, CNOT7, or CNOT8 
were cloned into the vector pFN21A (Promega). Active site mutants, CNOT7 D40A E42A and 
CNOT8 D40A E42A were created by Quikchange mutagenesis (Stratagene). Full length human 
PUM1 or PUM2 open reading frames were cloned into pFN21A and site directed mutagenesis 
was used to create PUM1 R6as (N1043S Q1047E) and PUM2 R6as (N921S Q925E). 
Recombinant proteins were expressed as Halotag (HT) fusions from the vector pFN18A 
(Promega), including HT-CNOT6, HT-PUM1 RBD (aa828-1176), and HT-PUM2 RBD (aa705-
1050). Renilla and firefly luciferase  reporters for Drosophila  cells were previously described 
(63). Drosophila protein expression constructs were made by inserting PUM1 coding sequence 
into pIZ V5 His6 (Invitrogen). 
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Cell culture and transfections. Human HEK293 cells were cultured at 37°C under 5% CO2 in 
DMEM with glucose and 1 x Penicillin/Streptomycin/Glutamine and 10% FBS (Gibco). 
Drosophila D.mel-2 cells (Invitrogen) were cultured as previously described (63). Transfections 
of human cells were carried out with FuGENE HD (Promega) at 3:1 volume lipid: µg DNA. For 
luciferase assays, 2 x 104 cells were plated in white-walled 96-well plates and, after 24 hrs, were 
transfected with 100 ng/well of plasmid DNA. For RNA purifications and 
coimmunoprecipitations, 6 x 105 cells were transfected with 3 µg plasmid DNA 24 hours after 
seeding. D.mel-2 cells were transfected with Effectene (Qiagen) as previously described (63). 
For human PUM1 expression and repression assays, 400 ng PUM1 expression vector was 
included in the transfection with reporters. 
Luciferase assays. Renilla (75 ng) and Firefly (25 ng) reporters were transfected into HEK293 
cells.  Forty-eight hours later, luciferase activity was measured with Dual-Glo reagent using a 
Glomax Multi+ luminometer (Promega). Relative light units (RLU) values were used to 
calculate a relative response ratio (RRR) by dividing the Renilla value from each well by the 
corresponding Firefly value.  Percent repression was then calculated as: (%) = 100 x (1- 
RRRvariable/ RRRcontrol) where RRRcontrol equals RRR RnLUC 3xPRE mt or RnLUC. A minimum 
of three replicates were used to calculate mean values and standard error of the mean. All results 
were verified in multiple independent experiments. Dual luciferase assays from Drosophila cells 
were performed as previously described (63). 
RNA interference. PUMs were knocked down in HEK293 cells using On-target Plus Smartpool 
siRNAs for PUM1 (L-014179-00), PUM2 (L-014031-02), GAPDH, or non-targeting control 
siRNAs (Dharmacon). HEK293 cells (2 x 104 cells per well) were plated into a 96-well plate. 
After 24 hours, cells were transfected with 10 fmoles of siRNAs using Dharmafect-1 
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(Dharmacon). After 48 hours, reporters were transfected using FuGENE HD. Twenty-four hours 
later, cells were analyzed by Dual-Glo assay or whole cell lysates were prepared for western-blot 
analysis in TNEM (50 mM Tris-HCl pH 8.0, 0.5% (v/v) Nonidet-P40, 0.5 mM EDTA, 2 mM 
MgCl2,) with 150 mM NaCl and protease inhibitors (1 mM PMSF, 50 µg/mL aprotinin, 50 
µg/mL pepstatin, 50 µg/mL leupeptin).  
RNAi in D.mel-2 cells was performed as previously described (63) using dsRNAs transcribed 
from PCR templates generated with the following oligonucleotides: LacZ control, forward 
primer, 5’-GGATCCTAATACGACTCACTATAGGGTGACGTCTCGTTGCTGCATAAAC, 
and reverse primer, 5’-
GGATCCTAATACGACTCACTATAGGGGGCGTTAAAGTTGTTCTGCTTCATC, Pop2, 
forward primer, 5’ -





GGATCCTAATACGACTCACTATAGGGCGAACGTATAGTTGGTGTGCGGCATT. The T7 
promoter sequence is underlined and the gene specific region is in bold. 
RNAi of POP2 and CCR4 was confirmed by measuring depletion of Halotag-deadenylase 
fusions. D.mel-2 cells were transfected with 100 ng pIZ HT-Pop2 or pIZ HT-CCR4 with 100 ng 
of control pIZ HT. 1 mL cell suspension was harvested and lysed for 1 hour on ice in TNEM 
with 150 mM NaCl. HT was labeled with fluorescent Halotag ligand, TMR (Promega) for 30 
minutes. Lysates were analyzed by SDS-PAGE and fluorescence detection with a Typhoon Trio 
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Fluorescence Imager (GE). Depletion was calculated relative to samples treated with LacZ 
control dsRNA and normalized to HT internal control. 
Coimmunoprecipitations. Plasmids expressing FLAG-tagged human PUM1 and PUM2 were 
transfected into 6 x 105 HEK293 cells with HT fusions of CNOT6, CNOT6L, CNOT7, or 
CNOT8. Cells were lysed in TNEM with 150 mM NaCl and protease inhibitors. HT fusions 
were labeled with TMR ligand and treated with 10 units RNase ONE and 4 µg RNase A 
(Promega). Extracts were then bound overnight with end-over-end rotation at 4°C to pre-
equilibrated anti-FLAG beads (Sigma). Beads were washed twice with TNEM with 250 mM 
NaCl and once with TNEM with 500 mM NaCl. Bound protein complexes were eluted with 
FLAG peptide (Sigma) at 4°C and passed over Micro Bio-Spin columns (Bio-Rad) to collect 
eluates. Eluates were analyzed by SDS-PAGE and fluorescence emission at 580 nm on a 
Typhoon Trio to detect TMR-labeled Halotag fusions. Western blots were performed and probed 
with a monoclonal anti-FLAG M2 antibody (Sigma). 
Western blotting. HEK293 cells were lysed in TNEM with 150mM NaCl and protease inhibitors. 
D.mel-2 lysates were prepared from 1 mL cell suspension in 75 µL TNEM with 150 mM NaCl 
and protease inhibitors, lysed on ice for 1 hour, and centrifuged to remove cell debris. Lysates 
were analyzed by western blotting with anti-V5. PUM1 antibodies were from Bethyl 
Laboratories (A300 201A) and Abcam (80216).  PUM2 (K-14) antibody was from Santa Cruz 
Biotechnology (sc-31535) or Bethyl Laboratories (A300-202A). Antibody to GAPDH was 
obtained from Applied Biosystems (AM4300). T7 tag antibody was from Novagen (69522-3). 
V5 antibody was from Invitrogen (37-7500). HRP conjugated secondary antibodies were 
obtained from Thermo Scientific (anti-Mouse IgG, 31430) and KPL (Anti-Goat IgG, 14-13-06 
and Anti-Rabbit IgG, 074-1516). 
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Purification of recombinant proteins. To purify PUM1 (aa828-1176) and PUM2 (aa705-1050) 
RNA binding domains and control CNOT6, pFN18A-based plasmids (Promega) encoding 
Halotag fusions of each protein were introduced into KRX e. coli strain (Promega) and induced 
with 0.1% (w/v) rhamnose for 12 hours at 20⁰C.  Proteins were purified using Halolink resin 
(Promega). Beads were washed extensively with TNEM with 1000 mM NaCl and then 
equilibrated in TNEM with 250 mM NaCl. To confirm purification of the respective proteins, 
AcTEV protease (Invitrogen) was used to cleave CNOT6, PUM1 RBD and PUM2 RBD from an 
aliquot of the Halolink beads. The eluted proteins were analyzed by coomassie stained SDS-
PAGE (Fig. 4B). The remaining Halolink bound proteins were used for Halotag pulldown 
assays. pMAL plasmids (NEB) encoding MBP tagged CNOT6, CNOT7, and CNOT8 were 
transformed into the BL21 Gold E. coli strain and induced with 0.3 mM IPTG for 16 hrs at 20°C. 
Proteins were purified with the Amylose affinity resin (NEB). Beads were washed three times 
with TNEM with 1000 mM NaCl and 1 mM DTT and three times with deadenylation buffer (50 
mM Tris pH 8.0, 1 mM MgCl2, 50 mM NaCl, 20% glycerol and 1 mM DTT). Proteins were 
eluted with 10 mM maltose in deadenylation buffer.  
In vitro deadenylation assays. Deadenylase activity of purified wild type or mutant CNOT7 and 
CNOT8 enzymes was confirmed by incubating 1 µM of each enzyme with 200 fmol of a 36 
nucleotide RNA substrate with a 5’ Cy5 fluorescent label and, on the 3’ end, a 10 nucleotide 
poly(A) tail (see PRE RNA sequence below) in 20 µL of deadenylation buffer (64). Control 
reactions contained 10 mM EDTA to chelate Mg2+. Reactions were incubated at 30ºC for up to 
120 minutes. Equal volume of 98% formamide and 20 mM EDTA was added, the samples were 
heated to 95ºC for 5 minutes and then resolved on a 10% polyacrylamide, 7 M urea gel. Products 
were detected using a Typhoon fluorescence imager.  
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In vitro binding of PUMs and CCR4-NOT deadenylase subunits.  Recombinant prey proteins 
included MBP-CNOT7, MBP-CNOT8 or control MBP. For Halotag pulldown assays, 50 nM of 
prey protein was added to 50 µL of TNEM with 250 mM NaCl and 10 µLs of Halolink beads 
bound with HT-CNOT6, HT-CNOT7 or HT-CNOT8 bait proteins (1 µg each). Halolink beads 
alone served as a negative control. Binding reactions were incubated with rotation for 2 hours at 
4°C. Beads were washed 4 times with 1 mL TNEM containing 500 mM NaCl and 0.5% Tween-
20. Beads were collected by centrifugation at 1000 x g for 5 minutes. Bound proteins were eluted 
in 20 µL SDS-PAGE loading dye by heating at 95°C for 5 minutes. Fifty percent of eluted 
proteins were then analyzed by SDS-PAGE and western blotting using anti-MBP monoclonal 
antibody conjugated to horseradish peroxidase (NEB). 
Gel shift assays. PRE RNA ligand, 5’-
TTGTTGTCGAAAATTGTACATAAGCCAAAAAAAAAA, was labeled with Cy5 
(Dharmacon). PRE mt RNA ligand, 5’-
TTGTTGTCGAAAATACAACATAAGCCAAAAAAAAAA, was labeled with Dylight 650 
(Dharmacon). RNA ligands were synthesized, deprotected and PAGE purified prior to gel shift 
assays. PUM1 RBD or PUM2 RBD were allowed to bind to 200 fmol (10 nM) of RNA ligand in 
deadenylation buffer for 30 minutes at 37°C. Samples were then analyzed on a 6% 
polyacrylamide gel with 1 x TB running buffer at 300 volts at 4°C. Gels were imaged with a 
Typhoon Trio.  
Purification of PUMs and mass spectrometry. Halotag, HT-PUM1, or HT-PUM2, expressed 
from plasmid pFN21A, were purified using the Halotag Mammalian Pulldown system 
(Promega). T150 flasks were transfected with each plasmid and after 48 hours, cells were 
washed with phosphate buffered saline (PBS), and harvested at 2000 x g at 4⁰C. Cells were 
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suspended in 1 mL Mammalian Lysis Buffer with Protease Inhibitor Cocktail (Promega). Cells 
were passed through a 25 gauge needle 5 times, incubated for 5 minutes at 4°C, and then 
centrifuged for 5 minutes at 14000 rpm. Halolink beads were then diluted with TBS (100 mM 
Tris-HCl pH 7.5 and 150 mM NaCl) and incubated with the cell extract for 15 minutes at room 
temperature with rotation.  Beads were washed three times with 10 ml TNEM with 250 mM 
NaCl, followed by three washes with the same buffer lacking IGEPAL. Proteins were eluted with 
10 units of AcTEV protease (Invitrogen) in 20 mM Tris-HCl pH 8.0 and 300 mM NaCl. Peptides 
were prepared from each sample as follows:  First, disulfide bonds were reduced with 2 mM 
DTT at 37°C for 30 minutes and blocked with 4 mM iodoacetamide at 23°C for 30 minutes in the 
dark. The blocking reaction was quenched by bringing the final concentration of DTT to 4 mM. 
Next, sequencing grade trypsin (Promega) at a 1:50 (mass:mass) enzyme to sample ratio was 
added and incubated overnight at 37°C. Peptides were then analyzed using nanoflow liquid 
chromatography (Waters) coupled to an ETD-enabled hybrid linear ion trap-orbitrap mass 
spectrometer (Thermo Scientific) via electrospray (65). Separation and data-dependent sampling 
conditions were used as previously described (66,67). Post-acquisition data processing was 
performed using DTA generator and the COMPASS software suite as previously described (68). 
Protein identifications were assigned by searching the human International Protein Index 
database with the peptide mass spectra from two independent analyses using the open mass 
spectrometry search algorithm (OMSSA) (67,69). A false discovery rate threshold of 1% was 
applied to filter false positive identifications (67,70). To eliminate contaminants that bind 
Halolink resin or Halotag, an identical analysis was performed on control Halotag purifications. 
All proteins detected in both the control and PUM complexes were excluded. 
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RNA purifications and cDNA preparation. RNA was purified from HEK293 cells harvested 48 
hours after transfection using the Maxwell 16 simplyRNA LEV cells kit and a Maxwell 16 
instrument (Promega). RNA was eluted in 50 µL nuclease free water and treated with Turbo 
DNase (Ambion).  
For first strand cDNA synthesis, RNA (1000 ng) was annealed with random hexamers (500 ng) 
(IDT) at 70⁰C for 5 minutes and cooled on ice. Reverse transcription was performed in reaction 
buffer with 3 mM MgCl2, 500 mM each dNTP, 0.5 µL RNasin Plus, and 1 µL GoScript reverse 
transcriptase (Promega). RT was omitted in control samples. 
Quantitative PCR. Multiplexed quantitative PCR was used to detect Renilla and Firefly reporter 
mRNAs. Reactions were carried out in 25 µL reactions with the Plexor 2-step kit (Promega). 5 
µL cDNA was combined with 2 x Plexor Master Mix (Promega) and 100 nM each of the 
fluorescent primers (Biosearch Technologies). Reactions were performed in triplicate using a 
CFX96 Real-Time PCR instrument (Bio-Rad). The conditions used were: 1) 95°C for 2 minutes, 
2) 95°C for 5 seconds, 3) 60°C for 35 seconds.  Steps 2-3 were repeated for a total of 40 cycles.  
Each reaction was subjected to thermal melting and curves gave single peaks with the expected 
melting temperature. Amplification efficiencies for each primer set were optimized at 100% 
efficiency. Cycle thresholds (Ct) were measured using CFX Manager software (Bio-Rad) and 
imported in Plexor Analysis Software (Promega). Data was analyzed by the comparative Ct 
method (71,72). Ct values were measured and normalized to an internal control firefly luciferase 
mRNA where ΔCt = CtRenilla – Ctfirefly. Differences in mRNA levels were calculated using the 
ΔΔCt method whereby ΔΔCt = ΔCttarget – ΔCtcontrol.  “Control” indicates RnLUC lacking PREs 
and “target” indicates RnLUC 3xPRE.  Changes in mRNA expression are represented as fold 
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change values, where fold change = 2-ΔΔCt. From fold change we calculated percent repression, 
which equals 100 x (1- fold change).  
To confirm RNAi depletion of deadenylase mRNAs, qPCR was carried out using GoTaq qPCR 
(Promega). Cycling conditions were as follows: (i) 95°C for 3 minutes, (ii) 95°C for 10 sec, (iii) 
65°C for 30 sec, and (iv) 72°C for 40 sec. Steps (ii) through (iv) were repeated for a total of 40 
cycles. Negative control reactions were performed in the absence of template or reverse 
transcriptase. Cycle thresholds (Ct) were measured using the CFX Manager software and 
analyzed using the ΔΔCt method (71,72). ΔCt was calculated by normalizing to the Rpl32 gene 
Ct values. We then calculated ΔΔCt as follows: ΔΔCt= ΔCt(target RNAi)- ΔCt (control RNAi). 
qPCR primer sequences are as follows: Firefly: Forward primer: 5’-
dGATCCTCAACGTGCAAAAGAAGC-3’, Reverse primer: 5’-d FAM-isoC-
TCACGAAGGTGTACATGCTTTGG-3’, Renilla: Forward primer: 5’-d CAL Fluor Orange 
560-isoC-CGCAACTACAACGCCTACCTTC-3’, Reverse primer: 5’-
dCCCTCGACAATAGCGTTGGAAAA-3’, Rpl32: Forward primer: 5’-
dGCCCAAGGGTATCGACAACAG-3’, Reverse primer: 5’-d 
GCACGTTGTGCACCAGGAAC-3’, Dm Pop2: Forward primer: 5’-d 
TGGACAATGCCCTCGGCC-3’, Reverse primer: 5’-d 
GGCCACATAGTGGTACTTCTGCACC-3’, Dm Ccr4: Forward primer: 5’-d 
CTCGTCATACTCGGCCTCATGG-3’, Reverse primer: 5’-d 
CGTAAAAATGCAGGCTGGTCG-3’. 
Poly(A) selection and northern blot analysis. Total RNA samples from HEK293 cells expressing 
RnLUC, RnLUC 3xPRE, RnLUC 3xPREmt and FfLUC control were purified and then poly-
adenylated mRNA was selected from 20 µg total RNA by the PolyAtract mRNA Isolation 
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System (Promega). RnLUC HSL and FfLUC RNAs were reverse transcribed and amplified by 
qPCR as described above.  
For northern blots, mRNA samples were precipitated, suspended in 5 µL of 10 mM EDTA, 10 
mM EGTA, and prepared for gel electrophoresis in 5% glycerol, 1 mM EDTA, 0.025% (w/v) 
bromophenol blue, 0.025% (w/v) xylene cyanol FF with 1 x MOPS, 3.7% formaldehyde, and 
25% formamide. Samples were boiled for 5 minutes and separated on a 1% agarose gel with 
formaldehyde in 1 x MOPS. Following transfer to NY+ membrane (Millipore), RNA was UV 
crosslinked and prehybridized in Ultra-Hyb buffer (Life Technologies) at 68°C for at least one 
hour. Northern probe templates for FfLUC and RnLUC were amplified by PCR using GoTaq 
(Promega) and the following primers:  
FF fwd: 5’-CGTGGACGAGGTGCCTAAAG,  
FF rev: 5’ GGATCCTAATACGACTCACTATAGGTTACACGGCGATCTTGCCGC,  
Rn fwd: 5’-CAAGCCCGACGTCGTCCAGATT,  
Rn rev: 5’-GGATCCTAATACGACTCACTATAGGTTACTGCTCGTTCTTCAAGCACGC.   
Reverse primers contained the T7 promoter sequence. Riboprobes were transcribed with UTP-
[α-32P] using T7 MaxiScript kit (Life Technologies) and purified by G25 Sephadex columns. 
Blots were hybridized with probes overnight at 68°C with rotation. Blots were washed twice for 
15 minutes with 2X SSC (300 mM NaCl, 30 mM sodium citrate) + 0.1% SDS and twice for 30 
minutes with 0.1% SSC (15 mM NaCl, 1.5 mM sodium citrate) + 0.1% SDS. Blots were exposed 





Human PUM1 and PUM2 reduce protein expression and mRNA levels. To study regulation by 
PUMs, we developed a luciferase reporter assay that recapitulates sequence specific repression. 
Three binding sites for PUM1 and PUM2, designated PUM Response Elements (PRE), were 
inserted into a minimal 3’UTR of an mRNA encoding Renilla luciferase (RnLUC 3xPRE, Fig. 
1A). This PRE sequence UGUACAUA is a high affinity binding site for PUM1 and PUM2 (7). 
As a control for specificity, the UGU sequence of the PRE, which is crucial for PUM binding, 
was mutated to ACA to disrupt PUM binding (Fig. 1A, RnLUC 3xPREmt). Electrophoretic 
mobility shift assays confirm that PUM1 and PUM2 bind to the PRE with nearly equivalent 
affinity (Fig. 1B). Importantly, neither PUM bound the PREmt (Fig. 1B). As an additional 
control, a Renilla luciferase reporter lacking PRE sequences was tested (Fig. 1A, RnLUC).  
Each reporter was transfected into the human HEK293 cell line. As an internal control, a 
plasmid encoding firefly luciferase was cotransfected (Fig. 1A, FfLUC). Expression of each 
luciferase was subsequently measured (Fig. 1C and D). Renilla expression from RnLUC 3xPRE 
was substantially repressed relative to RnLUC 3xPREmt or RnLUC (Fig. 1C). To normalize 
variations in transfection efficiency, the Renilla activity for each sample was divided by 
corresponding Firefly luciferase activity (Fig. 1D). From these values, we calculated a percent 
repression value, as a measure of PUMs repressive activity (Fig. 1E). The presence of the PRE 
elements in RnLUC 3xPRE elicited 71% repression relative to control reporters (Fig. 1F), 
indicating potent, specific repression by endogenous PUM1 and/or PUM2. 
Having established that PRE dependent repression reduces protein output, we wished to 
determine if the effect is manifested by changes in mRNA level; therefore, we purified RNA and 
performed multiplexed quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
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to measure levels of reporter mRNAs (Fig. 1F). RnLUC Ct values were normalized to the 
internal control, FfLUC, to yield a ΔCt value (71,72). From ΔCt values we calculated fold 
change for each sample, relative to negative control RnLUC (71,72). The fold change of RnLUC 
3xPRE mRNA was 0.22, indicating it was reduced by 78% relative to RnLUC mRNA (Fig. 1G, 
3xPRE). Consistent with repression by PUMs, mutation of the PREs alleviated regulation (Fig. 
1G, 3xPREmt). Northern blotting was then performed using purified mRNA to visualize reporter 
transcripts (poly(A) affinity purification was necessary for detection).  Detection of FfLUC 
served as an internal control. Quantification of the data revealed that RnLUC 3xPRE mRNA was 
reduced 74% relative to RnLUC and RnLUC 3xPREmt (Fig. 1G), concordant with qRT-PCR 
results (Fig. 1F). Together, these findings demonstrated that PUM repression of the PRE bearing 
reporter substantially reduces protein and mRNA levels, and the reporters provide sensitive 
sensors for post-transcriptional repression by PUMs.  
Both PUM1 and PUM2 are expressed in HEK293 cells (Fig. 2A). To demonstrate that the 
PRE-dependent repression is caused by endogenous PUM1 and PUM2, each protein was 
depleted by RNA interference (RNAi). Transfection of non-targeting control siRNAs had no 
effect on PUM expression (Fig. 2A, Control). Treatment with siRNAs corresponding to PUM1 
or PUM2 efficiently depleted the respective proteins (Fig. 2A, PUM1, PUM2). Treatment of 
cells with both PUM1 and PUM2 siRNAs substantially depleted both PUM1 and PUM2 (Fig.2A, 
PUM1+PUM2). 
We then measured the effect of depletion of PUM1, PUM2, or both on reporter 
expression. The control siRNAs had no effect on repression of RnLUC 3xPRE (Fig. 2B, 65% 
repression) relative to mock transfection without siRNA (Fig. 2B, None). Likewise, transfection 
of siRNAs to GAPDH had no effect on repression (Fig. 2B, GAPDH). Depletion of each PUM 
99  
individually caused modest loss of repression (Fig. 2B). Depletion of both PUM1 and PUM2 
together substantially reduced PUM repression to only 15% (Fig. 2B, PUM1+PUM2). We 
conclude that both PUMs repress the PRE-bearing reporter. We also tested the impact of over-
expression of PUMs but did not observe enhancement of repression (data not shown), indicating 
that PUM expression is not limiting. Together, these observations indicate that both PUM1 and 
PUM2 cause PRE-dependent repression, and that they have overlapping regulatory roles. The 
results in Figures 1 and 2 validate the specificity and sensitivity of the PUM repression assay. 
 
PUM1 and PUM2 repress individually. Having shown that PUMs have overlapping capabilities 
to repress, we next assessed whether PUM1 and PUM2 individually exhibit repressive activity. 
To do so, we created a new reporter that responds to exogenously introduced PUM1 or PUM2. 
First, each PUM was programmed to bind a new PRE sequence (designated PRE UGG) by 
altering the RNA recognition amino acids of the sixth PUF repeat (R6as)(Fig. 3A)(7,63). 
Importantly, wild type PUMs do not bind UGG efficiently (7,11). A corresponding reporter, 
RnLUC 3xPRE UGG, was created by changing the nucleobase at position 3 of the PRE from 
uracil to guanine (Fig. 3A and B). The reporters were then transfected into cells and regulation 
by endogenous PUMs or by PUM1 with altered specificity (PUM1 R6as) was measured. PUM1 
R6as, fused to Halotag, was expressed from a transfected plasmid. As a control, a plasmid 
expressing only Halotag protein was introduced. As observed in Fig. 1, endogenous PUMs 
repressed the RnLUC 3xPRE but, importantly, did not affect RnLUC 3xPRE UGG, nor the 
negative controls RnLUC or RnLUC 3xPREmt (Fig. 3C, Halotag). Expression of PUM1 R6as 
specifically repressed the RnLUC 3xPRE UGG reporter by 64% (Fig. 3C). PUM1 R6as did not 
change repression of RnLUC 3xPRE by endogenous PUMs, nor did it regulate RnLUC or 
100  
RnLUC 3xPREmt (Fig. 3C). Next, we compared the repressive activity of PUM1 or PUM2 using 
the RnLUC 3xPRE UGG. PUM1 R6as repressed the reporter by 75% and PUM2 R6as repressed 
by 69% (Fig. 3D), relative to the Halotag control. We conclude that PUM1 and PUM2 can 
independently repress mRNAs, and that PUMs can be programmed to specifically repress new 
target mRNAs. 
 
PUM1 and PUM2 interact with CCR4-NOT deadenylase complex subunits. We hypothesized 
that PUM1 and PUM2 may recruit co-repressor proteins to mediate repression. PUM complexes 
had not been previously biochemically analyzed. To identify co-repressors, we purified PUM1 
and PUM2 complexes and identified associated proteins. First, PUMs were expressed in 
HEK293 cells as fusions to Halotag and affinity purified. Purified complexes were eluted and 
tryptic digests were then analyzed by nanoflow-reversed-phase liquid chromatography and 
electrospray ionization using a hybrid linear ion trap-orbitrap mass spectrometer. Peptide 
sequences and protein identifications were assigned by use of high accuracy mass spectral data 
(<10 ppm mass measurement) with a 1% false discovery rate cut off (67,70). To eliminate false-
positives, an identical analysis was performed on control Halotag purifications; proteins detected 
in both the control and PUM complexes were excluded as contaminants. As a result of this 
analysis, multiple subunits of the CCR4-NOT (CNOT) deadenylase complex (61,73) were 
detected in purified PUM complexes including CNOT1, CNOT2, CNOT4 and CNOT10 (data 
not shown). 
Association of CNOT subunits with PUMs prompted us to investigate interaction of 
deadenylase enzyme subunits with PUMs. The CNOT complex interacts with heterodimers 
formed by pairing of CNOT6 or CNOT6L with CNOT7 or CNOT8 deadenylases (47,60-62). To 
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analyze association of PUMs with these enzymes, FLAG-tagged PUM1 and PUM2 were 
expressed in cells that co-expressed Halotag fusion proteins of CNOT7, CNOT8, CNOT6 or 
CNOT6L. Cell extracts were prepared and treated with RNase One and RNase A to destroy 
RNA. Halotag fusions were fluorescently labeled with TMR fluor and detected in the cell lysates 
(Fig. 4A, Input). Next, PUM complexes were immunopurified using anti-FLAG monoclonal 
antibody and specifically eluted with FLAG peptide. Purification of PUM1 and PUM2 was 
confirmed by western blot of the eluates (Fig. 4A). CNOT6, CNOT6L and CNOT8 were 
strongly detected in both PUM1 and PUM2 eluates while CNOT7 was weakly detected (Fig. 
4A). The interactions were specific, because none of the deadenylases or the Halotag control 
protein associated with the anti-FLAG resin (Fig. 4A, Control). This data demonstrates that 
PUMs associate with CNOT deadenylase complexes. Because the PUM-deadenylase association 
was detected in RNase treated extracts, protein interactions likely mediate the contacts and not 
RNA. 
 
PUM1 and PUM2 bind the CNOT7 and CNOT8 deadenylases in vitro. To further investigate the 
interaction of PUMs with deadenylase enzymes, we performed in vitro protein interaction assays. 
As bait proteins, recombinant Halotag fusions of PUM1 and PUM2 were purified and 
immobilized to halolink beads (Fig. 4B). These proteins were active in RNA binding assays (Fig. 
1B). As a positive control, a Halotag fusion of CNOT6 was also purified. Recombinant CNOT7 
and CNOT8, fused to maltose binding protein (MBP) were then purified and used as prey 
proteins. First, the enzymatic activity of each deadenylase was demonstrated by deadenylating a 
5’ Cy5 fluorescently labeled RNA substrate with 10 nucleotide poly(A) tail (Fig. 4C). CNOT7 
and CNOT8 progressively deadenylated the substrate over time. As a control, chelation of Mg2+ 
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with EDTA inactivated CNOT7 and CNOT8 (Fig. 4C, EDTA). Further, mutation of the 
magnesium coordinating residues (D40 and D42) within the active site of each enzyme to alanine 
blocked deadenylation (Fig. 4C). 
Having demonstrated that CNOT7 and CNOT8 were active, we then measured binding to 
PUMs. Each prey was added to beads bound with CNOT6, PUM1, PUM2 or negative control 
beads. None of the prey proteins bound to control beads (Fig. 4D). The positive control, CNOT6, 
bound both CNOT7 and CNOT8, as expected (47), but not MBP (Fig. 4D). PUM1 and PUM2 
bound to both CNOT7 and CNOT8, but not the control MBP (Fig. 4D). Therefore, human PUMs 
specifically interact with POP2 orthologs in vitro. Together with the results from co-
immunoprecipitation studies (Fig. 4A), we conclude that PUMs bind either CNOT7 or CNOT8. 
We speculate that the preference for CNOT8 observed in Fig. 4A could result from additional 
factors in vivo that might modulate the interaction or differences in relative affinity. Because 
CNOT6/6L bind CNOT7 or CNOT8, their co-purification with PUMs is likely the result of 
heterodimerization. 
 
Deadenylation inhibitors alleviate PUM repression. The observation that PUMs bind 
deadenylases suggests that deadenylation may be required for PUM mediated repression. To 
address this hypothesis, we used the observation that mutations in the catalytic residues of 
deadenylases render them inactive (Fig. 4C), and when over-expressed in cells, these mutants 
block deadenylation in a dominant negative manner (74-77). Therefore, we expressed mutant 
CNOT8 (CNOT8 mt) in which magnesium ion coordinating residues D40 and E42 were changed 
to alanine. The impact of these mutant deadenylases on PUM repression of RnLUC 3xPRE 
reporter was then measured. CNOT8 mt expression plasmid was transfected over a range from 0 
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to 85 nanograms (Fig. 5A). The CNOT8 mt protein was fused to Halotag to facilitate detection 
(Fig. 5B). A reciprocal gradient of the plasmid expressing only Halotag was used to balance 
transfections and Halotag alone served as a negative control. When Halotag alone was expressed 
(Fig. 5A, 0 ng CNOT8 mt), PUMs repressed the RnLUC 3xPRE by 77% relative to RnLUC, 
consistent with earlier observation (Fig. 1). Transfection of 20, 50 and 85 ng of the CNOT8 mt 
plasmid reduced PUM repression in a dose dependent manner to 58, 51, and 40%, respectively 
(Fig. 5A). The effect of CNOT8 mt was specific to PUM repression; neither RnLUC nor RnLUC 
3xPREmt reporter was affected (Fig. 5A). Dose dependent expression of HT and HT-CNOT8 mt 
in these samples was confirmed by fluorescence detection (Fig. 5B). We conclude that CNOT8 
mt has a dominant negative effect that inhibits repression by PUMs.  
We next tested the ability of a catalytically inactivated mutant CNOT7 to affect PUM 
repression by the same strategy. Transfection of 20, 50, and 85 ng of CNOT7 mt expression 
plasmid reduced PUM repression from 78% to 56, 50 and 48%, respectively (Fig. 5C and 5D). 
Again, the effect was specific to the 3xPRE bearing reporter; RnLUC and RnLUC 3xPREmt 
reporters were not significantly affected. Together these results demonstrate that dominant 
negative mutant deadenylases block PUM repression, indicating that deadenylation plays an 
important role in PUM repression. 
 
Depletion of deadenylases inhibits PUM repression. To corroborate the results above, we 
attempted to measure the impact of depletion of human deadenylases on PUM repression. 
Though we tested multiple siRNAs for each deadenylase, we were unable to substantially deplete 
CNOT7/8 and CNOT6/6L. Instead, we employed Drosophila D.mel-2 cells, which offer three 
advantages: 1) RNA interference elicited by dsRNA is highly efficient in these cells, 2) 
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Drosophila possess one copy each of POP2 (i.e. CAF1) and CCR4 (i.e. TWIN), thus 
circumventing the potential redundancy of deadenylases in human cells (47,78,79), and 3) 
human PUMs actively repress in D. mel-2 cells (see below). 
We first confirmed the efficacy of RNAi mediated knockdown of deadenylases. To 
measure depletion of each protein, Halotag fusions of POP2 or CCR4 were co-expressed with a 
Halotag internal control. Cells were then treated with dsRNAs corresponding to either POP2 or 
CCR4 and, after 48 hours, levels of the Halotag fusion proteins were measured. POP2 and CCR4 
were depleted by 99 and 94%, respectively (Fig. 6A), demonstrating efficient RNAi knockdown.  
We then tested the ability of human PUM1 to repress RnLUC 3xPRE in D.mel-2 cells. PUM1 
repressed reporter protein expression by 45% relative to the empty expression vector (Fig. 6B). 
Simultaneous depletion of CCR4 and POP2 reduced repression to 28% (Fig. 6B). This effect was 
reflected at the mRNA level: PUM1 reduced RnLUC 3xPRE mRNA by 44% (Fig. 6C) and 
depletion of CCR4 and POP2 alleviated PUM1 mediated reduction of the mRNA to 19% (Fig. 
6C). POP2 and CCR4 mRNAs were depleted from these samples by 82% and 94%, respectively, 
as ascertained by qRT-PCR. Therefore, the POP2 and CCR4 deadenylases are necessary for 
efficient repression by PUM1. 
We sought to determine if the reduction in PUM1 repression was due to depletion of 
CCR4, POP2 or both. RNAi knockdown of CCR4 did not reduce PUM1 repression (Fig. 6D, 
CCR4, 58% repression) whereas PUM1 repression was significantly abrogated by knockdown of 
POP2 (Fig. 6D, POP2, 39% repression). This result may reflect the fact that POP2 is the 
predominant deadenylase in Drosophila (78,79). This finding supports the conclusion that 
deadenylases are important for PUM repression, and that PUM1 can repress by recruiting the 
deadenylase complex via a conserved interaction with POP2 orthologs. 
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PUMs also repress by a poly(A) independent mechanism. We next asked: is the poly(A) tail, and 
therefore deadenylation, absolutely necessary for repression by PUMs?  Replication dependent 
histone mRNAs lack a poly(A) tail; rather, their 3’ ends are formed by cleavage after a histone 
stem loop (HSL) structure (80). Translation of histone mRNAs is promoted by the 5’ cap and 
HSL, and degradation occurs via the 5’ decapping pathway (80). Consequently, the HSL 
provides a means of examining PUM repression in the absence of a poly(A) tail. We removed 
the cleavage/polyadenylation elements from the Renilla luciferase reporter and, in its place, 
inserted sequences encoding the HSL to drive 3’ end formation of the RnLUC HSL reporter (Fig. 
7A). To verify that the RnLUC HSL lacked a poly(A) tail, this mRNA was expressed in cells. As 
a positive control, the poly-adenylated RnLUC reporter was separately expressed. As an internal 
control, both samples also expressed the poly-adenylated FfLUC mRNA. Total RNA was 
purified from each sample and then mRNAs were then purified using oligo(dT) magnetic beads 
to enrich poly(A) mRNA. Using qRT-PCR, each mRNA was detected in the poly(A) selected 
fraction and normalized to the total amount. The poly(A) selected RNA contained less than 6% 
of RnLUC HSL mRNA whereas 100% of the control RnLUC mRNA was poly(A) selected (Fig. 
7B). As expected, the FfLUC internal control was highly enriched in the poly(A) fraction (80-
100%). These results confirm that at least 94% of the RnLUC HSL mRNA is not poly-
adenylated. 
To measure PUM repression, PREs were inserted into the 3’ UTR to create RnLUC 
2xPRE HSL and 4xPRE HSL (Fig. 7A). The two and four PREs conferred 22% and 57% 
repression, respectively (Figure 7C). To determine if repression of HSL reporters by PUMs 
affected their mRNA level, we measured the levels of each mRNA by qRT-PCR. PUM 
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repression did not reduce the RnLUC 2xPRE HSL reporter mRNA and, in fact, the 4xPRE HSL 
mRNAs was more abundant than RnLUC HSL mRNA (Fig. 7D). This indicates that PUM 
repression of the HSL reporters may occur at the translational level, rather than by direct 
activation of mRNA degradation pathways. From these data we conclude that PUMs can repress 
mRNAs lacking poly(A) tails and, therefore, can also repress by a deadenylation independent 
mechanism. 
Discussion 
 Our results demonstrate that both human PUM1 and PUM2 are potent repressors that 
reduce levels of target mRNAs and cause a corresponding decrease in protein expression (Fig. 
1).  Endogenous PUMs have overlapping function and act redundantly to repress protein 
expression (Fig. 2). We show that human PUM1 and PUM2 repress autonomously and can be 
programmed to regulate new mRNAs, which offers potential therapeutic value for developing 
designer PUMs to reduce expression of deleterious genes (Fig. 3)(81,82). Furthermore, our 
results identify two modes of repression: deadenylation mediated repression and a deadenylation 
independent mechanism. 
Our data provide the first evidence that human PUMs use deadenylase enzymes as co-
repressors. PUMs physically associate with CNOT deadenylase subunits, including the four 
known deadenylase enzymes, CNOT6, 6L, 7 and 8 (Fig. 4), mediated by direct binding to human 
Pop2 orthologs, CNOT7 and CNOT8 (Fig. 4). The association of CNOT6 and 6L with PUMs is 
likely bridged via CNOT7 and CNOT8. Thus, we propose that PUMs recruit multiple 
deadenylase complexes to efficiently repress target mRNAs. The regulatory role of deadenylases 
in PUM repression is supported by the ability of dominant negative CNOT7 and CNOT8 mutants 
to inhibit PUM repression (Fig. 5). Importantly, these dominant negative mutants were 
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previously shown to inhibit deadenylation when expressed in vivo (74-77,79). Further support is 
provided by data showing that depletion of deadenylase enzymes reduces the magnitude of PUM 
repression (Fig. 6). Therefore, we conclude that deadenylation is necessary to achieve robust 
repression. 
Removal of the poly(A) tail through concerted action of PUMs and deadenylases is 
anticipated to reduce translation efficiency and, at the same time, initiate degradation of the 
mRNA by either 5’ decapping mediated decay, 3’ decay by the exosome, or both pathways (83). 
This model is supported by our observation that protein and mRNA levels are concomitantly 
reduced by PUM repression. In accordance with this model, a previous study concluded that 
PUM1 promoted degradation of target mRNAs (33). It is noteworthy that we were unable to 
detect partially or fully deadenylated mRNAs, likely because these intermediates are unstable 
and low abundance. 
Our results, combined with past data, indicate that PUF repression via deadenylation is a 
conserved mechanism. Correlations between deadenylation and PUF regulation were 
documented by studies in model organisms (29,35,38-41). Compelling evidence came from 
yeast, where PUFs were shown to accelerate mRNA deadenylation and degradation (42-
45,84,85). The Ccr4-Pop2 deadenylase is required for repression by yeast PUFs (43-45). In all 
cases, including human PUMs (Fig. 4), the highly conserved PUF RNA binding domain was 
sufficient for interaction with Pop2 orthologs (35,43,45,86); therefore, the PUF repeat domain is 
likely responsible for deadenylation mediated repression. 
While deadenylases are important for PUM repression, several observations provide 
evidence for a second poly(A) independent repression mechanism. First, dominant negative 
CNOT7/8 mutants do not completely block repression in vivo (Fig. 5). Second, depletion of 
108  
deadenylases does not fully alleviate Pum repression (Fig. 6). The third, more telling finding is 
that PUMs repress target mRNAs with a 3’ HSL, indicating that a poly(A) tail - and 
consequently deadenylation - is not absolutely essential. Taken together, these data support an 
additional deadenylation independent repression mechanism.  
Deadenylation dependent and independent mechanisms may function together to achieve 
maximal regulation. Indeed, the magnitude of repression of HSL mRNAs was less than that 
observed with polyadenylated reporter. Our results are reminiscent of a study that analyzed 
repression by the Drosophila PUF protein, Pumilio, wherein embryos were injected with reporter 
mRNAs either bearing a poly(A) tail or lacking a tail. Pumilio repressed the poly(A) mRNA 
most efficiently and, to a lesser degree, the tail-less RNA (40). Other mRNA regulators have also 
been reported to repress by deadenylation independent mechanisms. For instance, artificial 
tethering of the miRNA effector protein GW182 or the CNOT complex can inhibit HSL 
reporters, suggesting that PUM recruitment of CNOT might cause translation repression 
independent of deadenylation (87,88)  
How do PUMs cause deadenylation independent PUM repression? In addition to 
deadenylation, PUMs could activate another mRNA decay step, such as decapping; though the 
observation that the PRE containing HSL target mRNA were not degraded argues against this 
hypothesis (Fig. 7). Alternatively, PUMs might interfere with translation, supported by work in 
model organisms indicating that PUFs can inhibit translation (48,51,89). Germane to this idea, 
PUFs were recently reported to bind to a translation elongation factor (51). Furthermore, we 
recently characterized conserved repression domains in the N-terminus of Drosophila and human 
PUFs that may elicit deadenylation independent repression (63). Future investigations will 
evaluate these possible mechanisms.
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Figure 3.1. Repression by human PUM1 and PUM2 reduces protein and mRNA levels.   
A. A luciferase reporter assay was developed to study PUM repression in human cells.  Three Pumilio 
Response Elements (PRE) were inserted into the 3’ UTR of Renilla luciferase (RnLUC) to create the reporter 
RnLUC 3xPRE. As a control, those sites were mutated in RnLUC 3xPREmt to block PUM binding. Firefly 
luciferase (FfLUC) was cotransfected as an internal control.  B. Gel shift assay showing that PUM1 and PUM2 
bind to PRE RNA with nearly equal affinity, but do not bind the mutant PRE (PREmt). PRE RNA was labeled 
at the 5’ end with Cy5 fluor, whereas PREmt had a Dylight650 fluor, accounting for the difference in 
mobilities.  C.  Graph of Renilla reporter activity. Relative luminescence units (RLU) are normalized to the 
activity of the transfection efficiency control, FfLUC, shown in D.  E. Percent repression of luciferase 
expression from RnLUC 3xPRE and RnLUC 3xPREmt, calculated relative to RnLUC.  F. Reporter mRNA 
levels were measured by multiplexed qRT-PCR and fold changes, relative to RnLUC and normalized to 
FfLUC, are plotted.  G. Northern blot detection of Renilla reporters and the control, FfLUC, from equal 
amounts of poly(A) selected mRNA. Relative expression levels were calculated by normalizing Renilla mRNA 
in each sample to the FfLUC mRNA in that sample.  mRNA from mock transfected cells demonstrates 
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Figure 3.2. PUM1 and PUM2 repress RnLUC 3xPRE.  
A.  Endogenous PUM1 and PUM2 were depleted from HEK293 cells using siRNAs, as indicated at the top. 
Control indicates non-targeting control siRNAs.  Western blot of PUMs using specific antibodies. GAPDH 
western blot on the same samples served as a loading control.  B.  Graph of percent repression of RnLUC 
3xPRE, calculated relative to RnLUC, in samples treated with the siRNAs indicated at the top.  “None” 
designates that the samples were mock transfected without siRNAs.  “Control” indicates non-targeting control 









































Figure 3.3. PUM1 and PUM2 repress individually.  
A. Wild type PUMs bind to the wild type (WT) PRE sequence. Altered specificity PUMs (R6as) were created 
by changing RNA recognition amino acids of repeat 6 from NYQ to SYE, thereby binding to the altered PRE 
with a UGG sequence.  Numbers indicate the PUF repeats, aligned to corresponding PRE ribonucleotide.  B.  
Diagram of Renilla luciferase (RnLUC) reporters with three PREs (RnLUC 3xPRE), with mutant PREs (UGU 
changed to ACA) that cannot bind PUMs (RnLUC 3xPREmt) or reporter that is bound specifically by alter 
specificity PUMs (RnLUC 3xPRE UGG).  C. Regulation of each reporter calculated as percent repression 
relative to RnLUC reporter. Endogenous PUM1 and PUM2 repress RnLUC 3xPRE but not RnLUC 3xPRE 
UGG (Halotag samples). Halotag was expressed as a negative control. PUM1 R6as, expressed as a Halotag 
fusion, specifically represses RnLUC 3xPRE UGG.  D. PUM1 R6as and PUM2 R6as repressed the RnLUC 
3xPRE UGG reporter. Both PUM1 R6as and PUM2 R6as proteins were expressed as fusions to Halotag. 
Percent repression was calculated relative to reporter expression in samples transfected with Halotag control. 
Mean values are graphed and standard error of the mean is indicated. 
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Figure 3.4. PUM1 and PUM2 interact with deadenylase subunits of the CNOT complex.  
A. Deadenylases, fused to Halotag, coimmunoprecipitate (Eluate) with FLAG-tagged PUM1 and PUM2 from 
RNase treated extracts (Input). As a negative control (Control), mock immunoprecipitations were performed 
with anti-FLAG beads from samples expressing Halotag (HT) protein and Halotag deadenylase fusion proteins. 
Proteins were detected in input extracts or purified FLAG eluates by fluorescence labeling with the Halotag 
ligand TMR or by anti-FLAG western blot. B. Coomassie staining of recombinant, purified bait proteins: 
CNOT6, PUM1, and PUM2. PUMs were active for RNA binding (Fig. 1B). C.  In vitro deadenylation assay 
using wild type CNOT7 and CNOT8 or mutant CNOT7 mt and CNOT8 mt with Cy5 labeled RNA substrate 
with 10 nucleotide poly(A) tail (Cy5-RNApA10) or, as a marker, substrate lacking a tail (Cy5-RNApA0). EDTA 
was added as a negative control to chelate Mg2+ and thus inhibit deadenylation. D. Western blot (anti-MBP) of 
in vitro binding of recombinant, purified PUM1 and PUM2 to CNOT7 and CNOT8. Halolink bound PUM1 and 
PUM2 were incubated with MBP fusions of CNOT7 or CNOT8. As a positive control, CNOT7 and CNOT8 
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Figure 3.5. Dominant negative deadenylases alleviate PUM repression.  
A. Expression of a dominant negative CNOT8 mt inhibits PUM repression in HEK293 cells. Graph of percent 
repression, relative to the RnLUC, of the indicated reporters in cells transfected with increasing amounts of 
plasmid expressing CNOT8 mt protein. B. Expression of the Halotag-CNOT8 mt fusion protein was confirmed 
by fluorescent TMR labeling and detection on SDS-PAGE gel from the samples in panel A. Halotag alone was 
used to balance transfected mass of DNA and is therefore also detected. C. Dominant negative CNOT7 mt 
inhibits PUM repression. Graph of percent repression relative to RnLUC control of the indicated reporters in 
cells transfected with increasing amounts of plasmid expressing CNOT7 mt protein. D. Expression of Halotag-
CNOT7 mt fusions was confirmed by TMR detection on SDS-PAGE from the samples in panel C. Halotag 
alone was used to balance transfected mass of DNA and is therefore also detected.  In all graphs, mean values 
are graphed with standard error of the mean. 
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Figure 3.6. Depletion of deadenylases reduces PUM repression.  
A. RNAi depletion of Halotag fusions of Drosophila CCR4 (HT-CCR4) and POP2 (HT-POP2) deadenylases in 
D.mel-2 cells, assayed by SDS-PAGE and TMR fluorescence detection.  Halotag (HT) alone served as an 
internal control.  Percent knockdown of each protein is indicated below the figure.  B. Human PUM1 represses 
RnLUC 3xPRE reporter by 45% in D.mel-2 cells, relative to empty expression vector, pIZ. RNAi depletion of 
endogenous CCR4 and POP2 reduced repression to 28%. C. RnLUC 3xPRE mRNA levels were measured from 
samples in panel B using multiplexed qRT-PCR to determine the fold change in mRNA levels relative to empty 
expression vector, pIZ.  PUM1 reduced mRNA levels 44% on the control sample versus only 19% when 
deadenylases were depleted by RNAi.  D. RNAi depletion of endogenous POP2 inhibits PUM1 repression 
whereas knockdown of endogenous CCR4 does not. Non-targeting double-stranded RNA corresponding to the 
bacterial LacZ gene served as a negative control. Statistical significance is indicated with *, representing 





































































































































Figure 3.7. Poly(A) independent repression by PUMs.  
A. Renilla luciferase reporters (RnLUC) that lack a 3’ poly(A) tail were created by replacing the cleavage/poly-
adenylation sites with a histone stem loop (HSL) processing signal. Two or four PREs were inserted into the 
3’UTR to created RnLUC 2xPRE HSL and RnLUC 4xPRE HSL, respectively.  B. Graph of fold enrichment of 
RnLUC HSL, RnLUC, and FfLUC internal control mRNAs in poly(A) selected fraction isolated using oligo-dT 
affinity purification. Fold enrichment was measured by qRT-PCR analysis of poly(A) selected mRNA, 
normalized to total, and calculated relative to polyadenylated RnLUC.  C. Graph of percent repression relative 
to RnLUC HSL for the indicated reporters showing that endogenous PUMs repress 2x and 4xPRE HSL 
reporters.  D. Graph of fold change in reporter mRNA levels measured by multiplexed qRT-PCR and calculated 







































































































































































CHAPTER 4  
 
Identification of mRNAs regulated by human Pumilio proteins 
 
 
This work was carried out in collaboration with Trista Schagat, Rich McEachin, and 
Ashwini Bhasi and is currently in preparation for publication. Schagat carried out PUM 
knockdown in HEK293 cells, RNA isolation, quality control, and library preparation. 
McEachin and Bhasi carried out analysis of RNA Seq raw data. Van Etten validated 
RNA Seq targets by qRT-PCR, and performed additional bioinformatics analyses 
including GO analysis. 
 
Introduction 
 Regulation of gene expression is a complex and highly regulated process: failure 
to properly control translation or decay of messenger RNAs results in aberrant gene 
expression and disease. PUF (Pumilio and FBF) proteins are a family of conserved 
eukaryotic RNA binding repressors that bind to specific sequences in the 3’ UTR of 
messenger RNAs (1). All PUFs are characterized by the presence of an RNA binding 
domain (RBD) that contains 8 α-helical modular repeats, each of which binds a single 
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ribonucleotide (2-7). The binding interaction between each repeat and RNA nucleotide is 
mediated by three amino acids that recognize and confer binding specificity (7).  
PUFs control many biological processes in model organisms including: stem cell 
proliferation, fertility, development, and learning and memory, (3, 4, 8-25). Mammalian 
PUFs are thought to play a role in cell proliferation, neural function, and fertility (24-30).  
PUFs are generally known to behave as repressors in model organisms(1, 31). It is 
largely understood that PUFs in model organisms promote mRNA decay: yeast PUFs 
promote decay through deadenylation, enzymatic removal of the poly (A) tail, and 
decapping, enzymatic removal of the 5’ cap (32-34). Drosophila and C. elegans PUF 
repression correlates with deadenylation (8, 22, 35-37). PUFs are thought to act in 
concert with a number of co-repressor proteins in order to control the stability and 
translation of target mRNAs (4, 22, 30, 32-36, 38-42). In yeast, PUFs enhance 
deadenylation by binding to the Pop2p deadenylase subunit to promote deadenylation by 
the deadenylase Ccr4p (32, 33). The interaction between PUFs and POP2 orthologs is 
conserved from yeast to human(33, 41). Since mRNA decay and translational control are 
intimately linked, downstream effects of PUF mediated mRNA decay include 
translational repression, though at least one study found that yeast and C. elegans PUF 
cause direct inhibition of translation (39).  
Humans have two canonical PUF proteins, called PUM1 and PUM2, which are 
highly similar and expressed widely among tissues. Among their conserved RNA binding 
domains they share 91% identity and outside that region they share 75% identity (43, 44). 
PUM1 and PUM2 bind with high affinity to the sequence UGUANAUA: we will refer to 
this sequence as the PUM response element (PRE) (45, 46). Human PUM1 and PUM2 
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cause repression of reporter mRNAs by deadenylation-dependent and independent 
mechanisms (41). Overexpression of PUM2 with NANOS3 inhibits PRE-containing 
E2F3 reporters in TCCSUP bladder carcinoma cells and the authors argue that 
microRNA mediated repression in this case is facilitated by PUMs (29). PUM1 was 
reported to repress the p27 tumor suppressor gene (25). Recent studies indicate that they 
bind to deadenylases and promote decay of target mRNAs (41, 46). Furthermore, 
overexpression of PUM2 represses ERK2 and p38α reporter genes in human embryonic 
stem cells (47). Together with work done in model organisms, these studies suggest that 
that human PUMs enact evolutionarily conserved mechanisms to promote decay of 
mRNA targets. 
While it is known that PUM1 and PUM2 cause mRNA decay and protein 
repression, the identities of their targets are less clear (41). RNP immunoprecipitation- 
microarray (RIP-Chip), studies indicate that both human PUM1 and PUM2 bind 
hundreds of mRNAs, yet this binding data remains largely unexplored with functional 
assays (28, 45, 46). In one instance, depletion of PUM1 by RNAi modestly stabilized five 
mRNAs (46). PAR-CLIP (photoactivatable-ribonucleoside-enhanced crosslinking and 
immunoprecipitation) and RIP-Chip (RNP immunoprecipitation –microarray) studies 
identified RNAs bound to PUM1 and PUM2. RIP-Chip and PAR-CLIP techniques rely 
on high quality antibodies to coimmunoprecipitate bound RNAs and provide detailed 
information about the identities of the RNAs bound. RIP-Chip employs microarray 
analysis to identify bound RNAs to RBPs: hundreds of mRNAs bound to human PUM1 
and PUM2 were identified using this technique (45, 46). PAR-CLIP relies on 
photactivation of incorporated 4-thiouridine (4SU) into RNA transcripts in cells (48). 
123  
Associated RBPs are then crosslinked to 4SU-labeled transcripts and immunoprecipitated 
from cultured cells, and subjected to deep sequencing (48). This technique enables high 
throughput identification of RNAs bound to specific proteins. Studies employing this 
technique identified 2847 bound RNA targets of PUM2-FLAG fusion proteins in 
HEK293 cells (48).  
We previously reported robust depletion of both PUM1 and PUM2. We also 
demonstrated that knockdown significantly de-repressed PUM target mRNAs. It is 
important to note that, since both PUM1 and PUM2 are potent repressors of reporter 
mRNAs containing a PRE, their functions may overlap in specific instances (41). 
Therefore, studies measuring regulation by either PUM1 or PUM2 alone may miss 
important regulatory information.  
Here we seek to identify target mRNAs repressed by PUM1 and PUM2 using 
RNAi of both PUM1 and PUM2 in human cells coupled with comparative RNA 
Sequencing (RNA-Seq) analysis between control and knockdown samples. RNA-Seq, or 
whole transcriptome shotgun sequencing, is a methodology that uses next generation 
sequencing to identify RNAs present across a broad dynamic range in a sequence library. 
This technique can therefore be used to detect changes in expression level among 
thousands of RNAs in response to depletion of PUM1 and PUM2. The advantages of 
RNA-Seq analysis are numerous: most importantly, its dynamic range is broad and 
quantitative (49). Furthermore, it is possible to carry out multiple replicates in one 
experiment. By knocking down PUM1 and PUM2 in HEK293 cells, we circumvent 
possible problems with the proteins’ potential overlapping functionality. 
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Few mRNAs that are directly regulated by PUMs have been reported; therefore, it 
is essential in order to understand the biological functions of PUMs. We sought to 
identify and validate mRNAs that are significantly regulated upon knockdown of PUMs 
in HEK293 cells. We took a multidimensional approach to identifying PUM regulated 
target mRNAs using the following assumptions: 1) Abundance of PUM target mRNAs 
should reproducibly change whenever the PUM is depleted. 2) PUM target mRNAs 
should contain a PRE motif.  The binding affinity and specificity of PUM1 and PUM2 
has been extensively analyzed and the PRE consensus corresponds to UGUANAUA(45). 
We previously showed that the presence of the PRE in an mRNA can elicit up to a 4-fold 
reduction in target mRNA abundance (41). To identify high confidence target mRNAs, 
we then compared those that are differentially regulated by PUMs to those that contain 
PREs and/or were experimentally shown to bind to PUMs in RIP-CHIP and PAR-CLIP 
studies (45, 46, 48). We identified over 1000 RNAs that were differentially expressed 
upon PUM knockdown and found that 486 of those RNAs contain predicted PREs. We 
found 287 that met the following criteria: 1) The RNA was differentially expressed in our 
dataset, 2) The RNA contains at least one PRE, and 3) The RNA was identified in 
previous RIP-Chip or PAR-CLIP analyses. Furthermore, we went on to demonstrate 
validation of multiple PUM targets by qRT-PCR analysis. Together, our results provide 
insight into the potential regulatory roles of PUMs in biological processes. Using highly 
sensitive RNA-Seq analysis, we identify a set of high confidence direct PUM RNA 
targets and, importantly, take into account the presence of both PUM1 and PUM2 in 
human cells.  
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Materials and methods 
Cell culture and siRNA transfections 
Human HEK293 cells were cultured at 37°C under 5% CO2 in DMEM with 
glucose and 1 x Penicillin/Streptomycin/Glutamine and 10% FBS (Gibco) as described 
previously (41). PUMs were knocked down in HEK293 cells using On-target Plus 
Smartpool siRNAs for PUM1 (L-014179-00), PUM2 (L-014031-02), or non-targeting 
control siRNAs (Dharmacon). For RNA Seq experiments, HEK293 cells (2 x 105 cells 
per well) were plated into a 12-well plate. After 24 hours, 500 µL culture medium was 
removed and cells were transfected with 100 fmoles of siRNAs using Dharmafect-I 
(Dharmacon). After 4-8 hours of siRNA treatment, 500 µL culture medium was 
refreshed. After 24 hours, 500 µL culture medium was removed and cells were 
transfected again with 100 fmoles of siRNAs using Dharmafect-I. After 4-8 hours of 
siRNA treatment, 650 µL culture medium was refreshed. Cells were harvested 48 hours 
after last transfection for RNA purification and RNA Seq experiments. 
Western blotting 
Protein lysates were created by lysing cells on ice in TNEMN-150 plus 1X 
protease inhibitor cocktail as described in (41). SDS PAGE loading buffer was added to 
samples to a final concentration of 1X and the samples were boiled for 10 minutes. 
Lysates were run on a 12% SDSPAGE gel for 1.5-2 hours at 100 volts and transferred at 
80V for 2 hours at 4°C. Blots were blocked in blotto (5%: 5g dried milk in 100 mL 1X 
PBS and 0.1% Tween-20) overnight at 4C. Blots were incubated in primary antibody for 
1 hour at room temperature with gentle rocking, washed 3 times for 10 minutes with 
blotto, and incubated in secondary antibody for 1 hour at room temperature with gentle 
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rocking. Blots were washed 3 times for 10 minutes with gentle rocking, developed with 
Millipore Immobilon reagent, and visualized with X-ray film. Antibodies used in these 
experiments were described in (41).  
RNA Seq  
Control samples were transfected in triplicate with nontargeting siRNA pools as 
described above. PUM knockdown samples were transfected in triplicate with PUM1 and 
PUM2 siRNA smartpools as described above. RNA-Seq analysis was performed on poly 
(A) enriched RNA isolated from HEK293 cells. Total RNA was purified using the 
Maxwell simplyRNA cells kit (Promega). Polyadenylated RNAs were isolated using 
oligo dT purification and prepared for sequencing according to manufacturer instructions 
for Illumina sequencing. Bar coded libraries for each sample were generated according to 
the Illumina TruSeq kit instructions. Purity and integrity of total RNA was using a 
Bioanalyzer before deep sequencing.  All total RNA samples had RIN values of 10, 
which is the highest possible value, and indicates that they are high quality nucleic acid 
samples.  
Samples were submitted to the University of Michigan Sequencing Core for 
Illumina sequencing, paired end, 100 base sequencing on an Illumina HiSeq instrument.  
Libraries were multiplexed in a single “lane”. More than 26 million sequence reads per 
sample were obtained for each of six samples: 3 control NTC siRNA and 3 PUM1/2 
knockdown. Low quality sequence reads were filtered by Illumina’s CASAVA software. 
The resulting dataset was subjected to FASTQC analysis and trimmed to give 86 good 
quality base reads.  
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The data analysis pipeline included analysis with the Tuxedo suite: 1) TopHat and 
Bowtie were used to map and align reads, Cufflinks was then used to quantify abundance 
of each transcript, and Cuffmerge and Cuffdiff (2.1) using a false discovery rate of  ≤0.05 
were used to assess differential abundance as described in (49). Relative abundance was 
reported in reads per kilobase of exon per million fragments (RPKM values).  
RNA purification and cDNA amplification with reverse transcriptase  
 Three replicates of cell populations transfected with either nontargeting control 
siRNA or PUM1/2 siRNA smartpools were harvested for RNA purification and qRT-
PCR analysis. RNA was purified from HEK293 cells in 6 well dishes after siRNA 
treatment using the Maxwell RNA simplyRNA cells kit as described previously, 
including the on bead DNase treatment (41). cDNA was synthesized using GoScript 
Reverse Transcriptase as indicated in manufacturer instructions and as described in (41). 
After cDNA synthesis, samples were diluted appropriately in nuclease free water and 
used for qPCR validation.  
Quantitative PCR 
qPCR was carried out using GoTaq qPCR (Promega). Cycling conditions were as 
follows: (i) 95°C for 3 minutes, (ii) 95°C for 10 sec, (iii) 65°C for 30 sec, and (iv) 72°C 
for 40 sec. Steps (ii) through (iv) were repeated for a total of 40 cycles. Negative control 
reactions were performed in the absence of template or reverse transcriptase. Cycle 
thresholds (Ct) were measured using the CFX Manager software and analyzed using the 
ΔΔCt method (50, 51). ΔCt was calculated by normalizing to the 18S gene Ct values. We 
then calculated ΔΔCt as follows: ΔΔCt= ΔCt(target RNAi)- ΔCt (control RNAi). All 
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primer set amplification efficiencies were optimized to 90-110% at 200 nM final 
concentration. qPCR primer sequences are as follows:  
ANO4 FWD: GAAGTACTTGATTCAGGAGATGATGTATG 
ANO4 REV: GAAGAAGTAAACAGAATTCAGGTCCTTGG 
NOVA2 FWD: CTCATCAGTCAGCGGGTCACCTAC 
NOVA2 REV: GAGGAGCAGGACTACACCAAGCTG 
DEK FWD: GCAAAAAGGTCTATGAAAATTATCCTACTTATG 
DEK REV: GAAAAGGAAATACATTCTCTTTGCTGG 
RET FWD: CTCGAGCCCTCCCTTCCACAT 
RET REV: AAGCATCCAGTTAGCATATACACTATCATTTG 
DUSP6 FWD: ACAACAGGGTTCCAGCACAG 
DUSP6 REV: AAACTGCTGAAGGGCCAGAC 
ETV4 FWD: CTGCGACCATTCCCAGATGATGTC 
ETV4 REV: CAAGGCCACCAGAAATTGCCAC 
L1CAM FWD: GGCGGCAAATACTCAGTGAAGG 
L1CAM REV: TACTCGCCGAAGGTCTCATC 
SCUBE1 FWD: GATCCGAGATGCCAAGTGCCA 
SCUBE1 REV: CGATCTCAAACTCTGCTGTG 
SMPDL3A FWD: CAAATCTCCAGGTTTTCCCTGCGC 
SMPDL3A REV: GAATAAAAACCACCTTTCCTTAAAGTACTAATAGC 
FZD8 FWD: GGCGAGCTCCGTGTCTTATCC  
FZD8 REV: CTTCGCTGCACTTGGCTCTCCT 
FMR1 FWD: CCGAACAGATAATCGTCCACGTAA 
FMR1 REV: GTGCGCAGCCGACTACCTTCA 
PUM1 FWD: CATGAACGACGGTCCCCACAG 
PUM1 REV: GCTTGGCCAGAATGTGCTTGC 
PUM2 FWD: ATGCAATACTGTCTCCGCGATCAG 
PUM2 REV: CTTTCTCAGGTCCATCTGTTTCAGC 
18S FWD: CAGCCACCCGAGATTGAGCA 
18S REV: TAGTAGCGACGGGCGGTGTG 
Results 
PUM1 and PUM2 regulate the abundance of more than 1000 mRNAs 
 PUM1 and PUM2 were depleted from HEK293 cells by RNA interference 
mediated knockdown with specific siRNAs.  Triplicate cell populations were treated with 
PUM1 and PUM2 siRNAs (PUM1/2 kd). Triplicate cell populations were treated with 
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non-targeting control siRNAs (NTC) as a negative control. Depletion of PUM1 and 
PUM2 in the PUM1/2 siRNA treated cells was confirmed by Western blot. Neither 
PUM1 nor PUM2 protein was detected in extract from cells treated with the PUM1 and 
PUM2 siRNAs, whereas both were readily detected in NTC extracts (Fig. 4.1A).  
Additionally, we previously demonstrated that RNAi depletion of PUM1 and PUM2 
using this method specifically alleviated PUM repression of a luciferase reporter  
containing PREs in its 3’ UTR (Fig. 3.1) (41). 
Total RNA was purified from each cell population, and the integrity of each RNA 
sample was verified by Bioanalyzer analysis. Next, poly-adenylated RNAs were purified 
from each sample using oligo-dT affinity purification. Barcoded cDNA libraries were 
generated for each sample according to Illumina Tru-Seq library generation method. The 
workflow for sample preparation and library generation is outlined in Figure 4.1B. 
Sequencing was performed with a HiSeq system (Illumina). More than 26 million reads 
per sample were obtained for each sample and corresponding to more than 18500 genes. 
Using this data, normalized expression values were determined for each gene in units of 
RPKM (reads per kilobase per million). The RPKM values spanned a range of 7 orders of 
magnitude (Range of 0.0009-1788) (Table 4.1, Supplemental table S1).  
The resulting RNA abundance data was analyzed to detect statistically significant 
changes in abundance between NTC and PUM1+2 kd conditions. 1035 genes were 
reproducibly, differentially expressed in the PUM1+2 knockdown sample  (Table 4.1).  
The complete list of differentially expressed targets is available in the supplemental 
information (Table S1).  Fold changes of these mRNAs ranged from 3.81 to 0.287, 
relative to the NTC control.  We note that fold changes with larger magnitudes were 
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observed but these did not meet criteria for statistical significance. As expected, PUM1 
and PUM2 mRNAs were present in the differentially regulated dataset and confirmed that 
they were depleted by corresponding siRNAs by 64% and 73%, respectively.  
Of the 1035 differentially regulated genes, 695 RNAs increased in abundance in 
the absence of PUMs, indicating that they are negatively regulated by PUM1 and PUM2 
(Fig. 4.2A, Table S1 in red). Conversely, 340 RNAs were reduced in abundance upon 
PUM knockdown, implicating PUMs in positive regulation those genes (Figure 4.2B, 
Table S1, highlighted in green).  One basic question that remained unanswered is: do 
PUM target RNAs fall within a specific expression range?  Are PUM targets abundant or 
rare? The results shown in Fig. 4.2 demonstrate that PUM regulated RNAs span all 
expression ranges detected: therefore, PUMs do not appear to preferentially regulate 
genes in a manner that depends on their expression level (Fig .4.2A, B).   
By imposing an arbitrary cutoff of ≤1.5 –fold or ≥1.5-fold for differential 
expression: we find that 387 genes are affected by knockdown of PUM1 and PUM2.  
These genes included 271 that increased in abundance whereas 116 of the RNAs 
decreased in abundance. Two mRNAs meeting this cutoff were previously identified as 
putative PUM1 targets in RIP-Chip studies, and were validated by qRT-PCR (45, 46). 
We next asked if PUM mRNA targets previously reported in the literature were 
differentially regulated in our dataset. The SLBP mRNA, which contains 1 3’ UTR PRE, 
was reported to be stabilized upon PUM1 knockdown (46). We corroborated its 
regulation in our dataset, and found that it is upregulated 1.55-fold upon PUM1/2 
knockdown. We also discovered that PCNA mRNA, which contains 2 PREs in its 3’ 
UTR, was upregulated 1.56-fold upon PUM knockdown. PCNA mRNA encodes a 
131  
nuclear protein involved in replication and was reported to be modestly stabilized by 
PUM1 knockdown in a previous study (46). Two other PRE containing mRNAs, CKS2 
and UBA2, were upregulated 1.48 and 1.41-fold, respectively, upon PUM1/2 
knockdown. Both mRNAs contain PREs in their 3’ UTRs. UBA2 mRNA encodes 
sumoylation ligase that is involved in p53 induced apoptotic activity and was identified in 
a RIP-Chip study examining PUF regulated mRNAs in PUM1 deficient mice: UBA2 
mRNA isolated from PUM1 deficient mice was upregulated in qRT-PCR studies (28). 
The CKS2 mRNA encodes a protein that binds the catalytic subunit of cyclin dependent 
kinases and is cell cycle regulated (46). Several mRNAs that were previously verified in 
RIP ChIP studies including p27, ERK-2, p38α, and E2F3, did not meet statistical tests in 
our study (25, 29, 47).   
 We next sought to gain insight into the physiological functions of genes encoded 
by mRNAs differentially regulated in our dataset. Gene ontology analysis was carried out 
using PANTHER analysis for each of three GO terms, biological process, molecular 
function, and cellular component, on our dataset of 1033 differentially regulated PUM 
target mRNAs (52, 53). Results from this study are shown in Table 4.2. Note that many 
genes fell into the “unclassified” GO term, and were thusly removed from the table. 
Several GO terms from three categories, Biological Process, Cellular Component, and 
Molecular Function, were enriched in our dataset (Table 4.2). Many genes in the dataset 
are involved in developmental processes, which is expected given what is known about 
PUF function in model organisms; here, we see that developmental process, system 
development, nervous system development, ectoderm development, and mesoderm 
development are statistically overrepresented in our dataset (Table 4.2). Furthermore, cell 
132  
communication, cell surface receptor linked signal transduction, and cell adhesion are 
also overrepresented in the dataset (Table 4.2).  
KEGG pathway analysis was carried out on the same list of mRNA targets using 
the DAVID functional annotation tool (Table 4.3) (54-56). Several pathways are enriched 
in our dataset including several cardiomyopathies, MAPK, cytokine, TGF-beta, and p53 
signaling pathways, as well as regulation of the actin cytoskeleton and melanogenesis 
(Table 4.3). It is important to note that axon guidance is enriched 2.59-fold (p-value 
1.29x10-4) in our dataset (Table 4.3). There is a great deal of work implicating 
Drosophila PUM in neuronal function and axon guidance, as well as in mammalian 
neurons; therefore, human PUMs may serve similar regulatory roles in the nervous 
system (16, 17, 21, 57-59). We also discovered that p53 signaling pathway is 
overrepresented in our dataset 2.34-fold (p-value 2.5x10-2): here, we show that PUMs 
affect expression of downstream targets of p53 signaling including CDKN1A (p21), 
SFN, Lrdd, BBC3, Cyclin D, BAI-1, RRM2B, Cyclin G, Cdc2, and CASP3 (Table 4.3). 
Further, it was shown that mammalian PUM1 represses regulators of the p53 pathway in 
mice (28). These analyses indicate that PUMs regulate multiple components of several 
pathways including cell proliferation pathways, tumor suppressor signaling, and neural 
function.  
Transcriptome-wide prediction of human PUM response elements 
 We next sought to determine the number of RNAs that contain predicted PUM 
response elements (PREs). We did so in order to extract the highest probability targets 
from our differentially regulated dataset. Direct targets of PUM proteins should contain at 
least one PRE; therefore, we selected only those RNAs for further analysis.  
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 We limited our search to the well-characterized, high affinity PRE consensus site 
UGUANAUA, which has been shown to be necessary and sufficient to confer PUM 
repression of a reporter mRNA (41). We compared differentially regulated genes in our 
dataset against the human transcriptome (UCSC genome version Hg19), which contains 
annotations for 40,901 RNAs, including 34,375 mRNAs and 6526 ncRNAs. Of those 
annotated RNAs, 9304 mRNAs had UGUANAUA PRE sites. This set of RNAs included  
isoforms produced by the same gene. When condensed, 5235 unique genes contained one 
or more predicted PRE motifs. 80.2% of predicted PREs are located in the 3’UTR. It is 
noteworthy that nearly all known PUF regulated mRNAs have PUF binding sites present 
in the 3’UTR. 16.4% of predicted PREs reside in coding sequences and only 2.0% of 
PREs of predicted PREs are located in the 5’ UTR of transcripts (Fig. 4.3A). Several 
genes contain PREs in multiple locations along the transcript: 67 genes contain at least 
one site in each untranslated region, and 7 genes contain at least one in the 5’ UTR, 
coding region, and 3’ UTR (Fig. 4.3A). Noncoding RNAs were discovered to contain 
PREs, sometimes in large numbers depending on the transcript: 764 of the total number 
of PREs identified (Fig. 4.3A). The discovery of polyadenylated noncoding in the 
differentially regulated dataset is surprising: there are no documented cases of PUF-
mediated regulation of a noncoding RNA to date.  
 Known PUF targets contain PREs in their 3’ UTRs, however, it has yet to be 
disproven that PREs are located elsewhere in the mRNA. Intriguingly, many mRNAs or 
ncRNAs contain more than one PRE. The average number of predicted PREs per 
transcript is ~ 1.5, however, the range is between 1 and 16 PREs in mRNAs and ncRNAs. 
RNAs are predicted to contain between 1 and 13 PREs in the 3’ UTR, 1-2 in the 5’ UTR, 
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and between 1-10 in the coding region (Figure 4.3B). Several ncRNAs identified in our 
dataset contain multiple predicted PUM sites, ranging between 1 per transcript and 16 in 
some RNAs: specifically, the ncRNA HCG11 contains 16 predicted PREs, and 
LOC647979 contains 15 predicted PREs.     
PREs are enriched in the 3’ UTR of target mRNAs 
To further narrow our list of strong direct PUM targets, we determined which 
RNAs contained PREs using our prediction analysis. We found that 486 PUM target 
RNAs, including ncRNAs and mRNAs, contain at least one PRE. 406 PRE-containing 
RNAs were upregulated in response to PUM knockdown, consistent with these being 
repressed by PUMs. The remaining 80 of PRE-containing RNAs, were downregulated 
upon PUM knockdown, which suggests that they are activated directly or indirectly in 
response to PUM activity.  
Next we sought to determine the locations of PREs in differentially regulated 
PUM target genes. Of those predicted sites found in upregulated mRNAs, 1199 PREs 
were found in the 3’UTRs of the 406 strong direct PUM targets we identified. 
Furthermore, 108 PREs are located in the ORF, and 6 PREs are in the 5’UTR. 214 
predicted PREs were found in the 80 genes potentially activated by PUMs: 189 sites are 
located in the 3’UTR, 17 are in the ORF, and 8 are in the 5’UTR. From these data, we 
conclude that mRNAs responsive to PUM regulation have PREs primarily in their 3’ 
UTRs. The RAD51AP1 mRNA contains one PRE in its 5’ UTRs and is upregulated in 
our differentially expressed dataset 1.3-fold. Furthermore, 12 upregulated mRNAs 
contain one PRE in their ORF but not in either UTR, including: BOD1L, COL21A1, 
DOCK9, DSEL, FBN2, GMCL1, KDR, NBEAL1, NCKAP5, NTS, SLC16A9, and 
135  
ZNF711. Four downregulated mRNAs including: FHL1, IFIT2, STAT1, and STOX2 
have a PRE only in their 5’ UTR. Ten mRNAs including: APPBP2, ATL3, CBWD1, 
CTDNEP1, IFIT1, IFIT3, NOL11, PKDREJ, PPP2R2A, and PPP2R2D are 
downregulated in our differentially expressed dataset and contain PREs in their ORFs 
only. Since a small percentage of PREs are located in the ORF and 5’UTR of target 
RNAs, the possibility that regulation occurs through sites located elsewhere in the mRNA 
cannot be ruled out.  
Identification of high confidence PUM RNA targets 
 Our next goal was to compare differentially expressed RNA targets that contain 
PREs with PUM bound (or associated) RNAs identified in RIP ChIP and PAR-CLIP 
studies (45, 46, 48). Morris et al. used RIP-Chip to identify PUM1 associated RNAs in 
HeLa S3 cells: 726 associated RNAs were identified in this study and several genes were 
validated by qRT-PCR (46). We know from previous work that PUMs have overlapping 
functions in human cells, and therefore, it is likely that many regulated PUM targets were 
omitted from the Morris study, as PUM2 was not considered for analysis (41). Galgano et 
al. performed RIP-Chip with antibodies to both human PUM1 and PUM2 in HeLa S3 
cells and thusly identified 1040 PUM1 and 435 PUM2 associated RNAs, about half of 
which contain PREs (45). Hafner et al. performed PAR-CLIP to identify PUM2 
associated RNAs and identified ~3000 transcripts associated with PUM2 isolated from 
HEK293 cells (48). Together, these analyses provide a list of PUM1 and PUM2 bound 
mRNAs. Experimental limitations imposed by PAR-CLIP and RIP-Chip, such as 
expression and detection of mRNAs, quality of antibodies used for immunopurification, 
and crosslinking efficiency, likely leave many associated RNAs from our purview.   
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The purpose of our analysis is to test whether or not previously established 
evidence of widespread PUM regulation and their targets agree with our own predictions 
and findings in order to generate a set of high confidence PUM target genes. First we 
identified those genes that met criteria for differential expression: this is called the 
“Response” dataset, and consists of 1033 genes either up- or down-regulated in response 
to PUM knockdown. We compared those to 5235 genes predicted to contain at least one 
PRE, called the “Predicted PRE” dataset, and found that 486 genes meet both sets of 
criteria (Fig. 4.4A). Together, RIP ChIP and PAR-CLIP studied yielded a set of 4071 
unique genes that bind either human PUM1, PUM2, or both: this will be referred to as the 
“Bound” dataset. We next compared the genes found in the Bound dataset to the 1033 
genes in the Response dataset. Comparison between Bound and Response yielded 389 
overlapping genes between our RNA Seq analysis and RIP-Chip and PAR-CLIP studies 
(Fig. 4.4B). We also compared the genes found in the Bound data with the Predicted PRE 
dataset and identified 2007 genes of 4071 Bound RNAs that met both criteria (Fig. 4.6C). 
Lastly, we compared all three studies to identify the highest confidence PUM targets: 287 
genes contain at least one predicted PRE, were discovered in RIP-Chip and PAR-CLIP 
assays to bind either PUM1 or PUM2, and met criteria for differential regulation in our 
RNA Seq studies (Fig. 4.4C).  
Biological significance of newly identified PUM target RNAs 
We next wanted to determine if PUMs control specific pathways. To do so, we 
performed gene ontology analyses using DAVID and PANTHER on high quality PUM 
target RNAs. We honed in on those target RNAs that are differentially regulated in our 
dataset. Our analyses in the following sections will focus on key features and known 
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roles of RNAs in the Response dataset that contain predicted PUM sites in order to gain a 
better understanding of their roles in biology and how PUM regulation might affect 
physiological processes. 
After identifying many hundreds of activated and repressed PUM targets, we 
sought to better understand their functional roles in human cells. We performed gene 
ontology analyses on each upregulated and downregulated dataset independently with the 
intention of finding specific pathways that are regulated by PUMs. Through these 
analyses we discovered that PUMs regulate genes encoding components of multiple 
biological processes including cell communication, nervous system, mesoderm, heart, 
and ectoderm development, as well as cell adhesion were statistically enriched with p-
values ≤ 0.05 (Table. 4.4). Interestingly, repressed PUM targets are statistically enriched 
in extracellular matrix categories, and appear to regulate genes involved in receptor 
activity and binding, and enzyme regulation (Table 4.4). KEGG pathway analysis 
indicated PUM regulated RNAs are involved in axon guidance, p53 signaling, and 
several other pathways (Table 4.3). We found that, of those RNAs identified in GO 
KEGG pathway analysis for the p53 signaling pathway, six contain predicted PREs 
including p21 (CDKN1A), p53R2 (RRM2B), PUMA (BBC3), Cyclin G (CCNG2), 
CDC2 (CDK1), and CASP3. This data supports that PUMs repress multiple components 
of biological pathways.  
We analyzed PUM roles in disease pathways using DAVID and discovered that 
repressed PUM targets are statistically enriched in disease pathways, which include 
disorders of lipid metabolism, as well as psychiatric conditions and developmental 
disorders (Figure S2). PANTHER analysis yielded no results with p-values ≤0.05 in 
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terms of statistical enrichment of activated PUM targets; intriguingly, however, activated 
targets were enriched in intracellular and cytoskeleton cellular components 
(Supplemental Fig. S2). 
Secondary validation of human PUM regulated mRNAs  
 We next sought to validate regulation of selected high confidence PUM mRNA 
targets. mRNAs were chosen based on their relevance to human disease, as well as their 
potential for PUM regulation (ie: they exhibited high fold change among differentially 
regulated genes). Expression of the following repressed PUM target mRNAs: SCUBE1, 
SMPLD3A, DEK, ANO4, FMR1, FZD8, L1CAM, NOVA2, and RET. Furthermore, the 
following activated PUM targets were analyzed: DUSP6, and ETV4. Knockdown of 
PUMs was performed in HEK293 cells in triplicate following the same protocol that was 
used to prepare RNA-Seq cDNA libraries: cells were then harvested for RNA purification 
and cDNA synthesis with reverse transcriptase.  
Next, we quantified changes between control and PUM k/d samples using 
quantitative PCR analysis: duplicate qPCR assays were carried out for each of three RNA 
samples for either PUM kd or NTC. We anticipated that relative changes in RNA level in 
qPCR assays would mirror changes seen in RNA-Seq analysis. Relative fold changes 
were calculated using the comparative Ct method by which we normalized each sample 
to the internal control 18S ribosomal RNA. We discovered that each selected gene was 
either increased or decreased upon knockdown of PUM1 and PUM2 to nearly the same 
degree as in RNA Seq experiments (Table 4.5). We wished to identify targets involved in 
key regulatory pathways and in human disease, and therefore chose a number of 
oncogenes and neural regulators to validate by qRT-PCR (Table 4.6). Additionally, all 
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validated targets contain at least one PRE, but several have multiple PREs (Table 4.7). 
Most sites lie in the 3’UTR of target mRNAs, however, the DEK oncogene contains three 
PREs, two of which are located in the 3’ UTR, but one is located in the ORF. It is 
unknown if the PRE located in the ORF confers regulation, as no PUM targets confirmed 
to date contain ORF or 5’ UTR PREs. 
DEK is an oncogene whose upregulation is associated with many cancers. Upon 
depletion of PUM1 and PUM2, DEK mRNA increased in abundance by 1.6 fold in 
theRNA Seq assay and 1.2-fold in the qRT-PCR assay (Table 4.5). Another PUM target, 
the mRNA encoding FMR1, deficiency of FMR1 causes Fragile-X mental retardation and 
premature ovarian failure in female patients is upregulated 1.3-fold in RNA Seq 
experiments and 1.4-fold in qPCR studies (Table 4.5). Two highly regulated mRNAs 
encode SCUBE1 and SMPDL3A, which are two proteins thought to be involved in 
vascular biology and bladder cancer, respectively. SCUBE1 is a marker of platelet 
activation and is thought to be upregulated in hypertension(60). SCUBE1 mRNA 
increases by 2.4-fold (RNA-Seq) and 2.2-fold (qPCR) upon PUM knockdown (Table 
4.5). SMPDL3A is characterized as a binding partner of DBCCR1 (deleted in bladder 
cancer 1), which when overexpressed, leads to upregulation of SMPDL3A (61). 
SMPDL3A mRNA increased 2.4-fold (RNA Seq) and 2.3-fold (qPCR) upon PUM 
knockdown from HEK293 cells (Table 4.5).  
Intriguingly, several high confidence PUM target mRNAs that we identified 
decreased in abundance upon PUM knockdown, which indicates that they may be 
directly activated by PUMs (Table 4.5). DUSP6 is a cytoplasmic dual-specificity 
phosphatase that is thought to target two MAP kinases, ERK1 and ERK2 (62). Our 
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analysis demonstrates that this mRNA decreased 0.5-fold in RNA Seq and 0.7-fold in 
qPCR analyses upon PUM knockdown (Table 4.5). ETV4, a transcription factor, 
decreased markedly in our dataset by 0.3-fold (RNA Seq), and 0.4-fold in qPCR assays 
(Table 4.5). Further study will be necessary to dissect the regulatory role human PUMs 
play in the control of these biological target mRNAs, and our results demonstrate their 
status as PUM targets and provide researchers a starting point for future mechanistic 
study.  
Discussion 
We identified 1033 RNAs that were differentially regulated when PUMs were 
depleted with siRNAs in HEK293 cells. 486 of those differentially regulated RNAs 
contain at least one PRE and were considered high quality PUM targets. That is not to 
say that targets that do not contain a PRE are not subjected to PUM-mediated regulation, 
however regulation of targets lacking a PRE are likely indirect targets, and are controlled 
by an intermediary factor affected directly by PUMs. Furthermore, we recognize the 
potential for false negatives in our experimental design: the cell population and 
subsequently purified RNA population was not a null PUM background, samples with 
too much variability between replicates were ignored as they did not pass statistical 
cutoffs, and many genes were not detected or were too low in this cell population. We 
detected four RNAs in our dataset that were previously identified as PUM targets, 
including SLBP, PCNA, CKS2, and UBA2. It is likely that we did not identify other 
targets, including many p53 regulators, MAP kinases, and p27, in our dataset because of 
limitations of our RNA-Seq experiment. RNA targets may have been missed because, 
under specific conditions, they have shortened 3’ UTRs lacking PRE elements necessary 
141  
for PUM repression. We are confident that those RNAs we identified that contain at least 
one PRE are high confidence PUM targets, but recognize that there may be many more 
RNA targets of PUMs that contain weaker PREs that could be responsive to regulation.  
Among those targets containing at least one PRE, 287 RNAs were associated with 
PUM1 or PUM2 in previous analyses (45, 46, 48). Gene ontological analyses indicate 
that several biological pathways are represented among our dataset of PUM targets that 
contain PREs, including developmental processes, tumor suppressor signaling pathways, 
and neural pathways. From these data, we conclude that both PUM1 and PUM2 are 
regulators of many RNAs involved in multiple pathways.  
486 RNA targets that contain at least 1 PRE are differentially expressed in 
HEK293 cells depleted of PUM1 and PUM2. Importantly, this is the first study that looks 
directly at levels of RNA in response to changes in endogenous PUM1 and PUM2 protein 
levels in human cells.  PREs are enriched in 3’ UTRs of high confidence targets we 
identified: it will be interesting in the future to test genes that contain PREs in several 
sites: this could provide insight into a new mode of PUF regulation, or possibly a 
mechanism by which PUF repression is strengthened in a combinatorial fashion.  
We compared RNA Seq, PRE prediction, gene ontology analyses, and 
comparison with other datasets to provide a high quality set of RNA targets of PUM 
regulation and demonstrate the tremendous potential for PUM control of many aspects of 
normal and abnormal physiological processes in humans. 406 targets in our dataset are 
strong candidates for PUM mediated repression, as they increase in abundance upon 
PUM knockdown and contain at least one PRE. We know that both PUMs are potent 
repressors of a reporter RNA containing 3 PREs in its 3’ UTR via deadenylation-
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dependent and independent means; therefore, our data suggest that these 406 genes are 
direct targets of PUMs but functional validation and PUMs’ effects on their decay 
remains to be shown (41). Regulation of these 406 RNAs likely impacts a breadth of 
biological processes and future work will focus on validating PUM regulation of RNAs 
involved specific pathways. Gene ontology analysis and previous studies suggest 
involvement of mammalian PUMs in nervous system function, development, and cell 
proliferation; therefore, it will be of future interest to focus on PUM regulation of these 
pathways.  
We were surprised to find that 80 PRE-containing RNAs were decreased in 
abundance upon PUM knockdown and are therefore candidates for activation by PUMs. 
PUM target activation has been demonstrated in few studies. This could occur by a 
number of mechanisms: PUMs may repress a repressor, which would in turn, result in 
upregulation of an indirect PUM target RNA. Since we find that 80 activated PUM target 
RNAs contain PRE, however, it is more likely that a direct activation mechanism exists 
to control the abundance of these RNAs. PUMs may carry out activation through a 
mechanism that is yet to be discovered: similar to their repressive mechanisms, PUMs 
may bind to the RNA through a specific interaction with the PRE, but instead recruit 
RBPs or effectors that activate their targets. Alternatively, other cis sequence elements 
may contribute to combinatorial control by several different RBPs including PUMs to 
activate RNA targets. Insertion of a PRE near a CPE (cytoplasmic polyadenylation 
element) results in a 2-fold enhancement of translation due to stabilization of cytoplasmic 
polyadenylation element binding protein (CPEB) on the mRNA (63). Furthermore, upon 
progesterone treatment in oocytes, PUM2 dissociation from the RINGO/Spy mRNA 
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results in translation of RINGO/Spy mRNA, which is required for CPEB activation and 
cytoplasmic polyadenylation of downstream targets (40). Therefore, combinatorial 
control by a number of RBPs to activate PUM target RNAs is a possible mechanism for 
activation. 
We validated eleven mRNA targets by qRT-PCR. We chose genes that represent 
a broad range of RNAs encoding proteins involved in numerous physiological functions. 
The potential for PUM regulation in various physiological processes and disease 
pathways is broad: for example, if PUMs are hyperactive or underactive in specific 
tissues, disease may ensue due to aberrant RNA repression. If PUMs were underactive in 
tissues and did not properly regulate the mRNA encoding the DEK oncogene, which 
contains 3 PREs, the protein DEK may be overproduced. DEK is involved in DNA 
double strand break repair and is often overexpressed in many cancers. Overexpression of 
DEK inhibits cell death and functions in cellular survival (64). Thus, PUM depletion or 
loss of function may contribute to cancer pathology by causing upregulation of its target 
mRNAs.  
Loss of PUM activity would also result in upregulation of its target mRNA, 
SMPDL3A, which has been linked to bladder tumorigenesis (61). The signal peptide 
SCUBE1, which contains a CUB-EGF domain, is expressed during early embryogenesis 
and is thought to be upregulated in heart disease and hypertension: recent studies employ 
SCUBE1 detection in diagnosis of Crimean-Congo hemorrhagic fever, viral illness that is 
potentially fatal and affects many regions of the world (60, 65). Intriguingly levels of 
SCUBE1, which is translocated to the surface of cells upon platelet stimulation, increase 
with worsening prognosis in CCHF, as the disease affects endothelial cells and 
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platelets(65). Perhaps a correlation between PUMs and SCUBE1 levels in viral infection 
exists; though this is purely speculative, it will be interesting to study direct regulation of 
SCUBE1 by PUMs in reporter assays.  
Eight ncRNAs with no known function were identified in our deep sequencing 
analysis. Intriguingly, the ncRNAs LOC647979 and HCG11 have 15 and 16 PREs, 
respectively. This finding raises the question: what purpose might a ncRNA containing 
15-16 PREs serve? Do these ncRNAs modulate PUM activity? Are they junk and might 
PUMs target them for removal?  Both HCG11 and LOC647979 ncRNAs are intergenic 
non-protein coding RNAs, and are nearly identical in sequence but are on separate genes 
on different chromosomes. One possibility for their function follows closely with the 
ceRNA hypothesis, proposed recently to describe how long noncoding RNAs, mRNAs, 
and pseudogenes communicate with one another using miRNA elements (66). Perhaps 
noncoding RNAs such as LOC647979 and HCG11 serve to bind PUMs and compete for 
PUM targets as a means of regulating gene expression, much like miRNA sponges (67-
69).  
Together, our data implicate PUMs as important regulators of many biological 
pathways in humans, likely through specific interactions with PREs. We depleted PUM1 
and PUM2 from human cells and discovered that they repress and activate nearly 500 
RNAs that contain PRE sequences, including several noncoding RNAs. We propose that, 
in addition to their known repressive function, PUMs are capable activators of genes 
through a mechanism that has yet to be identified. Further, we suggest that they may 
directly regulate ncRNAs, which must be verified in future experiments. Together, our 
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data provide a high quality set of PUM regulated targets, and suggest biological pathways 
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Figure 4.1. Library generation workflow and confirmation of PUM knockdown.  
A. PUM knockdown was confirmed by Western blotting. Input lysates from either NTC or PUM1/2 siRNA 
treated cell populations were titrated from 1-15 µL and probed for either PUM1, PUM2, or GAPDH (loading 
control). B. Workflow for RNA Seq library generation. RNA was poly (A) selected and fragmented, followed 
by cDNA synthesis and adapter ligation. Lastly, cDNA fragments with barcode adapters were PCR amplified 







N P siRNA (N= NTC, P= PUM1/2):


























Figure 4.2. RPKM values of RNAs identified in RNA Seq span 7 orders of magnitude.  
RPKM values of RNAs identified in NTC treated samples (blue line) and PUM1/2 siRNA treated samples (red 
line). A. Comparison of NTC to PUM1/2 kd RPKMs in 695 downregulated (repressed) RNAs. Note that 
RPKM values increased upon PUM knockdown. B. Comparison of NTC to PUM1/2 kd RPKM values for 340 











































Figure 4.3. PRE predictions.  
A. Distribution of the total number of predicted PREs in ncRNAs and mRNAs, organized either by their 
location. B. Bar graph representing the number of PREs per transcript, divided by location. Grey triangles 
represent the average number of PREs per region. Blue gradient bars represent the range in total number of 
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Figure 4.3. PRE predictions. A. Distribution of the total number of predicted PREs in ncRNAs and mRNAs, organized either by 
their location. B. Bar graph representing the number of PREs per transcript, divided by location. Grey triangles represent the aver-






Figure 4.4. Cross reference of predicted PREs, Bound RNAs, and Response RNAs.  
A. 1033 differentially expressed genes, “Response,” from our dataset were compared with 5235 RNAs 
predicted to have PREs, “Predicted PRE.” 486 contain a PRE and are differentially regulated in our dataset. B. 
1033 “Response” genes were compared with 4071 unique RNAs identified in RIP-Chip and PAR-CLIP studies, 
called the “Bound” dataset. 389 RNAs were differentially regulated and identified in the “Bound” dataset. C. 
Cross comparison of all three datasets, “Response,” “Predicted PRE,” and “Bound.” Of those RNAs, 287 were 






Total number of reads per sample 26 million x 6 samples 
Total number of genes identified  
Control 18685 
PUM k/d 18582 
Range of RPKM values  
Control 0.000924-1681 
PUM k/d 0.001311-1788 
Total # differentially expressed genes 1035 
Total UP 695 
Total DOWN 340 
Range fold change 3.81-0.287 




Table 4.1. RNA-Seq parameters and experimental statistics.   
More than 26 million reads were obtained in each of 6 samples (3 control, 3 PUM1/2 knockdown) from 18685 
and 18582 total genes, respectively. The range of RPKM values spanned 7 orders of magnitude in this analysis 







Table 4.2. PANTHER gene ontology analysis of 1033 differentially regulated PUM targets.  
1033 differentially expressed genes from our dataset were entered into PANTHER db and analyzed for 
statistical overrepresentation among three different GO categories: Biological Process (blue), Molecular 
Function (green), and Cellular Component (purple) (52, 53). Shown are GO terms that are statistically 
represented among PUM targets with p-values ≤0.05. The second column lists the total number of classified 
genes in the reference list, containing 20,000 genes. The third column lists the total number of genes in our 
dataset that match the corresponding GO analysis term listed in the first column. The fourth column lists the 
total number of predicted genes in each GO term category from the reference list. The fifth column indicates 
whether the GO term is overrepresented or underrepresented in our dataset. The last column lists p-values for 
each GO term represented in our dataset. Note that only GO terms with p-values ≤0.05 are listed here. 
 
  
Biological Process # genes in ref list (20000) # genes in set # genes expected Over/under? P-value
cellular process 6072 403 290.55 + 1.75E-12
cell communication 4224 288 202.12 + 7.88E-09
signal transduction 4019 274 192.31 + 3.10E-08
developmental process 2840 205 135.89 + 1.72E-07
system development 1911 149 91.44 + 4.97E-07
nervous system development 1146 98 54.84 + 5.75E-06
ectoderm development 1347 109 64.45 + 1.49E-05
cell-cell adhesion 724 69 34.64 + 1.58E-05
cell adhesion 1301 106 62.25 + 1.64E-05
cell-matrix adhesion 207 27 9.9 + 7.99E-04
mesoderm development 1347 101 64.45 + 1.23E-03
protein modification process 1330 96 63.64 + 8.78E-03
protein transport 1542 107 73.78 + 1.49E-02
intracellular protein transport 1542 107 73.78 + 1.49E-02
cell surface receptor linked signal transduction 2049 135 98.04 + 1.74E-02
transport 2679 169 128.19 + 1.94E-02
Molecular Function # genes in ref list (20000) # genes in set # genes expected Over/under? P-value
protein binding 3073 212 147.04 + 2.87E-06
receptor binding 1172 93 56.08 + 2.78E-04
metallopeptidase activity 233 28 11.15 + 2.05E-03
receptor activity 1852 128 88.62 + 2.96E-03
enzyme regulator activity 1216 89 58.19 + 9.04E-03
phosphatase activity 239 25 11.44 + 4.73E-02
Cellular Component # genes in ref list (20000) # genes in set # genes expected Over/under? P-value
extracellular matrix 558 61 26.7 + 1.73E-07
extracellular region 601 63 28.76 + 4.47E-07
Table 4.2
Table 4.2. PANTHER gene ontology analysis of 1033 differentially regulated PUM targets. 1033 differentially expressed genes 
from our dataset were entered into PANTHER db and analysed for statistical overrepresentation. Shown are GO terms that are 
stastically overrepresented in the RNA-Seq dat set with p-values <0.05. The second column lists the total number of classified 
genes in the reference list, containing 20,000 genes. The third column lists the total number of genes in our dataset that match the 
corresponding GO analysis term listed in the first column. The fourth column lists the total number of predicted genes in each GO 
term category from the reference list. The fifth column indicates whether the GO term is overrepresented or underrepresented in our 
dataset. The last column lists p-values for each GO term represented in our dataset. Note that only GO terms with p-values less 




Table 4.3. KEGG pathway analysis.  
1033 differentially expressed genes from our dataset were entered into the DAVID functional analysis tool and 
analysed for statistical overrepresentation using KEGG pathway analysis (54-56). Shown are KEGG terms that 
are overrepresented in our dataset (first column). The second column lists the total number of genes in our 
dataset that correspond to the given KEGG term. The fourth column lists the p-value: shown here are KEGG 




KEGG Pathway Term Count % PValue Fold Enrichment
Axon guidance 21 2.05 1.29E-04 2.59
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 15 1.46 2.16E-04 3.14
Regulation of actin cytoskeleton 28 2.73 3.58E-04 2.07
Dilated cardiomyopathy 16 1.56 5.19E-04 2.76
Hypertrophic cardiomyopathy (HCM) 15 1.46 7.14E-04 2.80
Aldosterone-regulated sodium reabsorption 9 0.88 3.39E-03 3.49
ECM-receptor interaction 12 1.17 1.51E-02 2.27
MAPK signaling pathway 27 2.63 1.57E-02 1.61
Gap junction 12 1.17 2.24E-02 2.14
p53 signaling pathway 10 0.97 2.50E-02 2.34
Endocytosis 19 1.85 3.87E-02 1.64
Chemokine signaling pathway 19 1.85 4.44E-02 1.61
TGF-beta signaling pathway 11 1.07 4.44E-02 2.01
Melanogenesis 12 1.17 4.46E-02 1.93
Table 4.3
Table 4.3. KEGG pathway analysis. 1033 differentially expressed genes from our dataset were entered into the DAVID functional 
analysis tool and analysed for statistical overrepresentation using KEGG pathway analysis. Shown are KEGG terms that are over-
represented in our dataset (first column). The second column lists the total number of genes in our dataset that correspond to the 
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Table 4.4. GO analysis of repressed PUM targets.  
PANTHER was used to calculate statistical enrichment of genes in specific GO categories in repressed PUM 
targets. 406 upregulated RNAs from our dataset were entered into PANTHER db and analysed for statistical 
overrepresentation (52, 53). Shown are GO terms that are stastically overrepresented in the RNA-Seq dataset 
with p-values <0.05. The second column lists the total number of classified genes in the reference list, 
containing 20,000 genes. The third column lists the total number of genes in our dataset that match the 
corresponding GO analysis term listed in the first column. The fourth column lists the total number of predicted 
genes in each GO term category from the reference list. The fifth column indicates whether the GO term is 
overrepresented or underrepresented in our dataset. The last column lists p-values for each GO term represented 




Biological Process # genes in ref list (20000)# genes in set # genes expectedOver/under?P-value
cellular process 6072 295 198.55 + 2.69E-13
cell communication 4224 224 138.12 + 1.06E-12
signal transduction 4019 216 131.42 + 1.08E-12
cell adhesion 1301 98 42.54 + 3.38E-12
cell-cell adhesion 724 65 23.67 + 9.12E-11
system development 1911 114 62.49 + 5.52E-08
nervous system development 1146 79 37.47 + 9.63E-08
developmental process 2840 148 92.87 + 8.50E-07
ectoderm development 1347 85 44.05 + 1.21E-06
cell-matrix adhesion 207 23 6.77 + 1.09E-04
cell surface receptor linked signal transduction 2049 105 67 + 5.14E-04
neurological system process 1917 99 62.69 + 7.52E-04
mesoderm development 1347 75 44.05 + 1.05E-03
system process 2159 107 70.6 + 1.74E-03
transport 2679 123 87.6 + 1.11E-02
heart development 286 23 9.35 + 1.73E-02
cell-cell signaling 1259 66 41.17 + 2.26E-02
visual perception 416 29 13.6 + 2.68E-02
transmembrane receptor protein tyrosine kinase signaling pathway 295 23 9.65 + 2.69E-02
protein transport 1542 77 50.42 + 2.81E-02
intracellular protein transport 1542 77 50.42 + 2.81E-02
protein modification process 1330 68 43.49 + 3.62E-02
Molecular Function # genes in ref list (20000)# genes in set # genes expectedOver/under?P-value
receptor activity 1852 113 60.56 + 1.58E-08
protein binding 3073 154 100.49 + 4.36E-06
receptor binding 1172 73 38.32 + 2.25E-05
metallopeptidase activity 233 23 7.62 + 6.62E-04
enzyme regulator activity 1216 65 39.76 + 1.29E-02
guanyl-nucleotide exchange factor activity 162 16 5.3 + 1.81E-02
small GTPase regulator activity 490 32 16.02 + 3.46E-02
Cellular Component # genes in ref list (20000)# genes in set # genes expectedOver/under?P-value
extracellular matrix 558 57 18.25 + 3.62E-12
extracellular region 601 59 19.65 + 6.73E-12
Table 4.4. GO analysis of repressed PUM targets. PANTHER was used to calculate statistical enrichment of genes in specific GO 
categories in repressed PUM targets. 406 upregulated RNAs from our dataset were entered into PANTHER db and analysed for 
st tistical overrepresentation. Shown are GO terms that are stastically overrepresented in the RNA-Seq dataset with p-values <0.05. 
The second column lists the total number of classified genes in the reference list, containing 20,000 genes. The third column lists the 
total number of genes in our dataset that match the corresponding GO analysis term listed in the first column. The fourth column lists 
the total number of predicted genes in each GO term category from the reference list. The fifth column indicates whether the GO 






Table 4.5. qRT-PCR validation of RNA Seq targets.  
Relative fold change of each validated PUM target RNA in our RNA Seq dataset (FC RNASEQ) (listed in 
column 2). The third column lists relative fold change calculated by qRT-PCR of each target (FC qPCR). 
mRNA derived from total RNA isolated form cells transfected with PUM1/2 siRNA versus NTC siRNA. qPCR 
assays were done in duplicate from triplicate RNA samples to control for pipetting error, transfection 
variability, and sample-to-sample variation. The last column gives standard error of the mean values for qPCR 
studies (SEM qPCR).  
Table 4.5
GENE NAME FC RNASEQ FC qPCR SEM qPCR
ANO4 2.295 2.1 0.2
DEK 1.629 1.4 0.1
DUSP6 0.478 0.8 0.0
ETV4 0.297 0.3 0.0
FMR1 1.267 1.4 0.2
FZD8 2.215 1.5 0.2
L1CAM 1.622 1.5 0.1
NOVA2 1.978 2.1 0.1
RET 1.944 1.9 0.1
SCUBE1 2.379 2.9 0.2
SMPDL3A 2.35 2.3 0.2
Table 4.5. qRTPCR validation of RNA Seq targets. Relative fold change 
of each PUM target RNA in our RNA Seq dataset (listed in column 2). The 
third column lists relative fold change calculated by qRT-PCR of each 
target mRNA derived from total RNA isolated form cells transfected with 
PUM1/2 siRNA versus NTC siRNA. qPCR assays were done in duplicate 
from triplicate RNA samples to control for pipetting error, transfection 
variability, and sample-to-sample variation. The last column gives standard 






Table 4.6. Known and proposed biological roles of validated PUM targets.  
We chose targets for qPCR validation that are putative oncogenes and neural regulators, as well as those RNAs 
that were changed most in RNA-Seq studies, including SCUBE1 and SMPDL3A. We determined 
“proposed/known biological role” from annotations in the NCBI GENE database.  
Gene ID Proposed/known biological role
ANO4 Anoctamin 4, calcium activated chloride channel
DEK Oncogene, contains SAP domain, binds DNA to induce positive supercoils, splice site selection, upreg assoc. with disease
DUSP6 Member of dual speci city protein phosphatase family- inactivates ERK2, possible role in several cancers, possible oncogene
ETV4 Role in branching morphogenesis in developing kidney
FMR1 Fragile X mental retardation, premature ovarian failure 
FZD8 Receptors coupled to beta-catenin signaling, upregulated in some cancers
L1CAM Corpus callosum, partial agenesis of, CRASH syndrome, Hirschprung disease, MASA syndrome
NOVA2 Autoantigen in paraneoplastic opsoclonus myoclonus ataxia associated with breast cancer, fallopian cancer 
RET Proto-oncogene involved in central hypoventilation syndrome, multiple endocrine neoplasisas, Hirschsprung disease. 
SCUBE1 Cell surface glycoprotein, may play role in vascular biology
SMPDL3A Acid sphingomyelinase-like phosphodiesterase 3a, upregulated in bladder cancer
Table 4.6
Table 4.6. Known and proposed biological roles of PUM targets. We chose targets for qPCR validation that are 
putative oncogenes and neural regulators, as well as those RNAs that were changed most in RNA-Seq studies, including 





Table 4.7. Number and location of PREs in validated PUM targets.  
All PUM targets chosen for validation contain at least one PRE. In the second column, we list the total number 
of PREs in each target gene. In the third column, we list the UGUANAUA sequence(s) found in each PUM 
target. In the last three columns, the distribution of predicted PREs is listed. Note that the majority of predicted 
PREs in PUM targets are enriched in the 3’ UTR, with the exception of DEK, which has an additional PRE in 
its coding region (CDS). 
 
  
G ene ID P UF  s ites Motif s equences 3' UT R 5' UT R C DS
ANO4 3 tgtacata, tgtacata, tgtaaata 3 0 0
DE K 3 tgtaaata, tgtatata, tgtatata 2 0 1
DUS P 6 2 tgtaaata, tgtaaata 2 0 0
E TV4 1 tgtacata 1 0 0
F MR 1 2 tgtagata, tgtacata 2 0 0
F ZD8 1 tgtatata 1 0 0
L1C AM 2 tgtaaata, tgtacata 2 0 0
NOVA2 1 tgtatata 1 0 0
R E T 1 tgtaaata 1 0 0
S C UB E 1 1 tgtaaata 1 0 0
S MP DL3A 2 tgtagata, tgtaaata 2 0 0
Table 4.7
Table 4.7. Number and location of PREs in validated PUM targets. All PUM targets chosen for validation contain 
at least one PRE. In the second column, we list the total number of PREs in each target gene. In the third column, we 
list the UGUANAUA sequence(s) found in each PUM target. In the last three columns, the distribution of predicted 
PREs is listed. Note that the majority of predicted PREs in PUM targets are enriched in the 3’ UTR, with the exception 








Several decades of work on the PUF family of RNA binding regulators have 
provided tremendous insight into mechanisms of posttranscriptional gene regulation in 
eukaryotes. PUFs in model organisms are repressors of mRNAs that bind the PRE and 
repress mRNA targets via several proposed mechanisms, and are generally correlated 
with mRNA decay. The high degree of homology between PUMs and other PUF family 
members’ RNA binding domains motivates a widespread acceptance of a role of human 
PUMs as repressors. Yet, limited data exists that verifies direct regulation PUM targets in 
cells. Given the tremendous potential for PUM regulation in posttranscriptional 
regulation, as evidenced by the many hundreds of putative PUM target genes identified in 
RIP-ChIP and PAR-CLIP binding studies in mammals and in model organisms, we found 
it crucial to not only investigate the modes of PUM regulation in human cells, but to 
identify regulated RNA targets of both human PUMs.  
Our studies demonstrate that mammalian PUMs may regulate many hundreds of 
mRNAs and give insight into mechanisms of PUM mediated repression in human cells. 
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In Chapter 2 we describe the development of luciferase-based assays that are well suited 
to quantitatively measure 3’ UTR directed regulation in cells (1). Together these analyses 
offer a streamlined approach to studying posttranscriptional regulatory mechanisms, 
which can be readily applied to studying other RNA regulatory systems. We provide a 
detailed guide to the construction of luciferase reporters that have RNA binding target 
sequences in their 3’UTRs, as well as to detect regulated luciferase reporter protein and 
mRNA levels. We provide insight into the regulatory mechanisms of both canonical 
human PUMs in Chapter 3: PUM1 and PUM2 can repress the same reporter mRNA, and 
each possesses potent intrinsic repression activity mediated by specific interactions with 
the PRE  
PUFs in model organisms act in concert with corepressor proteins to carry out 
RNA repression. PUFs in yeast cause shortening of the poly (A) tail and reduction in 
mRNA levels: they are thought to enhance deadenylation and decay via a conserved 
interaction with the POP2 subunit of the CCR4-POP2 deadenylase complex (2-4). In 
chapter 3 we demonstrate that an interaction between human PUMs and POP2 orthologs, 
CNOT7 and CNOT8, is vital for PUMs to carry out efficient repression of a target 
mRNA, which, in addition to prior in vitro evidence, provides further evidence that the 
POP2-PUF interaction is conserved in humans (3, 4). We observe a correlation between 
repression of luciferase protein and mRNA levels, indicating that human PUMs enhance 
mRNA decay, presumably through recruitment of the CCR4-NOT deadenylase complex 
via an interaction with CNOT7 or CNOT8. Our results extend evidence in model 
organisms to humans that brings to light a conserved model for PUF repression; in which 
PUFs recruit the POP2 subunit of the CCR4-NOT deadenylase complex to shorten the 
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poly (A) tail, enhancing mRNA decay and promoting translational repression. We also 
demonstrate that PUMs repress via a deadenylation-independent mechanism, which 
results in repression of a luciferase reporter that has a histone stem loop in place of a poly 
(A) tail, and find that these mRNAs are modestly stabilized when examined by qRT-
PCR.  
In addition to deciphering mechanisms of human PUM repression, we identified 
over 1000 differentially regulated RNAs that respond to changes to a reduction in PUM 
expression by RNAi-mediated silencing in HEK293 cells. 486 differentially regulated 
genes boast at least 1 PRE: intriguingly, about 15% of those targets were decreased upon 
PUM knockdown, meaning they are potentially activated by PUMs. This suggests a 
potential role for PUMs as activators, for which there is limited precedence in the 
literature (4, 5). We then demonstrate validation of several PRE- containing differentially 
expressed RNA targets by qRT-PCR analysis.  
 Collectively, our findings shed light on the potential for broad-reaching 
regulatory control by PUM1 and PUM2 proteins in many biological processes and 
demonstrate their direct regulation of several RNAs in human cells. 
Perspectives on PUM regulatory mechanisms and combinatorial control with 
corepressors 
Deadenylation-independent repression 
We demonstrated that PUMs repress via a conserved interaction with subunits of 
the CCR4-NOT deadenylase complex in Chapter 3. Interestingly, we discovered that 
PUMs repress even in the absence of a poly (A) tail, which suggests that PUMs repress 
using multiple mechanisms. Several studies implicate PUMs as direct regulators of 
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translation (1, 6, 7). Replacement of the poly (A) tail with a histone stem loop on the 
RnLUC 3xPRE reporter mRNA allowed the process of deadenylation to be bypassed and 
presumably, be decapped and degraded (2, 8). Importantly, the RnLUC 3xPRE HSL 
reporter was repressed by human PUMs, albeit to a lesser degree than the RnLUC 3xPRE 
p(A) reporter: therefore, PUMs cause repression in a manner independent of the poly(A) 
tail and consequently, of deadenylation. At first glance, the most likely scenario for 
repression involves an interaction between PUM and decapping factors, including Dcp1 
and Dcp2, to the 5’ end of the mRNA to remove the cap, which would be in alignment 
with normal histone metabolism. The decapped mRNA would then be subjected to rapid 
decay by exoribonuclease activity. Alternatively, PUMs may direct translational 
repression of the RnLUC 3xPRE HSL through another undetermined mechanism.  
Our evidence indicates that deadenylation-independent regulation of the RnLUC 
PRE HSL reporter occurs at the level of translation and not by decapping and subsequent 
mRNA decay, as RnLUC PRE HSL mRNAs are stabilized despite luciferase protein 
repression. One intriguing possibility is that human PUMs interact directly with the cap 
or with 4EBPs to interfere with translation initiation. 4EBPs are characterized by a 
YXXXLφ motif, where X is any residue and φ is hydrophobic, which they share with 
eIF4G: this motif is essential for the interaction between 4G or 4EBPs with eIF4E (3, 4, 
9). 4EBPs typically compete with eIF4G for binding to eIF4E: when bound to eIF4E, 
4EBPs block translation by preventing 4G binding, formation of the 4F complex, and 
stimulation of translation initiation (4, 10). An interaction between an eIF4E orthologs 
and a PUF protein promotes binding of the 4EBP to eIF4E (5, 11). Perhaps an interaction 
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between a human PUM and a 4EBP strengthens the interaction between the 4EBP and 
eIF4E, thereby reducing translation of the HSL reporter.  
An alternative mechanism for PUM regulation, though not likely in our RnLUC 
HSL reporter assays, is that 5’ decapping and degradation of a PUM RNA target occurs: 
there is precedent for 5’ decapping and decay initiated by PUF protein binding to a PRE 
in yeast. Yeast Puf5p requires the 4E binding protein (4EBP) EAP1 to promote 
decapping and mRNA degradation of the HO mRNA, rather than to inhibit translation 
initiation directly (12).  Further work will be necessary to understand if 4EBPs are 
involved in human PUM-mediated repression of mRNA targets. It is also possible that 
PUMs compete with the 5’ cap to prevent eIF4E binding: Xenopus PUM2 outcompetes 
eIF4E to bind to the 5’ cap and subsequent formation of the 4F complex in order to 
reduce translation (13).  
Convergence of miRNA and PUM regulatory pathways 
PUM and miRNA repression pathways involve recruitment of many of the same 
corepressors: for example, human PUMs and miRISC bind subunits of the CCR4-NOT 
deadenylase complex (2, 14). Recent work postulates that PUMs cooperate with the 
miRNA regulatory pathway (15-18). In vitro experiments in a recent study demonstrated 
that a complex consisting of PUM2, Ago, and eIF1A formed to block translation 
elongation independently of miRNA association (16). It is important to note that this 
study, while carried out with human PUM2, only looked at regulation conferred by the 
RBD. Further, this analysis did not address PUM1.  
We know that both PUMs are highly active and that they are widely expressed in 
tissues. Furthermore, there exists evidence that the Drosophila PUM confers the majority 
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of its repression through repressive 3 domains in its N terminus (19). When tethered, 
human PUM1 and PUM2 N termini repress a luciferase reporter in Drosophila cells, 
providing further evidence that the AGO-eEF1A-PUM translational inhibitory complex, 
while a tantalizing explanation for PUM mediated repression, is not the only mode by 
which human PUMs repress target mRNAs (19). Our laboratory demonstrated recently 
that neither human nor Drosophila PUMs require the interaction with the AGO-eEF1A 
inhibitory complex to carry out repression and that PUMs repress independently (2) 
(Weidmann et al., submitted). Furthermore, we showed that the PUM RBD in Drosophila 
enhances deadenylation through an interaction with PABP, which is entirely independent 
of the effects of binding either AGO or eEF1A (Weidmann et al., submitted). While a 
plausible mechanism in in vitro biochemical assays, it does not contribute, or contributes 
very weakly, to PUM repression in human and Drosophila cells (Weidmann et al., 
submitted).  
Another study describing the interplay between miRNAs and human PUMs 
postulates that PUM1 binds the mRNA encoding the PRE-containing tumor suppressor 
p27 to induce a structural change, leaving miR221/222 sites accessible for binding and 
repression (15). p27 downregulation is required for entry into the cell cycle from 
quiescent cells and thus, the repression mediated by PUM1 and miRNAs does point to a 
role for human PUM1 in cell proliferation, which is consistent with PUM function in 
other studies and PUF function in model organisms (17, 20).  
Taken together, these mechanisms are intriguing: miRNAs and PUMs recruit 
many of the same decay factors, like the CCR4-NOT complex, so it is likely the 
pathways converge and possibly cooperate. However, cooperative binding between 
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miRNAs and PUMs cannot be the sole mechanism of human PUM repression. Both 
PUMs are highly active repressors of a Renilla luciferase reporter in human cells, which I 
discussed in Chapter 3. Furthermore, the base pairing between the PRE and miR221/222 
is unique: no other miRNA seed sites are complementary to the PRE. PUFs in model 
organisms are repressors of many mRNAs and do so in the absence of the miRNA 
pathways: PUFs in yeast, for example, are potent repressors do not compete with 
miRNAs as there is no equivalent miRNA – induced silencing pathway in the organism. 
It is likely, however, that since 8 nucleotide PRE sites are predicted to be abundant in 
human mRNAs, which we discussed in Chapter 4, and miRNA sites are reported to be 
enriched surrounding PREs, cooperativity between PUMs and miRNAs is probable under 
certain conditions (18). Further work should focus on interrogating a direct cooperative 
interaction between pathways in cells: a simple way to test involvement of the miRNA 
pathway in PUM repression is to place known miRNA binding sites in proximity of the 
PRE in the RnLUC 3xPRE reporter. It will thusly be possible to measure synergism 
between miRNA binding sites and the PRE. From that data, we will gain a better 
understanding of cooperativity between miRNAs and PUMs, which will provide a strong 
foundation on which the nuances of PUM-miRNA cooperativity in posttranscriptional 
regulation can be studied. 
RNA target activation by PUMs 
We discovered that 340 genes were decreased by PUM knockdown in RNA Seq 
experiments; of those, 80 contain predicted PREs that are located in the 5’ and 3’ UTRs 
and in the coding region, and 35 were also in the Bound data set. This is indicative of 
direct activation of those targets by PUMs. We confirmed PUM dependent regulation of 
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two “activated” PUM targets, DUSP6 and ETV4, by qRT-PCR. There are two possible 
mechanisms to explain this activation: first, PUMs act directly on the mRNA and cause 
its activation by an unknown mechanism, likely by recruitment of another protein 
cofactor that activates translation. Second, loss of PUMs may upregulate a gene that 
typically represses the “activated” mRNA, thereby causing its downregulation upon PUM 
knockdown. The latter indirect model is less likely for mRNAs that have PREs and are 
bound by PUMs. The indirect model is a more likely explanation for the mRNAs that are 
downregulated and do not have PREs. 
Several published observations support the potential ability of PUFs to activate 
mRNAs. FBF in C. elegans is proposed to cause activation of translation of the egl-4 
mRNA via binding to its PRE in response to environmental stimuli (21). Furthermore, 
PUF9 in T. brucei stabilizes several mRNAs during S phase (22). One proposed 
mechanism of PUF activation is that C. elegans FBF binds the poly (A) polymerase 
GLD-2 to promote polyadenylation and activation of translation of the gld-1 mRNA (5). 
Perhaps PUM1 or PUM2 bind a GLD-2 type poly (A) polymerase, which will thereby 
extend the poly (A) tail to promote translation. In another example, CPEB in Xenopus 
assembles with different RBP complexes to either activate or repress translation. In 
Xenopus, upon insertion of a PRE near a cytoplasmic polyadenylation element, 
translation is increased 2-fold: it is thought that this activation is caused by stabilization 
of the CPE binding protein CPEB on the RNA (23). Given this evidence in Xenopus, one 
possibility is that PREs in proximity to CPEs in the UTR work in a combinatorial fashion 
to recruit proteins that activate translation.  A simpler model is that PUMs could bind and 
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displace another dominant repressor, resulting in “activation,” which is in actuality, de-
repression.  
In order to test direct activation by PUMs, we can create luciferase reporters that 
encode the entire ORF and 3’UTR of a potential target gene: for example, DUSP6. Then, 
we can mutate its PREs to determine if the specific interaction between PUMs and PRE 
is required for gene activation. It is also imperative that direct binding is demonstrated; 
this can be done employing gel shift assays with recombinant human PUM RBD and in 
vitro transcribed RNA encoding the gene of interest. It is important that this tests whether 
PUMs can cause activation of these genes using PRE sequences: whether they do so in 
the native setting cannot be elucidated using these assays. Demonstrating indirect 
regulatory control of activated genes may be more difficult to parse out if specific 
repressors are unknown: by taking a candidate gene approach, one might identify the 
intermediary protein(s) between activated RNA and PUF protein. Activity of those 
proteins can be modulated by creating inactive mutants or by depleting them with RNAi 
in concert with PUM knockdown to measure effects on target RNA activation. It may be 
that different RNA regulators exert combinatorial control to activate gene expression or 
downregulate gene expression in response to other cis elements in different locations in 
the mRNA. 
Widespread regulation of biological processes by PUMs 
Identification of RNA targets provided our laboratory and the research 
community with a tremendous amount of information regarding potential PUM targets in 
human cells. Very few direct targets of PUF regulation in model organisms and in 
humans have been validated: we confirmed regulation of 11 genes by qRT-PCR and 
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recognize that many more have yet to be validated. qRT-PCR provided a validation of the 
data obtained in RNA Seq data: analysis of mRNA decay and protein repression is 
necessary to confirm PUM target regulation. 
PUMs regulate hundreds of mRNAs including noncoding RNAs 
We demonstrated regulation of over 1000 RNAs, including messenger RNAs and 
ncRNAs, upon knockdown of PUMs in human cells: the RNAs we identified are 
involved in several biological pathways, including p53 signaling, axon guidance, and 
development. If PUM control fails or becomes hyperactive, one can imagine that 
regulation of many pathways would be greatly perturbed, leading to many diseases, 
including cancer. It is possible that PUMs control regulatory pathways by controlling 
individual components of many pathways, or by regulating several components within 
the same pathway. From our gene ontology data, it appears that PUMs repress individual 
RNAs across many biological regulatory pathways; though in some pathways, PUMs 
regulate many RNAs. For example, in the p53 signaling pathway, PUMs regulate six 
different mRNAs genes in the pathway, including p21 (CDKN1A), p53R2 (RRM2B), 
PUMA (BBC3), Cyclin G (CCNG2), CDC2 (CDK1), and CASP3, all of which contain at 
least one PRE.  
We discovered 8 ncRNAs that were regulated by PUMs in our RNA Seq analysis: 
3 of those contain PREs including NEAT1, LOC647979, and HCG11. None of the 
identified ncRNAs have a known function. Intriguingly, LOC647979 and HCG11 contain 
15 and 16 PREs, respectively. The observation that 2 ncRNAs containing 15 and 16 
PREs is puzzling: do these ncRNAs regulate PUM function in some way? Can they act as 
PUM sponges, in a manner akin to miRNA sponges? Do PUMs target their PREs in an 
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effort to clear them away because they are junk sequences? Many of these questions 
should be addressed in future experiments. One could easily adapt our luciferase based 
reporter assays to measure repression of (or by) these intriguing ncRNAs.  
We validated regulation of several genes identified in disease pathways including 
FMR1, DEK, RET, and ETV4, by qRT-PCR. Only a few genes have been identified as 
direct RNA targets of human PUMs, though evidence for functional regulation of those 
genes is limited, and very little is known about the biological implications of regulation 
of those RNA targets by PUM proteins. It has long been thought that PUMs bind very 
specialized subsets of genes in specific categories related to function, for example, 
development. Our results and those of others shed light on the possibility of extensive 
regulatory potential by PUMs in humans and other mammals (18, 20, 24, 25). We 
showed that PUMs appear to regulate multiple components of specific diverse pathways. 
Future work will examine the roles and functions of PUM targets in humans, as well as 
the distinct mechanisms by which they are regulated by PUM proteins and their 
corepressors. Given their high degree of sequence similarity and overlapping functions, it 
is likely that PUM1 and PUM2 are essential in mammals for proper development and 
function, though this remains to be seen. It is important to note that in reporter assays, 
PUM1 and PUM2 bind the same sequence and repress the same target, and both must be 
knocked down to lose repression in HEK293 cells. Altered expression levels of PUMs in 
different cells and tissues may distinguish specific roles for PUM1 and PUM2. It will be 
important to attempt to generate a PUM1/2 double knockout mouse in the future to 
understand whether PUMs are essential for development. If viable, a double knockout 
mouse would provide tremendous insight into effects on gross morphology and 
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development. However, in the likely case that a double knockout mutant is not viable, 
tissue specific depletion of PUMs could be utilized. 
Outlook and future directions 
 Through our work, we provide a demonstration of direct regulation by PUM1 and 
PUM2 in human cells: importantly, we established that each PUM is a repressor, and 
identified corepressor proteins that bind directly to PUMs to enhance mRNA decay. We 
also opened new avenues of inquiry into PUM function in humans: PUMs regulate many 
hundreds of RNAs including mRNAs and ncRNAs, which play roles in a broad range of 
biological processes.  
 Many questions remain unanswered in terms of understanding the mechanisms of 
PUM regulation. We showed that one facet of PUM repression involves a conserved 
interaction with the CCR4-NOT deadenylase complex, but another pathway is 
deadenylation-independent. It is important to continue to explore and characterize PUMs’ 
interactions with members of the deadenylase complex: CNOT7 and CNOT8 are active 
deadenylases, as are the CCR4 orthologs in humans. This differs from yeast in that POP2 
is thought to be a bridging interaction between CCR4 and the PUF protein (3, 4). 
Furthermore, since humans have two orthologs each of CCR4 and POP2, do PUMs 
preferentially interact with specific deadenylase subunits? We have evidence that PUM1 
and PUM2 bind all four subunits, though we have not yet measured their binding 
affinities. Deadenylase subunits form heterodimeric complexes, by which CNOT6 or 
CNOT6L bind to either CNOT7 or CNOT8: we do not yet know if PUMs prefer a 
particular configuration of POP2/CCR4 subunits within the larger deadenylase complex. 
We also do not fully understand which subunit carries out deadenylation: all four 
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subunits are thought to be catalytically active, which is different from the PUF-POP2 
deadenylation mechanism in yeast which points to CCR4 being the primary catalytic 
subunit for PUF-mediated deadenylation (3). To date, we have been unable to 
demonstrate a direct shortening of the poly (A) tail in human cells, as the reporter mRNA 
we used was very low in abundance, and thus efforts to characterize its poly (A) tail 
length by RNase cleavage and Northern blot analysis were unsuccessful. Now that we 
have identified and validated RNA targets in HEK293 cells, an alternative approach to 
using a reporter mRNA will involve measuring the effects of PUMs on poly (A) tail 
length of endogenous target RNA.  
In addition to a conserved deadenylation dependent mechanism, PUMs use a 
deadenylation-independent mechanism, which is less clearly understood. Histone 
mRNAs are typically degraded by 5’ decapping and decay, we initially suspected that, if 
PUMs repressed the RnLUC 3xPRE HSL reporter at all, we would see a commensurate 
reduction in mRNA levels of the reporter. We did not observe a reduction of reporter 
mRNA, and instead measured its stabilization despite a marked reduction in luciferase 
reporter protein. In this case, it is proposed that PUMs inhibit translation and do not 
affect mRNA levels. Several studies implicate PUFs in direct translational control and 
poly (A) independent mRNA repression, though a particular mechanism for such control 
remains to be elucidated (6, 7, 19).  
One likely scenario is that PUMs bind different corepressor proteins and 
complexes. Early in this project we pursued identification of members of the deadenylase 
complex as PUM corepressors because deadenylase complex subunits were identified in 
purified PUM complexes by mass spectrometry: our efforts yielded the finding that 
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PUMs interact with deadenylase subunits of the CCR4-NOT complex to cause a 
reduction of reporter protein and mRNA levels. In light of this, it is likely that many more 
corepressors bind to PUMs such as miRNAs, Nanos, and translational regulators like 
DAZL, DAZ, and BOL, for which there is evidence in the literature in mammals (15-18, 
26-28). Decapping and decay regulators and 4EBPs are possible corepressors in PUM 
regulation as well, though there is limited evidence for these interactions in model 
organisms and none in humans. A straightforward way to test involvement of candidate 
corepressor proteins is to systematically knock them down by RNAi in human cells and 
use the methods described in Chapter 2 to measure regulation of a reporter gene such as 
RnLUC 3xPRE. Coimmunoprecipitations to measure direct binding interactions as well 
as mutational analyses of corepressors proteins will provide useful experimental systems 
in which to measure their interactions with PUMs.  
We know that both fly PUM and human PUM RBDs confer very little repression 
in comparison with the full length or N-terminal region of PUMs alone (19). The fly 
PUM N terminus confers the majority of PUM repression in DMEL-2 cells and is 
composed of three modular and independent regulatory domains (19). How these 
domains cause repression is currently unknown, but studies to elucidate the mechanisms 
of fly and human PUM N termini are underway in our laboratory and will be useful in 
gaining a holistic understanding of PUM regulatory mechanisms. Furthermore, our 
laboratory recently demonstrated that the PUM RBD, which seems to repress by causing 
deadenylation, depends on an interaction with PABP to confer regulatory activity 
(Weidmann et al., submitted). It will prove useful in humans to interrogate the PABP –
poly (A) tail- PUM connection to determine if the PUM RBD in humans represses using 
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a similar mechanism and to see if deadenylation-dependent and independent mechanisms 
in PUMs are attributable to separable activities of protein domains. 
We identified PREs in the 3’ UTR of all genes we validated by qRT-PCR, though 
the mRNA encoding the DEK oncogene contains a PRE in its coding region. No one has 
demonstrated regulation of a RNA target through a direct interaction between a PUF 
protein and PRE in a location other than the 3’UTR. Future experiments should focus on 
understanding whether the location of the PRE affects the ability of PUMs to cause 
repression. Our task from this point forward is to demonstrate functional regulation of 
activated and repressed PUM targets in cells. I constructed several clones that take 
advantage of a luciferase cell-based assay format: the ORF and 3’ UTR of a target RNA 
was cloned into the pF5A mammalian expression vector and a NanoLuc luciferase ORF 
was inserted upstream of the target stop codon. I systematically mutated each PRE in the 
gene. Using these clones, which have been created for several putative PUM biological 
targets, we will measure direct regulation by human PUMs as a function of luciferase 
activity. Furthermore, creation of stable PUM1/2 knockdowns may be most useful in 
terms of studying the effects of PUM depletion on target RNAs. Similarly, regulation of 
ncRNAs identified in our RNA Seq analysis may shed light on the function of those 
ncRNAs, which is previously unknown, as well as on the potential for a new class of 
PUM targets. Alternatively, we may learn that PUMs are regulated by noncoding RNAs 
under certain conditions. PUM interactions through PREs located in ncRNAs highlights 
the urgency for the continued study of ncRNA functions and their biological significance.  
PUMs confer widespread regulation of target genes and cause repression in a 
number of ways. Future work will focus on defining poly (A) independent PUM 
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regulatory mechanisms and the involved corepressors, as well as the characterization of 
PUM mediated repression of newly identified RNA targets. Together, these avenues of 
inquiry will yield important information regarding mechanisms of posttranscriptional 
regulatory control of a broad range of biological pathways, and shed light on normal 
physiology and development, and how misregulation of posttranscriptional regulation 
conferred by PUMs contributes to human disease. Our insights into PUM direct targets, 
combined with evidence from other laboratories, are, colloquially, the tip of the iceberg 
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Supplemental Information for RNA-Seq Analysis 
 
Table S1  
GENE	   RPKM	  (Control)	   RPKM	  (PUM1/2	  kd)	   Fold	  change	   Diff	  exp	  >1.5-­‐fold?	  
PUM2	  	   25.989	   7.4502	   0.286667449	   YES	  	  
ETV4	  	   3.08002	   0.950251	   0.308520872	   YES	  	  
SPRY4	  	   1.14	   0.368495	   0.323240528	   YES	  	  
AKR7A2	  	   32.4012	   10.5002	   0.324068343	   YES	  	  
TAGLN	  	   18.0101	   6.28508	   0.348973647	   YES	  	  
NPPB	  	   2.83305	   1.04636	   0.369342196	   YES	  	  
PKDREJ	  	   0.526295	   0.195009	   0.370531988	   YES	  	  
ETV5	  	   2.30748	   0.872925	   0.378301919	   YES	  	  
PUM1	  	   36.4423	   14.0578	   0.385755866	   YES	  	  
HMX3	  	   3.6385	   1.41581	   0.389118101	   YES	  	  
TRIL	  	   0.576203	   0.224433	   0.389503987	   YES	  	  
ANXA2P3	  	   0.975128	   0.382048	   0.391792042	   YES	  	  
EDEM2	  	   8.72348	   3.41955	   0.391993055	   YES	  	  
CPA4	  	   1.81808	   0.740677	   0.407394949	   YES	  	  
FBXO36	  	   1.06666	   0.4683	   0.439032608	   YES	  	  
ANKRD54	  	   39.051	   17.3484	   0.444248866	   YES	  	  
LOC643650	  	   0.501647	   0.22974	   0.457971587	   YES	  	  
ELAVL1	  	   30.0266	   13.9118	   0.463316511	   YES	  	  
RSAD2	  	   1.70738	   0.79476	   0.465486102	   YES	  	  
VPS52	  	   0.589519	   0.283107	   0.480234182	   YES	  	  
TFDP3	  	   1.0376	   0.499759	   0.481647639	   YES	  	  
C17orf82	  	   1.02729	   0.49816	   0.484927172	   YES	  	  
CHPT1	  	   31.1883	   15.1517	   0.485811989	   YES	  	  
SLC25A15	  	   15.204	   7.43301	   0.488886001	   YES	  	  
DKFZP686I15217	  	   1.20543	   0.590892	   0.490192393	   YES	  	  
RASSF3	  	   13.3576	   6.63614	   0.496807893	   YES	  	  
ETV1	  	   1.93204	   0.972053	   0.503122634	   YES	  	  
TTC3P1	  	   23.9511	   12.0571	   0.503404843	   YES	  	  
TTC3	  	   29.5493	   15.1453	   0.512544439	   YES	  	  
ZCCHC3	  	   33.812	   17.4599	   0.516381063	   YES	  	  
DUSP6	  	   3.08956	   1.61869	   0.523921292	   YES	  	  
INSIG1	  	   131.917	   69.1701	   0.524343811	   YES	  	  
SUMF2	  	   62.9593	   33.1322	   0.526248456	   YES	  	  
PKI55	  	   4.36594	   2.30284	   0.527455395	   YES	  	  
MTNR1A	  	   1.45027	   0.769935	   0.530890415	   YES	  	  
KRT80	  	   9.26404	   4.93654	   0.532871655	   YES	  	  
SERTAD2	  	   14.8359	   7.94807	   0.535730746	   YES	  	  
IFIT3	  	   6.35219	   3.44035	   0.54160126	   YES	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ABHD16B	  	   5.12081	   2.79036	   0.544905516	   YES	  	  
SLC25A34	  	   1.0857	   0.598647	   0.551393819	   YES	  	  
SGCB	  	   13.4939	   7.51438	   0.556873289	   YES	  	  
C20orf177	  	   8.69808	   4.86385	   0.559187494	   YES	  	  
CTXN1	  	   18.8998	   10.6067	   0.561208202	   YES	  	  
REEP6	  	   6.44213	   3.62487	   0.56268211	   YES	  	  
FBXO27	  	   2.00753	   1.14222	   0.568970595	   YES	  	  
GNRHR2	  	   5.95493	   3.39258	   0.569709749	   YES	  	  
PDSS2	  	   5.49316	   3.12992	   0.569785179	   YES	  	  
CCL2	  	   5.06051	   2.90032	   0.573127887	   YES	  	  
ST3GAL3	  	   4.65369	   2.67202	   0.57417324	   YES	  	  
PAMR1	  	   1.21775	   0.702847	   0.577171113	   YES	  	  
SKAP1	  	   1.64831	   0.952544	   0.577891678	   YES	  	  
SYT12	  	   1.72696	   1.00889	   0.584199893	   YES	  	  
MPZL3	  	   3.98694	   2.34413	   0.587951069	   YES	  	  
C3orf34	  	   3.72287	   2.19009	   0.588278412	   YES	  	  
OAS2	  	   1.03959	   0.612577	   0.589250507	   YES	  	  
LOC100129961	  	   2.46859	   1.45628	   0.589924814	   YES	  	  
LOC729013	  	   4.05352	   2.39492	   0.590824272	   YES	  	  
DCPS	  	   12.0051	   7.09995	   0.591410187	   YES	  	  
DRD1	  	   0.624081	   0.372137	   0.59629494	   YES	  	  
TFDP2	  	   7.37994	   4.40573	   0.596986826	   YES	  	  
MX1	  	   2.75153	   1.64288	   0.59707911	   YES	  	  
LOC100129726	  	   3.08076	   1.83949	   0.597091113	   YES	  	  
NCRNA00173	  	   4.67817	   2.80688	   0.599995672	   YES	  	  
CREBL2	  	   12.4518	   7.47144	   0.600026865	   YES	  	  
ZNF853	  	   11.3275	   6.82871	   0.602844575	   YES	  	  
CCDC146	  	   0.993198	   0.599957	   0.604065543	   YES	  	  
FAM172A	  	   56.6166	   34.266	   0.60522983	   YES	  	  
DQX1	  	   0.721548	   0.437087	   0.605763266	   YES	  	  
DOHH	  	   10.9571	   6.64389	   0.606356011	   YES	  	  
PCNX	  	   10.6281	   6.49348	   0.610971505	   YES	  	  
ACYP2	  	   3.54819	   2.17298	   0.612418598	   YES	  	  
C19orf66	  	   1.58135	   0.980583	   0.620091492	   YES	  	  
SH3RF1	  	   6.47879	   4.0229	   0.620934071	   YES	  	  
CCND1	  	   38.1383	   23.7836	   0.623615633	   YES	  	  
IFI6	  	   35.1568	   21.9515	   0.624388989	   YES	  	  
LCOR	  	   7.3101	   4.57394	   0.625700863	   YES	  	  
PRELID2	  	   3.96683	   2.48661	   0.626851667	   YES	  	  
LRRC23	  	   3.54828	   2.22965	   0.628376007	   YES	  	  
FBXO9	  	   23.1386	   14.5677	   0.629583659	   YES	  	  
LHPP	  	   6.82504	   4.29763	   0.62968622	   YES	  	  
IFIT2	  	   3.11947	   1.96537	   0.630033305	   YES	  	  
FOS	  	   1.55645	   0.983684	   0.632003302	   YES	  	  
TEAD2	  	   23.5422	   14.9807	   0.636334391	   YES	  	  
TRAPPC9	  	   5.54526	   3.53792	   0.638008257	   YES	  	  
PARK2	  	   0.651414	   0.417558	   0.641003438	   YES	  	  
CAPN10	  	   15.1851	   9.755	   0.642405879	   YES	  	  
HOXA10	  	   40.5569	   26.0838	   0.643139677	   YES	  	  
APH1B	  	   4.48193	   2.88343	   0.643345665	   YES	  	  
MMP24	  	   3.40647	   2.19258	   0.643649863	   YES	  	  
TXNDC12	  	   56.9345	   36.9596	   0.649160445	   YES	  	  
IFI35	  	   4.68195	   3.04107	   0.64953042	   YES	  	  
ZNF599	  	   2.31339	   1.50267	   0.64955023	   YES	  	  
DOK3	  	   12.2072	   7.92953	   0.649576344	   YES	  	  
NFIC	  	   25.6107	   16.6515	   0.65017861	   YES	  	  
C11orf75	  	   9.90017	   6.44143	   0.650638005	   YES	  	  
IL6R	  	   4.94823	   3.22142	   0.651025519	   YES	  	  
PROM2	  	   1.095	   0.71393	   0.65199328	   YES	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IFIT1	  	   11.0639	   7.21618	   0.652226968	   YES	  	  
KILLIN	  	   1.30703	   0.852809	   0.65248064	   YES	  	  
PITPNC1	  	   9.39018	   6.13552	   0.653397572	   YES	  	  
INTS5	  	   11.0179	   7.21637	   0.654966489	   YES	  	  
TMCC2	  	   5.77851	   3.79674	   0.657043594	   YES	  	  
ATL3	  	   11.1197	   7.30966	   0.657363382	   YES	  	  
QRFPR	  	   1.93176	   1.27025	   0.65756162	   YES	  	  
LRRC20	  	   5.43459	   3.57885	   0.658531794	   YES	  	  
MSRB3	  	   11.7024	   7.7117	   0.65898293	   YES	  	  
PRORSD1P	  	   1.619	   1.06886	   0.660195404	   YES	  	  
SP140L	  	   2.28515	   1.50908	   0.66038534	   YES	  	  
VPS26A	  	   26.0107	   17.1866	   0.660748431	   YES	  	  
LOC728392	  	   16.3156	   10.7927	   0.661498138	   YES	  	  
CDH13	  	   0.801462	   0.531196	   0.662783228	   YES	  	  
DHRS1	  	   6.72319	   4.45624	   0.662815387	   YES	  	  
TGFBI	  	   1.40745	   0.934916	   0.664261406	   YES	  	  
TSPYL1	  	   42.138	   28.0255	   0.665089316	   YES	  	  
FAM101B	  	   33.0099	   21.9643	   0.665386269	   YES	  	  
HS1BP3	  	   8.4819	   5.65405	   0.666601745	   YES	  	  
RASEF	  	   25.0612	   16.719	   0.66712592	   NO	  	  
C15orf41	  	   7.3255	   4.89625	   0.668384415	   NO	  	  
LOC257396	  	   1.90353	   1.2787	   0.671750782	   NO	  	  
CCT6B	  	   2.25283	   1.51572	   0.672809042	   NO	  	  
ACTBL2	  	   6.7996	   4.60356	   0.677034849	   NO	  	  
LOC729678	  	   1.96109	   1.32777	   0.677055028	   NO	  	  
PEX6	  	   12.8813	   8.73474	   0.678092973	   NO	  	  
CACNG4	  	   3.17942	   2.15647	   0.67825891	   NO	  	  
TMEM117	  	   6.99284	   4.74604	   0.678700979	   NO	  	  
DAB1	  	   1.69921	   1.15516	   0.679825791	   NO	  	  
C2CD2	  	   4.97979	   3.39834	   0.682426701	   NO	  	  
SH3GL1	  	   47.515	   32.4514	   0.682971366	   NO	  	  
ZNF71	  	   7.2345	   4.94399	   0.68338998	   NO	  	  
CFDP1	  	   60.8163	   41.626	   0.68445519	   NO	  	  
NXPH3	  	   1.02048	   0.699378	   0.685340571	   NO	  	  
UBE2L3	  	   34.0035	   23.3605	   0.687001427	   NO	  	  
GDI2	  	   108.192	   74.3291	   0.687014284	   NO	  	  
MAML1	  	   21.0559	   14.5016	   0.688717862	   NO	  	  
DDOST	  	   172.765	   118.99	   0.68873839	   NO	  	  
ASTN1	  	   5.05615	   3.49122	   0.690490275	   NO	  	  
LBH	  	   21.1819	   14.6617	   0.692182801	   NO	  	  
PET112L	  	   8.41948	   5.82892	   0.692313315	   NO	  	  
PANK1	  	   9.10322	   6.31104	   0.693275653	   NO	  	  
ISG15	  	   27.1766	   18.8485	   0.693555865	   NO	  	  
SOCS5	  	   7.07006	   4.90509	   0.693783772	   NO	  	  
PPIP5K1	  	   4.36462	   3.02989	   0.694192652	   NO	  	  
MYL12A	  	   121.369	   84.4685	   0.695967094	   NO	  	  
TECR	  	   51.8277	   36.1916	   0.698305867	   NO	  	  
ZNF365	  	   2.31353	   1.61839	   0.699534444	   NO	  	  
MRPL1	  	   7.78732	   5.44853	   0.699667314	   NO	  	  
BRD2	  	   3.45206	   2.41537	   0.699689623	   NO	  	  
CECR2	  	   7.87411	   5.51776	   0.700747696	   NO	  	  
PHF15	  	   4.05801	   2.84437	   0.700925978	   NO	  	  
SOX3	  	   5.20449	   3.65362	   0.702013169	   NO	  	  
BIRC5	  	   73.4246	   51.552	   0.702108549	   NO	  	  
PER2	  	   1.18554	   0.832629	   0.702318333	   NO	  	  
CRLF3	  	   15.7641	   11.0857	   0.703223408	   NO	  	  
SNX8	  	   7.72	   5.42962	   0.703318953	   NO	  	  
SAAL1	  	   21.3235	   14.998	   0.703356004	   NO	  	  
CBWD1	  	   22.0773	   15.5612	   0.704850404	   NO	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MNAT1	  	   25.586	   18.0667	   0.706119371	   NO	  	  
CPEB1	  	   1.92013	   1.35611	   0.706262793	   NO	  	  
LOC147727	  	   12.619	   8.92592	   0.707341592	   NO	  	  
PCDHB2	  	   2.54299	   1.80197	   0.708604238	   NO	  	  
C21orf119	  	   18.4108	   13.0549	   0.709091644	   NO	  	  
SLC9A3	  	   2.31848	   1.64517	   0.709589713	   NO	  	  
BAZ2A	  	   31.5117	   22.4158	   0.711348778	   NO	  	  
STXBP6	  	   5.24842	   3.7397	   0.712538069	   NO	  	  
ZFHX4	  	   5.88501	   4.19694	   0.713157186	   NO	  	  
RAB43	  	   1.85935	   1.32634	   0.713331209	   NO	  	  
ABHD14B	  	   6.88762	   4.91785	   0.714013373	   NO	  	  
TOP1	  	   52.0962	   37.2358	   0.714750188	   NO	  	  
NRG2	  	   2.6206	   1.87354	   0.714927078	   NO	  	  
CALCOCO1	  	   33.9941	   24.3101	   0.715127308	   NO	  	  
SLC46A3	  	   5.80666	   4.1531	   0.715230914	   NO	  	  
H2AFY	  	   182.715	   130.801	   0.715876685	   NO	  	  
TTC33	  	   6.00999	   4.30472	   0.716260853	   NO	  	  
SRD5A3	  	   5.21996	   3.74014	   0.716507147	   NO	  	  
CAP2	  	   15.8192	   11.3369	   0.716650195	   NO	  	  
SQRDL	  	   4.97221	   3.56389	   0.716762468	   NO	  	  
FHL1	  	   122.496	   87.8151	   0.716881715	   NO	  	  
MAP2K6	  	   5.43931	   3.90004	   0.717009928	   NO	  	  
DUSP19	  	   1.43708	   1.03059	   0.717142637	   NO	  	  
C13orf1	  	   5.13176	   3.68757	   0.718578662	   NO	  	  
COMMD8	  	   8.53449	   6.14594	   0.720129863	   NO	  	  
SFN	  	   7.4979	   5.39947	   0.720130362	   NO	  	  
WDR1	  	   72.5845	   52.3253	   0.720886981	   NO	  	  
CTDNEP1	  	   44.8475	   32.3687	   0.721750947	   NO	  	  
SKA1	  	   17.3774	   12.5558	   0.722535311	   NO	  	  
SGK196	  	   5.68903	   4.11815	   0.723875252	   NO	  	  
ZNF658	  	   1.77134	   1.28294	   0.724274757	   NO	  	  
UBASH3B	  	   4.23548	   3.06868	   0.724518785	   NO	  	  
CLASP1	  	   16.1039	   11.6678	   0.724530335	   NO	  	  
NEFH	  	   4.40025	   3.18913	   0.724759377	   NO	  	  
PEPD	  	   46.8801	   34.0022	   0.725301632	   NO	  	  
FAM195B	  	   48.4997	   35.1855	   0.725478618	   NO	  	  
TSTD1	  	   49.0053	   35.5639	   0.725715003	   NO	  	  
CCNT1	  	   18.6821	   13.5794	   0.726866842	   NO	  	  
ZNF768	  	   57.4892	   41.8693	   0.728299621	   NO	  	  
KRT18	  	   131.865	   96.368	   0.730807325	   NO	  	  
ELFN2	  	   3.92596	   2.86977	   0.730972481	   NO	  	  
LRRC57	  	   7.53693	   5.51243	   0.731389084	   NO	  	  
ARHGAP31	  	   2.09397	   1.53472	   0.732922724	   NO	  	  
DIAPH3	  	   12.828	   9.40404	   0.733085309	   NO	  	  
SCFD2	  	   4.88975	   3.58513	   0.733193042	   NO	  	  
C11orf24	  	   22.1268	   16.2366	   0.733799588	   NO	  	  
STAMBPL1	  	   7.93635	   5.82629	   0.734128237	   NO	  	  
RPH3AL	  	   4.34885	   3.19293	   0.734202026	   NO	  	  
HSPA2	  	   15.9917	   11.7475	   0.734599592	   NO	  	  
LOC401022	  	   9.34575	   6.86807	   0.734887848	   NO	  	  
RYK	  	   16.334	   12.0196	   0.735864479	   NO	  	  
CYR61	  	   35.2461	   25.9518	   0.736302753	   NO	  	  
SRP14	  	   148.341	   109.252	   0.736488549	   NO	  	  
FAM64A	  	   28.9161	   21.2976	   0.736531432	   NO	  	  
SCN1B	  	   9.27167	   6.82936	   0.736583508	   NO	  	  
ZW10	  	   14.6492	   10.7959	   0.736967038	   NO	  	  
HOXA11-­‐AS1	  	   9.4885	   7.00165	   0.737909094	   NO	  	  
JARID2	  	   21.324	   15.7612	   0.739128957	   NO	  	  
IGF2BP2	  	   20.5351	   15.1801	   0.739229892	   NO	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AOC2	  	   4.26438	   3.15391	   0.739593782	   NO	  	  
PSMD8	  	   213.8	   158.369	   0.740734789	   NO	  	  
ITGB3	  	   3.69308	   2.73564	   0.740747625	   NO	  	  
KRT17	  	   288.454	   213.78	   0.741124591	   NO	  	  
ZNF217	  	   10.0982	   7.48724	   0.741443158	   NO	  	  
FOXN3	  	   11.4222	   8.47179	   0.741697597	   NO	  	  
GOLGA7	  	   31.3575	   23.2682	   0.742030298	   NO	  	  
NT5C2	  	   12.2932	   9.12592	   0.742355944	   NO	  	  
STOX2	  	   3.14984	   2.3385	   0.742418209	   NO	  	  
CORO2B	  	   7.41926	   5.50845	   0.742452688	   NO	  	  
NDUFS2	  	   51.3509	   38.1305	   0.742546357	   NO	  	  
CLIP3	  	   15.9486	   11.8501	   0.743013846	   NO	  	  
PPP2R2D	  	   27.0822	   20.1231	   0.743040112	   NO	  	  
SERTAD4	  	   20.4827	   15.2633	   0.745179556	   NO	  	  
RPTOR	  	   14.3953	   10.7298	   0.745371726	   NO	  	  
TNIK	  	   12.4082	   9.24884	   0.745382059	   NO	  	  
ZNF618	  	   12.7416	   9.49788	   0.745424426	   NO	  	  
CYB5R3	  	   88.7258	   66.1425	   0.745470413	   NO	  	  
MSN	  	   91.7235	   68.4077	   0.745802739	   NO	  	  
PAF1	  	   140.14	   104.524	   0.745854953	   NO	  	  
CCDC50	  	   11.1275	   8.30095	   0.745983176	   NO	  	  
CUX1	  	   23.1332	   17.2574	   0.746004377	   NO	  	  
UBE2QL1	  	   5.11783	   3.81863	   0.74614297	   NO	  	  
LPAR1	  	   10.801	   8.06325	   0.746528891	   NO	  	  
LOC283070	  	   8.30606	   6.2016	   0.746636012	   NO	  	  
C5orf55	  	   8.24971	   6.16014	   0.746710022	   NO	  	  
PTMS	  	   325.675	   243.236	   0.746867901	   NO	  	  
FAM116A	  	   12.7026	   9.50792	   0.748501442	   NO	  	  
CASP6	  	   9.7308	   7.28546	   0.748701215	   NO	  	  
ZFYVE9	  	   19.0161	   14.2384	   0.74875415	   NO	  	  
TMEM129	  	   25.7447	   19.2766	   0.748760378	   NO	  	  
APPBP2	  	   17.4154	   13.0403	   0.74878062	   NO	  	  
GNAI2	  	   61.0029	   45.7024	   0.749182965	   NO	  	  
EGR1	  	   9.50354	   7.12684	   0.749914487	   NO	  	  
WBP2	  	   74.4181	   55.8159	   0.750031452	   NO	  	  
HDAC8	  	   15.9026	   11.9276	   0.750042369	   NO	  	  
STAT1	  	   43.5343	   32.7133	   0.75143749	   NO	  	  
SLC2A3	  	   26.0248	   19.5583	   0.751524999	   NO	  	  
NFE2L1	  	   79.499	   59.8002	   0.752213446	   NO	  	  
TRIM25	  	   25.0829	   18.8839	   0.752861297	   NO	  	  
MGAT5B	  	   5.62915	   4.24036	   0.753284631	   NO	  	  
RNF26	  	   31.3624	   23.6437	   0.753884283	   NO	  	  
STYXL1	  	   13.5067	   10.1893	   0.754394467	   NO	  	  
MRPL40	  	   66.898	   50.4784	   0.754557631	   NO	  	  
FAF1	  	   33.6678	   25.4054	   0.754590582	   NO	  	  
SPOP	  	   24.0706	   18.1861	   0.75553317	   NO	  	  
BCKDHA	  	   42.2144	   31.9134	   0.75598473	   NO	  	  
SCD5	  	   23.2565	   17.5906	   0.756372596	   NO	  	  
AGPAT3	  	   33.0493	   25.0177	   0.756981528	   NO	  	  
IRF9	  	   16.1765	   12.2476	   0.757125834	   NO	  	  
USP7	  	   35.0094	   26.5119	   0.757280141	   NO	  	  
STXBP1	  	   17.8846	   13.5454	   0.757376729	   NO	  	  
WWP2	  	   13.9995	   10.6037	   0.757435529	   NO	  	  
BGLAP,PMF1,PMF1-­‐BGLAP	  	   40.1308	   30.4171	   0.757949167	   NO	  	  
SIVA1	  	   62.8628	   47.6474	   0.757958624	   NO	  	  
HERPUD2	  	   12.9728	   9.84924	   0.75922163	   NO	  	  
KRT8	  	   286.96	   218.042	   0.759834435	   NO	  	  
PTPN18	  	   13.7005	   10.4169	   0.760332835	   NO	  	  
DAG1	  	   23.7148	   18.0336	   0.760435611	   NO	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PKD2	  	   12.7949	   9.73027	   0.760483578	   NO	  	  
SMARCE1	  	   73.2634	   55.719	   0.760528912	   NO	  	  
ZNF777	  	   14.6566	   11.1714	   0.762210295	   NO	  	  
HADH	  	   28.75	   21.9183	   0.762376735	   NO	  	  
NEFM	  	   45.7308	   34.8658	   0.762413727	   NO	  	  
MGAT5	  	   12.6314	   9.63068	   0.76243698	   NO	  	  
GNG12	  	   31.5275	   24.0409	   0.762535812	   NO	  	  
HMGA2	  	   40.4182	   30.8234	   0.762612456	   NO	  	  
TPM3	  	   53.4881	   40.0162	   0.763007953	   NO	  	  
TKT	  	   128.237	   97.8695	   0.763189379	   NO	  	  
NT5DC2	  	   98.8474	   75.4402	   0.763197844	   NO	  	  
PCBD1	  	   60.4779	   46.1739	   0.763483032	   NO	  	  
FAM70A	  	   21.4587	   16.3957	   0.764059555	   NO	  	  
VAPB	  	   14.4161	   11.0411	   0.765889943	   NO	  	  
PAK1	  	   25.2077	   19.3117	   0.766102854	   NO	  	  
C6orf106	  	   45.3315	   34.7409	   0.766374254	   NO	  	  
RAB6A	  	   29.8483	   22.8856	   0.766730247	   NO	  	  
DCP1A	  	   6.89152	   5.2853	   0.766928506	   NO	  	  
TULP4	  	   7.29704	   5.59835	   0.767208708	   NO	  	  
FOXO4	  	   14.2316	   10.92	   0.767309222	   NO	  	  
NCS1	  	   21.86	   16.7819	   0.767698641	   NO	  	  
MESDC1	  	   20.7611	   15.9637	   0.768926177	   NO	  	  
NUP93	  	   43.9756	   33.8424	   0.769571886	   NO	  	  
NEAT1	  	   149.058	   114.718	   0.769617228	   NO	  	  
KIAA1191	  	   64.3084	   49.5624	   0.770698773	   NO	  	  
MRFAP1L1	  	   36.6082	   28.2385	   0.771371634	   NO	  	  
UBE2M	  	   44.297	   34.1739	   0.771472694	   NO	  	  
PSMB6	  	   154.793	   119.432	   0.771559863	   NO	  	  
SSH2	  	   11.3234	   8.7371	   0.771599439	   NO	  	  
FARP1	  	   22.1551	   17.1111	   0.772332507	   NO	  	  
MED22	  	   22.6148	   17.4792	   0.772907141	   NO	  	  
PPP2R2A	  	   22.1917	   17.1606	   0.773288145	   NO	  	  
PPIL1	  	   51.7686	   40.0519	   0.773670409	   NO	  	  
EXOC4	  	   28.4735	   22.0347	   0.773866171	   NO	  	  
GNG4	  	   8.05969	   6.24037	   0.774269115	   NO	  	  
MPDU1	  	   40.8017	   31.595	   0.774355525	   NO	  	  
KHSRP	  	   116.593	   90.2937	   0.774431747	   NO	  	  
BICC1	  	   14.7525	   11.4255	   0.774476302	   NO	  	  
PKM2	  	   801.999	   621.495	   0.774932739	   NO	  	  
AHCYL2	  	   10.2158	   7.92341	   0.775605533	   NO	  	  
PRMT6	  	   21.125	   16.3873	   0.775728117	   NO	  	  
GINS2	  	   56.5719	   43.9352	   0.776627124	   NO	  	  
LRRC8A	  	   25.1773	   19.5919	   0.778158529	   NO	  	  
PCGF3	  	   14.5572	   11.3305	   0.778345176	   NO	  	  
DHCR24	  	   108.833	   84.7726	   0.778925363	   NO	  	  
SLAIN1	  	   17.1388	   13.3538	   0.779157559	   NO	  	  
FNBP1	  	   18.2578	   14.256	   0.780815718	   NO	  	  
NUP188	  	   55.2041	   43.119	   0.781083127	   NO	  	  
PARP14	  	   8.29984	   6.48484	   0.781321381	   NO	  	  
SMARCD1	  	   46.9407	   36.676	   0.781325172	   NO	  	  
TUBA1B	  	   573.956	   448.633	   0.781650184	   NO	  	  
FLOT2	  	   84.5473	   66.2383	   0.783446682	   NO	  	  
NUAK1	  	   10.8229	   8.48144	   0.783656325	   NO	  	  
RTN3	  	   59.7573	   46.8328	   0.783716078	   NO	  	  
RBFOX2	  	   38.0633	   29.8368	   0.783873631	   NO	  	  
DCTN1	  	   68.1023	   53.3931	   0.784014369	   NO	  	  
SSU72	  	   74.4234	   58.3516	   0.784050236	   NO	  	  
XPR1	  	   8.10493	   6.36609	   0.785459068	   NO	  	  
GARS	  	   61.4128	   48.251	   0.785682864	   NO	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UBE2MP1	  	   86.7567	   68.1902	   0.785993889	   NO	  	  
C18orf10	  	   71.5982	   56.3016	   0.786355725	   NO	  	  
MKI67	  	   111.739	   87.92	   0.786836615	   NO	  	  
PFN1	  	   916.025	   722.299	   0.788514943	   NO	  	  
NOL11	  	   32.8284	   26.0018	   0.79205197	   NO	  	  
RAB1B	  	   77.7463	   61.6319	   0.792730286	   NO	  	  
CCT4	  	   154.037	   122.426	   0.794782493	   NO	  	  
CKAP5	  	   70.6424	   88.2448	   1.249176211	   NO	  	  
PRPS2	  	   72.8874	   91.6413	   1.257300063	   NO	  	  
GLG1	  	   27.8911	   35.0847	   1.257915489	   NO	  	  
PLEC	  	   11.1275	   14.0449	   1.262172416	   NO	  	  
SDHA	  	   97.7836	   123.702	   1.265059288	   NO	  	  
LOC642852	  	   11.8651	   15.0154	   1.265508327	   NO	  	  
TTF2	  	   30.4995	   38.6572	   1.267472108	   NO	  	  
LRP11	  	   28.9115	   36.6518	   1.26772164	   NO	  	  
MARK4	  	   17.2863	   21.9564	   1.270158026	   NO	  	  
KDM6A	  	   22.5181	   28.6036	   1.270250472	   NO	  	  
HIATL1	  	   34.4226	   43.7692	   1.271525152	   NO	  	  
EIF4B	  	   52.4846	   66.8031	   1.272814345	   NO	  	  
LOC647979	  	   59.4641	   75.7592	   1.274033312	   NO	  	  
DENND4C	  	   12.9397	   16.5007	   1.275196876	   NO	  	  
ADCY7	  	   11.3949	   14.5489	   1.276796852	   NO	  	  
MBD2	  	   40.6258	   51.8834	   1.277103987	   NO	  	  
PTPRA,VPS16	  	   74.2084	   94.8548	   1.278221625	   NO	  	  
SLC12A2	  	   14.3343	   18.3367	   1.279218759	   NO	  	  
DPY19L3	  	   25.2803	   32.3432	   1.279385467	   NO	  	  
KIF2A	  	   34.1468	   43.6981	   1.279710965	   NO	  	  
SACS	  	   14.3967	   18.4376	   1.28068618	   NO	  	  
ATF3	  	   49.6225	   63.565	   1.280972052	   NO	  	  
H1F0	  	   97.6946	   125.168	   1.281216249	   NO	  	  
ARID2	  	   13.6675	   17.5116	   1.281257101	   NO	  	  
HMGCR	  	   38.6245	   49.5154	   1.281967777	   NO	  	  
ODZ3	  	   14.793	   18.9686	   1.282269935	   NO	  	  
SEMA3C	  	   13.0278	   16.7107	   1.282692185	   NO	  	  
EPT1	  	   15.6244	   20.0463	   1.28301052	   NO	  	  
IRS2	  	   6.61538	   8.49105	   1.283530875	   NO	  	  
AIP	  	   44.7051	   57.4092	   1.284177832	   NO	  	  
FMR1	  	   54.3952	   69.8577	   1.284263287	   NO	  	  
SKI	  	   41.7994	   53.6915	   1.284504549	   NO	  	  
MOBKL1A	  	   6.47008	   8.31139	   1.284588245	   NO	  	  
CD2AP	  	   43.5104	   55.9909	   1.286841172	   NO	  	  
C4orf41	  	   10.4952	   13.5103	   1.287290803	   NO	  	  
NUP133	  	   54.7488	   70.5008	   1.287713814	   NO	  	  
C17orf79	  	   57.8105	   74.466	   1.288104822	   NO	  	  
LAMA1	  	   9.26114	   11.9293	   1.288106607	   NO	  	  
UBE2A	  	   60.1192	   77.4734	   1.288662078	   NO	  	  
COG7	  	   12.1892	   15.7127	   1.289065883	   NO	  	  
NPDC1	  	   45.2948	   58.3947	   1.289214214	   NO	  	  
DISC1,TSNAX	  	   40.0657	   51.6646	   1.289496628	   NO	  	  
TMEM165	  	   21.9447	   28.3172	   1.290393432	   NO	  	  
LDLR	  	   11.6512	   15.0371	   1.290604535	   NO	  	  
TBC1D4	  	   8.25287	   10.6514	   1.290626005	   NO	  	  
SLC44A2	  	   25.7778	   33.2761	   1.290880095	   NO	  	  
RABGEF1	  	   9.71987	   12.5534	   1.291517328	   NO	  	  
EPHA7	  	   39.5087	   51.0413	   1.291900535	   NO	  	  
LMBRD1	  	   17.6813	   22.8647	   1.293159294	   NO	  	  
NPNT	  	   19.4574	   25.1737	   1.293785994	   NO	  	  
CDKN1A	  	   143.127	   185.468	   1.295830482	   NO	  	  
KRAS	  	   18.8101	   24.3755	   1.295876291	   NO	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HBXIP	  	   60.2853	   78.1264	   1.295945457	   NO	  	  
DAB2IP	  	   18.6825	   24.2133	   1.296044272	   NO	  	  
ATP8A1	  	   6.88559	   8.92763	   1.296565419	   NO	  	  
PCDH9	  	   3.90294	   5.06378	   1.29742577	   NO	  	  
HCG11	  	   6.4371	   8.35346	   1.297704585	   NO	  	  
FAT4	  	   4.93336	   6.40249	   1.297795438	   NO	  	  
TMEM170B	  	   9.84687	   12.7793	   1.297800836	   NO	  	  
SCIN	  	   24.3003	   31.5531	   1.298463986	   NO	  	  
CEP120	  	   15.0188	   19.5164	   1.299458896	   NO	  	  
HSPA12A	  	   6.3296	   8.22656	   1.299696707	   NO	  	  
PIK3C3	  	   24.3924	   31.7065	   1.299849866	   NO	  	  
SNX25	  	   12.7098	   16.522	   1.299942671	   NO	  	  
EFNB1	  	   14.0171	   18.2245	   1.300162546	   NO	  	  
GPR173	  	   9.69791	   12.6097	   1.300249966	   NO	  	  
NIN	  	   18.3856	   23.907	   1.300313056	   NO	  	  
KLF3	  	   13.6155	   17.7105	   1.300766493	   NO	  	  
ANKRD12	  	   6.58963	   8.57519	   1.301315697	   NO	  	  
COMMD6	  	   13.9736	   18.1871	   1.301532196	   NO	  	  
SYPL1	  	   31.4036	   40.888	   1.302017645	   NO	  	  
USP6NL	  	   8.4585	   11.0155	   1.302293836	   NO	  	  
TMEM50B	  	   16.6795	   21.7291	   1.302747061	   NO	  	  
HEG1	  	   6.82928	   8.8993	   1.303109212	   NO	  	  
GSK3A	  	   103.674	   135.106	   1.303181474	   NO	  	  
SIN3A	  	   24.9277	   32.4963	   1.303623261	   NO	  	  
CELF2	  	   13.1521	   17.1519	   1.304116722	   NO	  	  
FAM199X	  	   24.4542	   31.9073	   1.304779481	   NO	  	  
SMCHD1	  	   34.1257	   44.555	   1.305615419	   NO	  	  
VKORC1L1	  	   22.3795	   29.2246	   1.305860692	   NO	  	  
RNF220	  	   27.3705	   35.7533	   1.306269886	   NO	  	  
ARRDC3	  	   8.47253	   11.0707	   1.306652942	   NO	  	  
BCAM	  	   24.3254	   31.7863	   1.306715437	   NO	  	  
GOLT1B	  	   15.2706	   19.9586	   1.306998966	   NO	  	  
CDH1	  	   6.13807	   8.02331	   1.307139395	   NO	  	  
NR2F1	  	   10.9187	   14.2791	   1.307763805	   NO	  	  
SEC24D	  	   8.75031	   11.4443	   1.307869867	   NO	  	  
NF1	  	   23.6896	   31.0075	   1.308911904	   NO	  	  
DDX21	  	   98.8712	   129.45	   1.309276677	   NO	  	  
KIF20B	  	   21.7191	   28.4509	   1.309944783	   NO	  	  
TUBGCP6	  	   30.6409	   40.1396	   1.310001079	   NO	  	  
ADAM9	  	   26.0955	   34.1936	   1.310324375	   NO	  	  
SQLE	  	   41.0783	   53.8573	   1.311087525	   NO	  	  
DSC2	  	   23.4883	   30.7983	   1.311218396	   NO	  	  
CDH11	  	   18.2631	   23.9536	   1.311588357	   NO	  	  
PTPN6	  	   8.96642	   11.7608	   1.311651088	   NO	  	  
TLE1	  	   27.3893	   35.9424	   1.312277654	   NO	  	  
ADAMTS16	  	   5.01947	   6.58862	   1.31261334	   NO	  	  
WIPI1	  	   13.4715	   17.6915	   1.31325675	   NO	  	  
PITPNM1	  	   17.5976	   23.1185	   1.313729271	   NO	  	  
RINL	  	   8.6837	   11.4086	   1.313793015	   NO	  	  
OSBPL8	  	   20.4636	   26.8894	   1.314009768	   NO	  	  
ZNF711	  	   159.251	   209.274	   1.314111782	   NO	  	  
MAN2A1	  	   12.465	   16.381	   1.314160059	   NO	  	  
MAGED2	  	   81.1295	   106.704	   1.315228986	   NO	  	  
CACNA1G	  	   3.54022	   4.65653	   1.315319242	   NO	  	  
C11orf9	  	   3.88031	   5.10501	   1.315618317	   NO	  	  
DNAJC6	  	   7.02419	   9.24666	   1.3164028	   NO	  	  
MDK	  	   167.606	   220.729	   1.316952216	   NO	  	  
CTTNBP2	  	   3.46533	   4.56685	   1.317867201	   NO	  	  
LRDD	  	   21.7975	   28.742	   1.318589045	   NO	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C9orf72	  	   9.51776	   12.5502	   1.31860641	   NO	  	  
ADAM10	  	   19.4132	   25.6104	   1.319224411	   NO	  	  
YTHDC2	  	   22.9234	   30.2451	   1.319398162	   NO	  	  
TCTN1	  	   14.7335	   19.4397	   1.319423769	   NO	  	  
WNT5A	  	   4.37244	   5.77042	   1.319724692	   NO	  	  
CXCR4	  	   48.0093	   63.4029	   1.320637942	   NO	  	  
FAM60A	  	   26.99	   35.6495	   1.320839344	   NO	  	  
WDR90	  	   14.7768	   19.5189	   1.320913505	   NO	  	  
LIG4	  	   9.24931	   12.2205	   1.321231252	   NO	  	  
RAD21	  	   58.0465	   76.6969	   1.321301771	   NO	  	  
MTMR12	  	   14.1419	   18.6866	   1.321363135	   NO	  	  
TEX15	  	   2.60382	   3.44172	   1.321796426	   NO	  	  
RBL1	  	   11.2492	   14.8725	   1.32209789	   NO	  	  
ZNF805	  	   3.20916	   4.24465	   1.322666185	   NO	  	  
TICAM2,TMED7,TMED7-­‐TICAM2	  	   32.6526	   43.1939	   1.322830303	   NO	  	  
PSD3	  	   7.52646	   9.96086	   1.32344478	   NO	  	  
PPA1	  	   52.3896	   69.34	   1.323545691	   NO	  	  
RBM6	  	   37.794	   50.0239	   1.323591562	   NO	  	  
HEY1	  	   37.8686	   50.1236	   1.323620004	   NO	  	  
RNF141	  	   7.0981	   9.39741	   1.323931978	   NO	  	  
SPAST	  	   9.37954	   12.4232	   1.324502898	   NO	  	  
IMPA1	  	   6.66206	   8.82452	   1.32459379	   NO	  	  
C11orf10	  	   91.9277	   121.853	   1.325526029	   NO	  	  
NRP2	  	   8.30216	   11.005	   1.325562781	   NO	  	  
RASGRP1	  	   2.23108	   2.9577	   1.325679475	   NO	  	  
AGPAT5	  	   13.3523	   17.7073	   1.326167496	   NO	  	  
SRPX	  	   7.4253	   9.84945	   1.326470876	   NO	  	  
ACAP3	  	   20.6755	   27.4292	   1.326650179	   NO	  	  
FBN1	  	   4.65553	   6.17765	   1.32694999	   NO	  	  
IRS4	  	   193.306	   256.705	   1.327975012	   NO	  	  
CCDC99	  	   28.2853	   37.5637	   1.328030242	   NO	  	  
RBMS1	  	   12.1833	   16.1811	   1.328133344	   NO	  	  
ITGB8	  	   3.74015	   4.96797	   1.328281568	   NO	  	  
CACNA2D2	  	   3.1723	   4.21445	   1.328515445	   NO	  	  
SPIRE2	  	   11.0629	   14.6983	   1.328608454	   NO	  	  
PLXNB2	  	   85.4012	   113.55	   1.329604343	   NO	  	  
ZMYND19	  	   61.0817	   81.3038	   1.3310659	   NO	  	  
CASP3	  	   23.3569	   31.1085	   1.331878981	   NO	  	  
NRP1	  	   15.3001	   20.3788	   1.331934373	   NO	  	  
RAD51AP1	  	   26.9873	   35.9682	   1.332784013	   NO	  	  
CXADR	  	   18.0587	   24.0755	   1.333181312	   NO	  	  
EN2	  	   8.49571	   11.3308	   1.333707224	   NO	  	  
MKNK2	  	   53.0321	   70.7772	   1.334609798	   NO	  	  
TGFBR2	  	   10.1258	   13.5147	   1.334683806	   NO	  	  
TTK	  	   42.0204	   56.1266	   1.335699062	   NO	  	  
XPNPEP3	  	   5.17184	   6.91005	   1.3360926	   NO	  	  
SECISBP2L	  	   11.217	   14.988	   1.33618151	   NO	  	  
PTPRJ	  	   4.18966	   5.59893	   1.336366757	   NO	  	  
LEMD3	  	   15.2495	   20.3928	   1.337269276	   NO	  	  
DPP8	  	   18.1449	   24.2658	   1.337329528	   NO	  	  
NRIP1	  	   8.89038	   11.8896	   1.33735641	   NO	  	  
MARCH6	   48.5124	   64.879	   1.337369388	   NO	  	  
PPP2R2C	  	   6.27701	   8.40499	   1.339011174	   NO	  	  
DYNC2LI1	  	   18.9592	   25.3919	   1.339289643	   NO	  	  
KLHL14	  	   4.23456	   5.67648	   1.340512805	   NO	  	  
DCBLD2	  	   16.6391	   22.3185	   1.341323288	   NO	  	  
FMNL2	  	   20.4251	   27.4081	   1.341887756	   NO	  	  
CHMP4C	  	   7.28309	   9.77585	   1.342267301	   NO	  	  
ZBTB41	  	   3.85969	   5.18095	   1.342322195	   NO	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NUP160	  	   22.8559	   30.696	   1.343021127	   NO	  	  
CSPG4	  	   1.27514	   1.71376	   1.343982171	   NO	  	  
STK38L	  	   10.3675	   13.9363	   1.344229994	   NO	  	  
JAG1	  	   11.6717	   15.6969	   1.344875851	   NO	  	  
PDE6D	  	   21.1263	   28.4254	   1.345495905	   NO	  	  
SCAMP5	  	   6.23516	   8.39307	   1.346088253	   NO	  	  
ADM	  	   18.9635	   25.5313	   1.346342063	   NO	  	  
TMF1	  	   9.45427	   12.7365	   1.347171012	   NO	  	  
IFI30	  	   22.2484	   29.9727	   1.347181283	   NO	  	  
PREX1	  	   2.55815	   3.44712	   1.347504415	   NO	  	  
KAL1	  	   15.65	   21.0942	   1.3478706	   NO	  	  
CHPF	  	   24.3632	   32.8425	   1.348039714	   NO	  	  
H3F3B	  	   188.016	   253.512	   1.34835464	   NO	  	  
SEC24B	  	   12.8878	   17.3842	   1.348888407	   NO	  	  
LRRC4B	  	   3.96969	   5.35712	   1.349502828	   NO	  	  
SFRP1	  	   4.62552	   6.24246	   1.349570179	   NO	  	  
RIF1	  	   23.2617	   31.3943	   1.349612275	   NO	  	  
NAV2	  	   5.75021	   7.76103	   1.349693664	   NO	  	  
FZD6	  	   16.3959	   22.133	   1.349914468	   NO	  	  
TCEA1	  	   10.8823	   14.7095	   1.35169626	   NO	  	  
PPP1R9B	  	   49.4452	   66.8527	   1.35205515	   NO	  	  
NCRNA00219	  	   14.0162	   18.9529	   1.352217291	   NO	  	  
ARHGAP28	  	   3.94033	   5.33088	   1.352904496	   NO	  	  
ERBB4	  	   2.44031	   3.3016	   1.352942007	   NO	  	  
SNX16	  	   2.68998	   3.64008	   1.353200861	   NO	  	  
IGFN1	  	   0.924076	   1.25047	   1.353211179	   NO	  	  
ID4	  	   91.1529	   123.385	   1.35360237	   NO	  	  
GRID1	  	   3.48937	   4.72811	   1.355003896	   NO	  	  
FAM72B	  	   5.0289	   6.81666	   1.355498954	   NO	  	  
GMCL1	  	   14.1826	   19.2576	   1.357828244	   NO	  	  
WDR17	  	   1.6998	   2.30811	   1.357867774	   NO	  	  
ARHGEF11	  	   14.6406	   19.8805	   1.357895069	   NO	  	  
SYTL1	  	   5.55735	   7.54874	   1.358332807	   NO	  	  
NPAT	  	   7.74922	   10.528	   1.358593635	   NO	  	  
PTK2B	  	   2.2082	   3.00137	   1.359191749	   NO	  	  
H3F3C	  	   91.8253	   124.814	   1.359260526	   NO	  	  
ODZ4	  	   1.01995	   1.3869	   1.359782587	   NO	  	  
ATP6AP2	  	   66.4596	   90.3721	   1.35980615	   NO	  	  
TUBGCP5	  	   8.06419	   10.967	   1.359960737	   NO	  	  
GFPT2	  	   4.32238	   5.88236	   1.360906546	   NO	  	  
PDCD10	  	   24.9297	   33.9345	   1.361210325	   NO	  	  
MATN3	  	   3.13754	   4.27184	   1.36152361	   NO	  	  
GTPBP2	  	   53.6365	   73.0366	   1.361695381	   NO	  	  
NDFIP1	  	   27.2912	   37.1626	   1.361705763	   NO	  	  
EFNA3	  	   9.59188	   13.0615	   1.361721809	   NO	  	  
GATM	  	   3.47795	   4.73609	   1.361745406	   NO	  	  
TTYH2	  	   2.6531	   3.61353	   1.362005	   NO	  	  
CDK1	  	   78.9864	   107.655	   1.3629579	   NO	  	  
ST14	  	   4.27956	   5.83478	   1.363405776	   NO	  	  
NRCAM	  	   11.8781	   16.199	   1.363770611	   NO	  	  
DSEL	  	   2.34215	   3.19446	   1.363899177	   NO	  	  
CHST6	  	   1.20928	   1.65213	   1.36621165	   NO	  	  
RAB14	  	   34.2544	   46.8107	   1.366563027	   NO	  	  
PTPRD	  	   10.0269	   13.7032	   1.366642597	   NO	  	  
RHPN1	  	   8.21137	   11.2225	   1.366705119	   NO	  	  
SSPO	  	   1.5843	   2.16584	   1.367068941	   NO	  	  
FBN2	  	   35.5906	   48.6732	   1.36758547	   NO	  	  
SLC38A2	  	   72.6865	   99.4142	   1.367711552	   NO	  	  
MYST1	  	   21.7679	   29.8393	   1.370790406	   NO	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PCDH1	  	   2.72727	   3.73857	   1.370808459	   NO	  	  
SBNO2	  	   14.5546	   19.9745	   1.372389507	   NO	  	  
LRRC40	  	   13.8647	   19.0322	   1.372712976	   NO	  	  
PLEKHA5	  	   15.5378	   21.3373	   1.373250674	   NO	  	  
DENND3	  	   3.96528	   5.4455	   1.373295412	   NO	  	  
ITGA4	  	   6.55272	   9.00028	   1.373517222	   NO	  	  
SNX10	  	   13.268	   18.2332	   1.374227635	   NO	  	  
BCL2L11	  	   16.7993	   23.0977	   1.374920307	   NO	  	  
ARFGEF2	  	   10.3269	   14.1994	   1.37498988	   NO	  	  
RAPGEF4	  	   5.00244	   6.88154	   1.37563812	   NO	  	  
EGFL7	  	   18.0345	   24.8092	   1.375650516	   NO	  	  
RHPN2	  	   22.866	   31.4578	   1.375742058	   NO	  	  
ABHD10	  	   10.3771	   14.2775	   1.37587366	   NO	  	  
APCDD1	  	   8.42878	   11.6029	   1.376578612	   NO	  	  
TNKS2	  	   31.3937	   43.2227	   1.376798089	   NO	  	  
TOPBP1	  	   29.3126	   40.3894	   1.377884538	   NO	  	  
CBFB	  	   34.4068	   47.4345	   1.378637344	   NO	  	  
DCUN1D4	  	   13.1775	   18.1719	   1.379011989	   NO	  	  
COLEC12	  	   6.87543	   9.48237	   1.379165891	   NO	  	  
FAM178A	  	   17.3121	   23.904	   1.380769977	   NO	  	  
CLK2P	  	   16.8889	   23.3203	   1.380806346	   NO	  	  
LTBP1	  	   22.2947	   30.7882	   1.380964277	   NO	  	  
ATAD1	  	   30.1472	   41.6412	   1.381263916	   NO	  	  
TRAPPC10	  	   22.9535	   31.7444	   1.382987388	   NO	  	  
HK2	  	   6.36254	   8.79935	   1.382992181	   NO	  	  
PTHLH	  	   6.56992	   9.09155	   1.383814919	   NO	  	  
HSP90B3P	  	   21.8147	   30.2085	   1.384774439	   NO	  	  
CDYL2	  	   6.67543	   9.24616	   1.385103708	   NO	  	  
PIKFYVE	  	   13.0993	   18.1571	   1.386110238	   NO	  	  
SLC40A1	  	   7.67617	   10.6493	   1.387322309	   NO	  	  
BRMS1L	  	   14.3758	   19.9595	   1.388403589	   NO	  	  
ZDHHC21	  	   6.75293	   9.37756	   1.388665378	   NO	  	  
TTC32	  	   9.05688	   12.5809	   1.389095704	   NO	  	  
CBX3	  	   104.695	   145.555	   1.390279549	   NO	  	  
CNOT8	  	   26.37	   36.6642	   1.390375919	   NO	  	  
RASA4	  	   1.60711	   2.23494	   1.390656394	   NO	  	  
MED17	  	   12.102	   16.8366	   1.391219443	   NO	  	  
MALT1	  	   15.3243	   21.3237	   1.391498159	   NO	  	  
EHBP1L1	  	   6.16498	   8.58153	   1.391979534	   NO	  	  
PCSK5	  	   12.4203	   17.3119	   1.393841968	   NO	  	  
SEZ6L2	  	   9.46244	   13.1984	   1.394825844	   NO	  	  
KCNK1	  	   20.2933	   28.3228	   1.395670133	   NO	  	  
ITGA6	  	   27.4236	   38.2743	   1.395672067	   NO	  	  
MAN1A1	  	   22.1148	   30.8818	   1.39643072	   NO	  	  
ZHX1	  	   13.101	   18.2961	   1.396545909	   NO	  	  
PDHX	  	   15.9744	   22.3112	   1.396682405	   NO	  	  
GPR126	  	   20.2629	   28.3058	   1.396924452	   NO	  	  
SLC9A2	  	   0.902387	   1.26148	   1.397933759	   NO	  	  
C6orf1	  	   13.1204	   18.3425	   1.398017093	   NO	  	  
JAG2	  	   8.93012	   12.4917	   1.398831316	   NO	  	  
GALNT7	  	   24.9685	   34.9469	   1.399640193	   NO	  	  
C19orf51	  	   2.82696	   3.95945	   1.400601949	   NO	  	  
FGFR2	  	   11.5061	   16.1213	   1.401111724	   NO	  	  
GK5	  	   4.89115	   6.85358	   1.401219529	   NO	  	  
ATP2B1	  	   25.8896	   36.2804	   1.401350654	   NO	  	  
C8orf73	  	   4.6281	   6.48809	   1.401888881	   NO	  	  
KCNH3	  	   2.78891	   3.91199	   1.402695636	   NO	  	  
KIAA1143	  	   7.66287	   10.7555	   1.403580685	   NO	  	  
ANKRD19	  	   11.386	   15.9884	   1.404222938	   NO	  	  
191  
ACVR1C	  	   0.857871	   1.20619	   1.406028658	   NO	  	  
SEMA5A	  	   1.52074	   2.139	   1.406554057	   NO	  	  
AP1AR	  	   9.28666	   13.0693	   1.407322527	   NO	  	  
GREB1	  	   2.52794	   3.55893	   1.407834748	   NO	  	  
SEPP1	  	   28.6914	   40.4182	   1.408722063	   NO	  	  
RRM2B	  	   13.0071	   18.3239	   1.40876991	   NO	  	  
TMEM59L	  	   14.7726	   20.8244	   1.409663677	   NO	  	  
CASP8AP2	  	   22.8091	   32.159	   1.409920679	   NO	  	  
KIF21B	  	   1.76734	   2.49553	   1.412021445	   NO	  	  
FAM72A	  	   6.37664	   9.00661	   1.412439429	   NO	  	  
ITGA2	  	   5.57575	   7.87713	   1.412748835	   NO	  	  
NCRNA00087	  	   2.08988	   2.95429	   1.413615731	   NO	  	  
BOD1L	  	   14.6693	   20.7468	   1.414302769	   NO	  	  
UBA2	  	   150.109	   212.358	   1.414691029	   NO	  	  
MZT1	  	   10.8783	   15.4047	   1.416099856	   NO	  	  
TMEM55B	  	   18.9977	   26.9036	   1.416150898	   NO	  	  
C6orf168	  	   4.77466	   6.7621	   1.416247098	   NO	  	  
CPNE7	  	   3.63414	   5.14771	   1.416486645	   NO	  	  
CACNA2D1	  	   10.361	   14.6773	   1.416593669	   NO	  	  
ADAMTS7	  	   5.01583	   7.10882	   1.417278224	   NO	  	  
BRP44L	  	   33.5845	   47.6041	   1.417440327	   NO	  	  
LBR	  	   85.2356	   120.818	   1.417461942	   NO	  	  
KIF27	  	   2.56683	   3.63975	   1.417990631	   NO	  	  
PACSIN1	  	   1.87052	   2.65279	   1.418209829	   NO	  	  
CD58	  	   6.94691	   9.8539	   1.418457574	   NO	  	  
ACSL3	  	   45.7985	   65.0325	   1.419970541	   NO	  	  
UBL3	  	   11.0093	   15.6368	   1.4203259	   NO	  	  
FREM2	  	   4.55404	   6.46905	   1.420509027	   NO	  	  
ANKRD33B	  	   9.31269	   13.2308	   1.420732554	   NO	  	  
RASSF6	  	   0.832112	   1.18228	   1.420817248	   NO	  	  
ATP1B2	  	   4.52825	   6.43386	   1.420827096	   NO	  	  
GCA	  	   4.30164	   6.12367	   1.423564637	   NO	  	  
SCN9A	  	   4.81366	   6.85619	   1.424318706	   NO	  	  
MYBL1	  	   4.21716	   6.00899	   1.424890445	   NO	  	  
NBEAL1	  	   3.40288	   4.85236	   1.425958505	   NO	  	  
LRRK2	  	   1.95226	   2.78455	   1.426323271	   NO	  	  
ITPR1	  	   2.94883	   4.20672	   1.426573421	   NO	  	  
VCAN	  	   50.718	   72.4103	   1.427704097	   NO	  	  
SVIP	  	   12.1951	   17.429	   1.429183338	   NO	  	  
PCGF2	  	   32.2035	   46.0554	   1.430135655	   NO	  	  
NELL2	  	   1.41668	   2.02652	   1.43047571	   NO	  	  
ACBD5	  	   15.9549	   22.8486	   1.432073957	   NO	  	  
LTBP4	  	   20.6617	   29.5951	   1.432361851	   NO	  	  
CD24	  	   33.6158	   48.2407	   1.435060938	   NO	  	  
LRP6	  	   12.0199	   17.252	   1.435285759	   NO	  	  
LONRF1	  	   8.00208	   11.4857	   1.435339483	   NO	  	  
ARPP19	  	   43.4298	   62.4493	   1.43793753	   NO	  	  
C2orf89	  	   6.2425	   8.97808	   1.438218627	   NO	  	  
YEATS4	  	   25.8383	   37.1817	   1.439011379	   NO	  	  
JMJD1C	  	   14.2089	   20.4499	   1.439235822	   NO	  	  
TLL1	  	   0.50132	   0.721941	   1.440080041	   NO	  	  
GRK4	  	   1.34137	   1.93229	   1.440531292	   NO	  	  
SCAPER	  	   7.76518	   11.1864	   1.440591203	   NO	  	  
PANK3	  	   27.2677	   39.2932	   1.441018643	   NO	  	  
ARHGAP23	  	   6.13036	   8.83788	   1.44165904	   NO	  	  
RNF128	  	   11.0765	   15.9691	   1.441715001	   NO	  	  
MRPS36	  	   6.25508	   9.02264	   1.442448689	   NO	  	  
USP32	  	   14.3779	   20.7405	   1.442528678	   NO	  	  
SORBS1	  	   3.60251	   5.20234	   1.444089341	   NO	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FAM49A	  	   1.47766	   2.13448	   1.444506805	   NO	  	  
ENHO	  	   5.88743	   8.50576	   1.444732105	   NO	  	  
BHLHE22	  	   1.67292	   2.41963	   1.446352296	   NO	  	  
HIST3H2A	  	   35.8468	   51.9067	   1.448013447	   NO	  	  
CILP2	  	   2.21141	   3.20511	   1.449353988	   NO	  	  
MSX1	  	   8.30483	   12.0492	   1.450863707	   NO	  	  
GRAMD1B	  	   2.70408	   3.92441	   1.451289164	   NO	  	  
FAM76B	  	   9.02945	   13.1054	   1.451408878	   NO	  	  
SOX11	  	   16.9721	   24.636	   1.451554761	   NO	  	  
BTG1	  	   14.114	   20.4958	   1.452159578	   NO	  	  
TSPAN4	  	   9.80694	   14.2509	   1.453149364	   NO	  	  
ENPP2	  	   9.48993	   13.7999	   1.454163007	   NO	  	  
TMEM47	  	   7.1845	   10.4481	   1.454262798	   NO	  	  
MGAT4A	  	   5.89822	   8.58166	   1.454956479	   NO	  	  
IFNGR2	  	   37.984	   55.2714	   1.455120874	   NO	  	  
HAPLN4	  	   0.87994	   1.28103	   1.455817993	   NO	  	  
SLC43A2	  	   6.51848	   9.4959	   1.456766852	   NO	  	  
ZFAND5	  	   22.5035	   32.7876	   1.456999114	   NO	  	  
FAM169A	  	   10.513	   15.3219	   1.45742536	   NO	  	  
PSMB10	  	   6.28184	   9.1641	   1.458824162	   NO	  	  
ACVRL1	  	   1.02275	   1.49278	   1.459580721	   NO	  	  
SSTR2	  	   1.21579	   1.77508	   1.460018854	   NO	  	  
LOC100127983	  	   13.0174	   19.006	   1.460045167	   NO	  	  
EIF4ENIF1	  	   18.4004	   26.8884	   1.461295554	   NO	  	  
BRD7	  	   15.7017	   22.9594	   1.462223659	   NO	  	  
SASS6	  	   14.2788	   20.897	   1.463499243	   NO	  	  
SORT1	  	   33.8033	   49.5034	   1.464454124	   NO	  	  
NPAS1	  	   2.85988	   4.18835	   1.464520106	   NO	  	  
LEO1	  	   17.4194	   25.5161	   1.464811477	   NO	  	  
UNC5D	  	   1.02031	   1.49461	   1.464859198	   NO	  	  
ABAT	  	   4.22324	   6.18697	   1.464981047	   NO	  	  
ACAP2	  	   6.87028	   10.0665	   1.465218681	   NO	  	  
COG3	  	   5.86965	   8.60364	   1.465785502	   NO	  	  
CRIP2	  	   3.92457	   5.75558	   1.466549737	   NO	  	  
CCDC61	  	   3.38086	   4.95974	   1.467005215	   NO	  	  
BBC3	  	   23.5751	   34.5904	   1.467242161	   NO	  	  
C14orf147	  	   14.9396	   21.9234	   1.467464904	   NO	  	  
FBN3	  	   0.374728	   0.550168	   1.468181166	   NO	  	  
CEP135	  	   7.03067	   10.3238	   1.468393873	   NO	  	  
C4orf31	  	   2.20377	   3.23714	   1.468914068	   NO	  	  
TMEM128	  	   5.13791	   7.54979	   1.469427317	   NO	  	  
POLR2F	  	   29.1874	   42.9382	   1.471124147	   NO	  	  
EGF	  	   0.618702	   0.910931	   1.472325851	   NO	  	  
MATK	  	   1.62878	   2.39874	   1.472723915	   NO	  	  
BAI1	  	   1.90834	   2.81433	   1.474755715	   NO	  	  
DAAM1	  	   7.10725	   10.4851	   1.475271005	   NO	  	  
CKS2	  	   151.482	   223.533	   1.475641226	   NO	  	  
TBK1	  	   14.861	   21.9329	   1.475870359	   NO	  	  
BTG2	  	   37.2875	   55.0441	   1.476206963	   NO	  	  
ABCA7	  	   7.85985	   11.6105	   1.477186517	   NO	  	  
RDH10	  	   7.45991	   11.0309	   1.478688329	   NO	  	  
PRODH	  	   2.44792	   3.62085	   1.479154754	   NO	  	  
TMEM100	  	   1.3676	   2.02373	   1.479767994	   NO	  	  
SBF2	  	   6.81476	   10.0864	   1.480082916	   NO	  	  
COL21A1	  	   3.87665	   5.73804	   1.480156784	   NO	  	  
SNCAIP	  	   0.760572	   1.12578	   1.48017833	   NO	  	  
NPTN	  	   66.9929	   99.242	   1.481381268	   NO	  	  
AGA	  	   6.00157	   8.89223	   1.481649291	   NO	  	  
KLF15	  	   1.49805	   2.22056	   1.482296443	   NO	  	  
193  
UGT3A2	  	   3.29064	   4.8786	   1.482568743	   NO	  	  
KCNC3	  	   1.51035	   2.23937	   1.482680759	   NO	  	  
CRISPLD1	  	   3.09977	   4.59676	   1.482935655	   NO	  	  
SERPINE2	  	   27.0189	   40.0682	   1.482968548	   NO	  	  
NCKAP5	  	   0.878279	   1.30397	   1.484690277	   NO	  	  
TNFRSF9	  	   0.584292	   0.868816	   1.486953982	   NO	  	  
SNX9	  	   30.5083	   45.3666	   1.487025101	   NO	  	  
SLC6A15	  	   15.5522	   23.1326	   1.487416829	   NO	  	  
ARRDC4	  	   18.5182	   27.5637	   1.488469851	   NO	  	  
PRDM1	  	   0.585635	   0.87193	   1.488861959	   NO	  	  
ATP1B1	  	   47.3613	   70.5284	   1.489157141	   NO	  	  
TSC22D1	  	   24.2886	   36.1783	   1.489516392	   NO	  	  
NRG1	  	   1.40284	   2.09116	   1.490654591	   NO	  	  
PCDH10	  	   1.03858	   1.54961	   1.492044951	   NO	  	  
LRP5	  	   21.419	   31.9596	   1.492119415	   NO	  	  
WWC3	  	   12.4015	   18.5136	   1.492854954	   NO	  	  
PRSS8	  	   1.42317	   2.12634	   1.494094086	   NO	  	  
ITGAV	  	   38.5062	   57.6469	   1.497083822	   NO	  	  
HS6ST2	  	   22.1354	   33.2645	   1.502778103	   YES	  	  
TCIRG1	  	   2.39658	   3.60696	   1.50504435	   YES	  	  
SERPINI1	  	   1.96944	   2.96621	   1.506115071	   YES	  	  
CR2	  	   2.64624	   3.98587	   1.506239308	   YES	  	  
PTPRK	  	   22.9724	   34.633	   1.507586729	   YES	  	  
EML1	  	   13.8332	   20.9094	   1.511535644	   YES	  	  
SNAP91	  	   2.89565	   4.38518	   1.514405966	   YES	  	  
KIF3A	  	   10.7992	   16.3621	   1.515118885	   YES	  	  
FAM107B	  	   12.75	   19.3264	   1.515792213	   YES	  	  
NRXN2	  	   0.994234	   1.50809	   1.516835884	   YES	  	  
NUDT4	  	   5.59617	   8.48875	   1.516884249	   YES	  	  
GABRQ	  	   7.57725	   11.4987	   1.51753522	   YES	  	  
ANKRD24	  	   0.600573	   0.911521	   1.517752974	   YES	  	  
ADRA2A	  	   0.65766	   0.99817	   1.517759286	   YES	  	  
IMPACT	  	   16.8583	   25.6003	   1.518553777	   YES	  	  
SLC16A9	  	   4.77382	   7.26036	   1.520870168	   YES	  	  
HMGXB4	  	   20.4798	   31.1573	   1.521362553	   YES	  	  
ABCG4	  	   1.22308	   1.86213	   1.522493427	   YES	  	  
ARL6IP1	  	   142.555	   217.233	   1.523853276	   YES	  	  
ARFGEF1	  	   11.5342	   17.5854	   1.524629821	   YES	  	  
SPAG1	  	   5.4978	   8.38299	   1.524790462	   YES	  	  
IGSF9	  	   1.66118	   2.53521	   1.526152363	   YES	  	  
FNDC1	  	   1.84338	   2.81412	   1.526612596	   YES	  	  
NAA38	  	   4.61992	   7.05751	   1.527624539	   YES	  	  
MTM1	  	   4.70812	   7.19597	   1.528415719	   YES	  	  
PRDM8	  	   2.03587	   3.11299	   1.529069519	   YES	  	  
CACNA1H	  	   6.77031	   10.3562	   1.529648317	   YES	  	  
IRX3	  	   9.67146	   14.7959	   1.529852964	   YES	  	  
KLHDC7A	  	   0.373717	   0.57176	   1.529925073	   YES	  	  
FAM105A	  	   4.78293	   7.32057	   1.530564666	   YES	  	  
CD55	  	   19.8676	   30.409	   1.53058058	   YES	  	  
ISCU	  	   39.4779	   60.4727	   1.531810678	   YES	  	  
GRIK5	  	   1.78938	   2.74171	   1.532207831	   YES	  	  
FNDC5	  	   1.48917	   2.28403	   1.533763455	   YES	  	  
ECEL1	  	   6.38454	   9.79402	   1.534020752	   YES	  	  
TCF24	  	   2.25647	   3.46201	   1.534260014	   YES	  	  
DACT3	  	   2.57474	   3.9508	   1.534442942	   YES	  	  
ELAVL2	  	   9.91264	   15.2117	   1.534579088	   YES	  	  
PDE10A	  	   5.60491	   8.60535	   1.535321722	   YES	  	  
GNAI1	  	   17.3004	   26.5704	   1.535828367	   YES	  	  
ADSSL1	  	   2.30031	   3.53842	   1.538238279	   YES	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KIAA1432	  	   16.637	   25.5981	   1.538620036	   YES	  	  
LAT2	  	   0.858762	   1.32239	   1.539883278	   YES	  	  
LOC100130691	  	   0.34735	   0.535013	   1.540268645	   YES	  	  
SYT1	  	   0.372862	   0.575776	   1.544207901	   YES	  	  
NTRK3	  	   1.81756	   2.80814	   1.545006599	   YES	  	  
ADAMTS5	  	   3.64393	   5.64105	   1.548068167	   YES	  	  
DNAJB4	  	   8.49969	   13.1782	   1.550430654	   YES	  	  
HES2	  	   0.499729	   0.774833	   1.550506958	   YES	  	  
SLC25A12	  	   7.45057	   11.5548	   1.550868109	   YES	  	  
SH2D3C	  	   1.62719	   2.52363	   1.550916484	   YES	  	  
APLP1	  	   11.666	   18.1145	   1.552761228	   YES	  	  
SLBP	  	   48.2154	   74.9074	   1.553598809	   YES	  	  
CHUK	  	   20.7717	   32.3152	   1.555728167	   YES	  	  
HIST1H2BJ	  	   7.95635	   12.3905	   1.55730983	   YES	  	  
C1D	  	   7.89582	   12.3061	   1.558553847	   YES	  	  
CRTAC1	  	   2.94781	   4.59526	   1.558869329	   YES	  	  
PCNA	  	   310.656	   485.177	   1.561781902	   YES	  	  
PCDH17	  	   2.53548	   3.96184	   1.562557197	   YES	  	  
TTC35	  	   18.5123	   28.9291	   1.562698004	   YES	  	  
HERC2P2	  	   17.2627	   26.993	   1.56365908	   YES	  	  
IGDCC3	  	   1.10769	   1.73307	   1.564584958	   YES	  	  
MED4	  	   15.9905	   25.0279	   1.565169606	   YES	  	  
FAM46C	  	   2.10464	   3.29742	   1.56673589	   YES	  	  
DLAT	  	   22.4696	   35.2438	   1.568515733	   YES	  	  
EPHA3	  	   2.9853	   4.68281	   1.56862337	   YES	  	  
PSMG2	  	   39.2133	   61.5397	   1.569356373	   YES	  	  
ENTPD2	  	   1.03117	   1.61852	   1.569597882	   YES	  	  
CDHR1	  	   3.57333	   5.61429	   1.571162063	   YES	  	  
GUCY1B3	  	   7.17235	   11.2819	   1.572966559	   YES	  	  
SOSTDC1	  	   1.10207	   1.73444	   1.573793222	   YES	  	  
UBE2B	  	   16.4005	   25.8175	   1.574184893	   YES	  	  
CNTN4	  	   5.2036	   8.19554	   1.574972895	   YES	  	  
WDR19	  	   7.57247	   11.9281	   1.575194523	   YES	  	  
GBGT1	  	   7.87788	   12.4117	   1.575517741	   YES	  	  
GDF6	  	   1.17798	   1.85603	   1.575601833	   YES	  	  
RAC2	  	   1.68538	   2.65897	   1.577668393	   YES	  	  
TBX1	  	   15.3336	   24.2195	   1.579508828	   YES	  	  
SH3TC1	  	   0.566849	   0.896079	   1.580806737	   YES	  	  
UNC5A	  	   1.36545	   2.15997	   1.581872147	   YES	  	  
C6orf154	  	   1.52847	   2.41893	   1.582588304	   YES	  	  
RTN4RL1	  	   1.81022	   2.86518	   1.582783576	   YES	  	  
LGR4	  	   19.0485	   30.1516	   1.582881221	   YES	  	  
DAGLA	  	   3.76117	   5.96685	   1.586434547	   YES	  	  
FOLR1	  	   4.33191	   6.87452	   1.586949259	   YES	  	  
SCUBE3	  	   1.99443	   3.16594	   1.587391516	   YES	  	  
HSPA13	  	   29.0183	   46.0658	   1.587478442	   YES	  	  
ACHE	  	   1.88151	   2.98954	   1.588902941	   YES	  	  
RAPGEF5	  	   6.0183	   9.56998	   1.590146845	   YES	  	  
ABCG1	  	   1.8924	   3.01559	   1.593525383	   YES	  	  
CYP26A1	  	   1.38919	   2.2148	   1.594309805	   YES	  	  
MAP9	  	   7.21855	   11.5144	   1.595116726	   YES	  	  
MAK	  	   1.24533	   1.98684	   1.595427444	   YES	  	  
IARS2	  	   66.872	   106.705	   1.595653057	   YES	  	  
GATSL3	  	   1.99917	   3.19035	   1.595835561	   YES	  	  
CCKBR	  	   4.3499	   6.95458	   1.598790605	   YES	  	  
FGD4	  	   3.48682	   5.57863	   1.599919148	   YES	  	  
LOC100329109	  	   6.33081	   10.1375	   1.601294873	   YES	  	  
MICA	  	   1.58342	   2.53672	   1.602056468	   YES	  	  
CCNA1	  	   4.27296	   6.84946	   1.602978416	   YES	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CLCNKB	  	   0.808868	   1.29688	   1.603328451	   YES	  	  
GCLC	  	   23.9971	   38.4966	   1.604219995	   YES	  	  
ITGA11	  	   0.32663	   0.524028	   1.604345652	   YES	  	  
TLR3	  	   0.637834	   1.02393	   1.605326778	   YES	  	  
FOXA3	  	   0.829804	   1.33261	   1.605938895	   YES	  	  
TERT	  	   1.39822	   2.24723	   1.607215074	   YES	  	  
LRRN1	  	   0.951599	   1.53096	   1.608830124	   YES	  	  
PSMG4	  	   21.9432	   35.3224	   1.609715801	   YES	  	  
PRRX1	  	   0.43204	   0.697101	   1.613509419	   YES	  	  
FST	  	   4.41621	   7.12699	   1.61382372	   YES	  	  
KNDC1	  	   0.354271	   0.571806	   1.61403739	   YES	  	  
SLC4A7	  	   4.70766	   7.60055	   1.61450734	   YES	  	  
PRKCD	  	   14.2158	   22.952	   1.614542032	   YES	  	  
TOMM6	  	   149.036	   240.639	   1.614638279	   YES	  	  
ARHGEF4	  	   1.81691	   2.94601	   1.621442653	   YES	  	  
ISCA2	  	   15.3577	   24.907	   1.621787727	   YES	  	  
HIAT1	  	   25.5897	   41.5375	   1.623212635	   YES	  	  
RAB3GAP2	  	   12.5756	   20.452	   1.626328844	   YES	  	  
C13orf36	  	   0.431412	   0.70242	   1.628186543	   YES	  	  
DEK	  	   175.007	   285.047	   1.628779151	   YES	  	  
LIN54	  	   6.05493	   9.86267	   1.628867215	   YES	  	  
GPCPD1	  	   6.05462	   9.86948	   1.630073481	   YES	  	  
PDE1B	  	   2.18835	   3.57011	   1.63141407	   YES	  	  
NCKAP1L	  	   0.877022	   1.43222	   1.63304325	   YES	  	  
SHISA2	  	   4.46196	   7.29149	   1.634146131	   YES	  	  
IGF2,INS,INS-­‐IGF2	  	   9.0784	   14.8432	   1.635004946	   YES	  	  
PLIN1	  	   0.516527	   0.846065	   1.637987106	   YES	  	  
TRAPPC4	  	   28.0584	   45.9644	   1.638168774	   YES	  	  
SEMA3F	  	   1.95823	   3.21199	   1.640251454	   YES	  	  
LPL	  	   4.22397	   6.9291	   1.640424277	   YES	  	  
RABGGTB	  	   29.6157	   48.6787	   1.643679481	   YES	  	  
EMR2	  	   0.523552	   0.860622	   1.643813926	   YES	  	  
PGM2L1	  	   6.08158	   10.0132	   1.646485721	   YES	  	  
PCSK9	  	   0.754191	   1.24278	   1.647824959	   YES	  	  
PPP1R1A	  	   2.65719	   4.38006	   1.64837787	   YES	  	  
DNER	  	   3.44393	   5.71166	   1.658468948	   YES	  	  
SOX8	  	   1.73592	   2.88268	   1.660605061	   YES	  	  
MOSPD2	  	   10.2667	   17.0702	   1.66267708	   YES	  	  
ADAMTS18	  	   0.668308	   1.11119	   1.662689757	   YES	  	  
DCK	  	   12.3201	   20.5084	   1.664637451	   YES	  	  
PAIP1	  	   9.72504	   16.194	   1.665186768	   YES	  	  
RHBDL3	  	   3.94337	   6.57569	   1.667529172	   YES	  	  
SLC7A11	  	   1.47672	   2.46685	   1.670494231	   YES	  	  
ICAM5	  	   4.19121	   7.00794	   1.672056966	   YES	  	  
TPPP3	  	   2.83794	   4.75908	   1.676951541	   YES	  	  
RECK	  	   6.55997	   11.0076	   1.678001494	   YES	  	  
TBC1D14	  	   17.8693	   30.0043	   1.679100985	   YES	  	  
RGS5	  	   1.11266	   1.8685	   1.679319806	   YES	  	  
CCNG2	  	   8.45252	   14.2329	   1.683863275	   YES	  	  
SHANK1	  	   0.794915	   1.34066	   1.686551064	   YES	  	  
RGS17	  	   0.990327	   1.67541	   1.691776515	   YES	  	  
MEGF9	  	   11.2773	   19.0896	   1.692745401	   YES	  	  
MMP11	  	   1.74691	   2.95899	   1.693845161	   YES	  	  
NOP16	  	   22.9517	   38.9454	   1.696841723	   YES	  	  
NGFR	  	   3.62375	   6.16871	   1.702298456	   YES	  	  
DES	  	   0.998975	   1.70767	   1.70942248	   YES	  	  
STXBP3	  	   17.1061	   29.2762	   1.71144627	   YES	  	  
PNRC2	  	   2.24438	   3.84316	   1.712352831	   YES	  	  
ATP13A3	  	   22.2267	   38.0922	   1.713801476	   YES	  	  
196  
FGFR3	  	   6.00752	   10.2986	   1.714277897	   YES	  	  
ATRN	  	   23.1413	   39.7276	   1.716744094	   YES	  	  
LYPD6	  	   5.80253	   9.96219	   1.716869043	   YES	  	  
ARL8A	  	   23.8238	   41.036	   1.722479723	   YES	  	  
CITED1	  	   5.12072	   8.83745	   1.725821194	   YES	  	  
EDA	  	   3.68034	   6.3635	   1.72905289	   YES	  	  
GYLTL1B	  	   4.25476	   7.367	   1.731473131	   YES	  	  
ZNF706	  	   6.96202	   12.0557	   1.73163156	   YES	  	  
CDR1	  	   1.25856	   2.17952	   1.731751592	   YES	  	  
LAMC3	  	   2.12046	   3.68968	   1.740040638	   YES	  	  
PTPRB	  	   1.20376	   2.09508	   1.740448349	   YES	  	  
HIST2H2BA	  	   2.75846	   4.81175	   1.744359017	   YES	  	  
CCDC64	  	   2.55873	   4.47735	   1.749830282	   YES	  	  
C7orf57	  	   0.951494	   1.66553	   1.750434405	   YES	  	  
DOCK9	  	   5.9287	   10.4055	   1.755103366	   YES	  	  
KIF21A	  	   11.38	   20.0544	   1.76225659	   YES	  	  
CALM2	  	   201.369	   354.957	   1.762718378	   YES	  	  
CBFA2T3	  	   0.338624	   0.597459	   1.764373503	   YES	  	  
CRLF1	  	   7.54655	   13.3374	   1.767351501	   YES	  	  
NOV	  	   4.71945	   8.34732	   1.768705683	   YES	  	  
NPY	  	   3.3024	   5.85779	   1.773797109	   YES	  	  
MND1	  	   12.1457	   21.5563	   1.774810508	   YES	  	  
MEGF6	  	   0.951772	   1.69109	   1.776776233	   YES	  	  
VAV3	  	   2.98402	   5.30396	   1.777456188	   YES	  	  
ITGAX	  	   0.62203	   1.10677	   1.779287941	   YES	  	  
AK7	  	   0.517809	   0.921616	   1.779838082	   YES	  	  
CA2	  	   11.8034	   21.0316	   1.781827901	   YES	  	  
GNL3	  	   59.0684	   105.315	   1.782938574	   YES	  	  
NECAB1	  	   1.28405	   2.29307	   1.785805551	   YES	  	  
ATP1A3	  	   3.80968	   6.8218	   1.790647051	   YES	  	  
NTS	  	   1.17519	   2.10783	   1.793613448	   YES	  	  
C6orf165	  	   0.668533	   1.20195	   1.797884074	   YES	  	  
SLIT2	  	   31.5087	   56.7033	   1.79960964	   YES	  	  
VSTM2B	  	   3.21864	   5.80245	   1.802767067	   YES	  	  
ELFN1	  	   0.661049	   1.19228	   1.803619484	   YES	  	  
HIST1H1C	  	   39.7552	   71.7332	   1.804370995	   YES	  	  
L1CAM	  	   2.84601	   5.15661	   1.811873206	   YES	  	  
DLX5	  	   2.11959	   3.84109	   1.812187207	   YES	  	  
LRP2	  	   2.42048	   4.40434	   1.819617229	   YES	  	  
ITGB6	  	   0.369844	   0.681375	   1.842330637	   YES	  	  
HHEX	  	   9.00722	   16.6029	   1.843286085	   YES	  	  
MMP17	  	   1.87061	   3.45291	   1.845877739	   YES	  	  
ADAMTS9	  	   1.80938	   3.34627	   1.849406033	   YES	  	  
SEMA3D	  	   3.05836	   5.65676	   1.849607304	   YES	  	  
EBF2	  	   0.628075	   1.16664	   1.857481703	   YES	  	  
SFRP2	  	   1.72042	   3.1993	   1.859595706	   YES	  	  
C8orf4	  	   0.678124	   1.26197	   1.86096897	   YES	  	  
EBF1	  	   0.649926	   1.21414	   1.868114651	   YES	  	  
PVRL4	  	   5.82453	   10.9002	   1.871428591	   YES	  	  
CHRM4	  	   0.769352	   1.44378	   1.876620591	   YES	  	  
DCLK3	  	   0.534729	   1.00981	   1.888449232	   YES	  	  
PRKCG	  	   0.418687	   0.791189	   1.889690547	   YES	  	  
TSPAN2	  	   1.62995	   3.08321	   1.891603872	   YES	  	  
SHISA3	  	   0.756324	   1.43495	   1.897272626	   YES	  	  
NMUR2	  	   1.11723	   2.12017	   1.897697448	   YES	  	  
LGR5	  	   12.8508	   24.3896	   1.897903974	   YES	  	  
SARDH	  	   0.50834	   0.965381	   1.899087001	   YES	  	  
CDK7	  	   12.5282	   23.859	   1.904421736	   YES	  	  
ANPEP	  	   0.382604	   0.728977	   1.90530505	   YES	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CTNND2	  	   0.417249	   0.79516	   1.905721103	   YES	  	  
ISLR2	  	   0.517278	   0.988696	   1.911343397	   YES	  	  
CFI	  	   1.25676	   2.40311	   1.912155698	   YES	  	  
GABRR2	  	   0.478872	   0.922323	   1.926032437	   YES	  	  
CDKN1C	  	   2.16335	   4.18335	   1.933736205	   YES	  	  
THBS2	  	   1.42656	   2.76014	   1.934826228	   YES	  	  
RASGRP2	  	   0.686864	   1.33149	   1.938512449	   YES	  	  
PDZRN3	  	   1.15813	   2.2494	   1.94226762	   YES	  	  
EDEM3	  	   10.9235	   21.3211	   1.951849749	   YES	  	  
LRAT	  	   0.266461	   0.521448	   1.956942003	   YES	  	  
TAS2R5	  	   0.802419	   1.57297	   1.960287149	   YES	  	  
GRHL1	  	   5.92872	   11.6604	   1.966757384	   YES	  	  
UNC50	  	   24.6037	   48.4393	   1.968785585	   YES	  	  
ONECUT3	  	   1.05538	   2.07957	   1.970445709	   YES	  	  
SEL1L	  	   18.3655	   36.377	   1.980726931	   YES	  	  
TJP3	  	   0.528191	   1.04972	   1.98739274	   YES	  	  
PCDH20	  	   0.729436	   1.455	   1.994690621	   YES	  	  
WNT11	  	   4.4967	   8.99786	   2.000984511	   YES	  	  
STARD8	  	   0.93483	   1.87808	   2.009017318	   YES	  	  
FAM78B	  	   0.404337	   0.814028	   2.013241162	   YES	  	  
NOVA2	  	   1.5606	   3.14753	   2.016872662	   YES	  	  
NOTCH3	  	   13.1609	   26.6222	   2.022822877	   YES	  	  
SNCG	  	   1.20291	   2.45634	   2.041995943	   YES	  	  
MAP4K3	  	   11.6166	   23.7843	   2.047438333	   YES	  	  
ARHGEF10L	  	   5.18394	   10.7628	   2.076177802	   YES	  	  
PLAT	  	   16.1172	   33.5528	   2.081797872	   YES	  	  
CPXM1	  	   8.69207	   18.2024	   2.094143057	   YES	  	  
RET	  	   0.800883	   1.69499	   2.116396592	   YES	  	  
ADAMTS3	  	   2.53918	   5.39984	   2.126601921	   YES	  	  
WNT3A	  	   0.781171	   1.66157	   2.127014694	   YES	  	  
PNRC1	  	   33.2197	   70.7549	   2.129906353	   YES	  	  
PCDH19	  	   0.993341	   2.12932	   2.143591499	   YES	  	  
PLIN5	  	   0.265511	   0.572607	   2.15661702	   YES	  	  
CHP2	  	   0.678583	   1.46754	   2.16266469	   YES	  	  
CLVS2	  	   0.335429	   0.73028	   2.177148779	   YES	  	  
ALDH1A3	  	   9.82035	   21.5886	   2.198348329	   YES	  	  
PHACTR1	  	   0.406072	   0.893475	   2.20028438	   YES	  	  
ERLEC1	  	   23.9708	   52.969	   2.209729844	   YES	  	  
ADCYAP1	  	   0.341201	   0.758738	   2.223727487	   YES	  	  
CCDC12	  	   18.7211	   41.9351	   2.240001968	   YES	  	  
VLDLR	  	   22.1755	   49.996	   2.2545664	   YES	  	  
CREB3L1	  	   1.25	   2.87154	   2.297237472	   YES	  	  
CCDC85A	  	   0.326896	   0.752217	   2.301094129	   YES	  	  
KDR	  	   0.409105	   0.955675	   2.336015748	   YES	  	  
DGKK	  	   0.405859	   0.952339	   2.346482987	   YES	  	  
FZD8	  	   7.80374	   18.5671	   2.37925516	   YES	  	  
SCUBE1	  	   0.391749	   0.933083	   2.381829263	   YES	  	  
ANO4	  	   0.60233	   1.45329	   2.412786063	   YES	  	  
SMPDL3A	  	   5.59529	   13.9115	   2.486299338	   YES	  	  
GOLIM4	  	   54.9989	   138.864	   2.524854059	   YES	  	  
DNASE1L2	  	   4.57875	   11.6706	   2.548856231	   YES	  	  
DOCK10	  	   0.258363	   0.662671	   2.564895414	   YES	  	  
LEFTY2	  	   0.294947	   1.12481	   3.813617101	   YES	  	  
 




Category Term Count % PValue 
GENETIC_ASSOCIATION_D
B_DISEASE_CLASS PSYCH 41 5.899280576 0.005833855 
GENETIC_ASSOCIATION_D
B_DISEASE_CLASS DEVELOPMENTAL 19 2.73381295 0.074206641 
OMIM_DISEASE 
Six new loci associated with blood low-density 
lipoprotein cholesterol, high-density lipoprotein 
cholesterol or triglycerides in humans 6 0.863309353 0.010178811 
OMIM_DISEASE 
Newly identified loci that influence lipid concentrations 
and risk of coronary artery disease 5 0.71942446 0.02629997 
OMIM_DISEASE 
Common variants at 30 loci contribute to polygenic 
dyslipidemia 6 0.863309353 0.031560847 
 
Table S2. DAVID GO analysis of PUM repressed targets and disease associations.  
